PREDICATE,SUBJECT_NAME,OBJECT_NAME,cause_category,factuality_score,Factuality_Score,Cancer_Type
AFFECTS,Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FGFR2 gene|FGFR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA1 gene|BRCA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NDUFB3|TNFAIP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RAD51,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Topotecan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ACSL4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body mass index,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolites,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,anthracene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"oxoguanine glycosylase 1, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Topoisomerase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Methylcholanthrene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C-reactive protein level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Proliferation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoma of the Large Intestine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phytoestrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single Nucleotide Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CD44 gene|CD44,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Cycle Progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MTRR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MTA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Growth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DYRK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Velcade,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormone replacement therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lycopene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMURF1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Metabolic Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"DNA, Mitochondrial",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polyphenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Etodolac,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MST1R gene|MST1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lactation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Well in self,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Human Papillomavirus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TARBP2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tobacco smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Annexin A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAD51,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BCL9 gene|BCL9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GATA3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,beta-cryptoxanthin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Pathways,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TARBP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SELENOP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polyphenols,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Weight Gain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pleiotropism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Enhancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GATA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prognostic Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Monocyte Chemoattractant Protein-1|CCL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Complication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,kahweol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,INPP5J,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,heparanase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fitness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Progestins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTGS2 gene|PTGS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nitrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GLTSCR2 gene|NOP53,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Polymorphism, Genetic",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERBB2 gene|ERBB2,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,TP53 gene|TP53,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine therapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,BRCA2 gene|BRCA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Base Excision Repair,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumor Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis Inhibitors,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adiponectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CENPN,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Reproductive History,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Menopausal Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KISS1R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ABCB1 gene|ABCB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Regular exercise,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antisense RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF410,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diabetes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Total cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nuts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Psychosocial problem,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Red meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lesion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Single Nucleotide Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hypothalamic inhibiting factor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,DNM1 gene|DNM1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Heterocyclic Amines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primigravida,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phosphotransferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Stromal Cell-Derived Factor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Enzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Isoflavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Taxotere,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERBB2 gene|ERBB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,S100A7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Calcium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antioxidants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,educational intervention,Malignant neoplasm of breast,Educational Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,anthracene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Opioid, delta",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Amino Acyl-tRNA Synthetases|TRNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AKR1C3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PGR gene|PGR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Radial scar,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,methyl 4-azidophenylacetimidate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Methionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Catechol O-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TLR3 gene|TLR3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vascular Endothelial Growth Factor Receptor-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dihydroxyacetone sulfate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estradiol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Apoptosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Taxanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fulvestrant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BSG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thromboembolic event,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CXCR4 gene|CXCR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Alpha-MMC protein, Momordica charantia",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ovarian Serous Adenocarcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,EGFR gene|EGFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HRH4 gene|HRH4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,6-sulfatoxymelatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Methylnitrosourea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carrier of disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Fatty Acids, Omega-6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Not significant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Citrate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,RASAL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Estrogens, Synthetic",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bilateral salpingectomy with oophorectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Arginine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drug resistance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Wine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Menopause,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sulfuretin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Proto-Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Expression,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FGF10 gene|FGF10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HSF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Iodine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Protein Expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Clusterin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytokine Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRKACA gene|PRKACA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Dietary Fats,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Eosinophilia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin Resistance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MAD2L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Drugs, Investigational",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Urokinase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Neoplasm Metastasis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gamma-tocotrienol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TERT gene|TERT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EGFR gene|EGFR,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Oxidative Stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Solvents,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,palm oil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tongue feature,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Blueberries,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,ITK gene|ITK,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,inhibitors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Triclosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Threonine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Medical History,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progestins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CLOCK gene|CLOCK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CA-15-3 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNAs,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Genomic Stability,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNAs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,bevacizumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prior Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Medical Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ATM Gene Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,inner centromere protein|INCENP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN132 gene|MIR132,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Tumorigenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xenograft procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ginkgo biloba extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCNB1 gene|CCNB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chemokine receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Germ-Line Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vimentin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MTR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Carotenoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adverse reactions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oxidoreductase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Baclofen,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Diphosphonates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Folate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ORALIT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,c-myc Genes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carotenoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,alpha-carotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Treatment Protocols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DHX9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cigarette Smoking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,stromelysin 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Worried,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BARD1 gene|BARD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Raloxifene Hydrochloride,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,ERBB3 gene|ERBB3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Somatic mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ANO1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Klinefelter's Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Translation, Genetic",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha Tocopherol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogens,Breast Carcinoma,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Carrier status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Doxorubicin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,distilled alcoholic beverage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Flap Endonuclease-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Contraceptives, Oral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Whole milk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARITY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lymph Node Involvement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body Weight Changes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,osteopontin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Progestins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cessation of life,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Ether, Ethyl",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,humoral defense mechanism (sensu Vertebrata),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,gonadotropin inhibitor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Adverse effects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BRCA2 gene|BRCA2,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,High fat diet NOS,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polychlorinated Biphenyls,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,protein kinase C eta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Steroid hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Conflict (Psychology),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYR61,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,anastrozole,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dietary Modification,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Childbirth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prostate-Specific Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Previous pregnancies 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infertility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proanthocyanidins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemotherapy-Oncologic Procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Systemic Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Folate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Atypical lobular hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BCHE|SNORA73A|ENOPH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumor Angiogenesis,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant Neoplasms,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,inhibitors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogen Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Norplant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Chemicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cholecalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Menopausal symptom,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Matrix Metalloproteinases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,E-Cadherin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,"Herpesvirus 4, Human",Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene-Environment Interaction,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Galectin 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aromatase Inhibitors,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperinsulinism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DNA Adducts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ethylnitrosourea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beverages,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Axillary Lymph Node Dissection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Meat intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Free estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Mammary Tumor Virus, Mouse",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Cytomegalovirus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Linoleic Acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KAT6A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vegetables,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibroblast Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Carcinogens, Environmental",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Methylnitrosourea,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Deficiency of testosterone biosynthesis,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,SV40 T Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hydroxyestrones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary Fiber,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinogens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Androgens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pesticides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mastectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,dehydroepiandrosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oils,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen excess,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Dactinomycin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Aromatase Inhibitors,Breast cancer metastatic,Treatments,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Early Diagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin C intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Combined Oral Contraceptives,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proto-Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TFF1 gene|TFF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Breast cancer recurrent,Malignant neoplasm of breast,Other,0.0174,0.3386613386613387,Female Breast Cancer
CAUSES,Serum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,v-Ha-ras Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary Fats,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Genes, Dominant",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dysplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dehydroepiandrosterone Sulfate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tetradecanoylphorbol Acetate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Nuclear Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PREDICTED,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,methylurea,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Birth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Fibrocystic Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ras Oncogene,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Estrogen Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fibronectins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Egg Food Product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tenascin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cholestyramine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Progestins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ovulatory,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,4'-deoxydoxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Imidazole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,paracrine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Fats, Unsaturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Somatomedins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Early menarche,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Triceps skin fold thickness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Genes,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,c-myc Genes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cancer-Predisposing Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pregnancy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Thyroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CATHEPSIN D|CTSD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fusion procedure,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,"Contraceptives, Oral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PNMA3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hormone replacement therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,body mass,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytotoxic Chemotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Amplification,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histopathology,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fluoroscopy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Diseases,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Cystic Fibrosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gonadotropin-Releasing Hormone Analog,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"Genes, Suppressor",Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Therapeutic procedure,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Fatty Acids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Alkaline Phosphatase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cholera Toxin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Propionate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Contraceptive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,alpha-latrotoxin receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Acute leukemia,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Methoxamine,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,diphenyl,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,leukemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Relaxin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Fucose,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Receptors, Progesterone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glycol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,soy protein isolate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Peptide Nucleic Acids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant","Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,adjuvant therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,estrophilin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA1 gene|BRCA1,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Combination Chemotherapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Breast Fibrocystic Change, Proliferative Type",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,G-Actin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Theophylline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Androgens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cisplatin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Digitoxin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aggressive behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infection,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cancer-Predisposing Gene,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Screening mammography,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Schistosomiasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gonadorelin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Communication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Familial cancer of breast,Sporadic Breast Carcinoma,Other,0.0185,0.0,Female Breast Cancer
AUGMENTS,Ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C-Peptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polychlorinated Biphenyls,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Dietary fat intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Carcinoma,Malignant neoplasm of breast,Other,0.0166,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tamoxifen,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Retinoblastoma Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Brain hemorrhage,"Carcinoma, Ductal, Breast",Demographic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alleles,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mammography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"(meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(II)",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lymphocyte Specific Protein Tyrosine Kinase p56(lck)|LCK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Long menstrual cycle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Viral Oncogene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lymphocyte Specific Protein Tyrosine Kinase p56(lck)|LCK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hereditary Malignant Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tobacco,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, Nuclear",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta catenin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Carcinogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,vitamin analog,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Tumor Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,celecoxib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,COMT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Retinoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hereditary Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prostaglandins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,stearic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,steroid hormone receptor,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,CUL4A gene|CUL4A,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Antioxidants,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CAMP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Dietary Fats,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polyamines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Silicones,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Glycosylated hemoglobin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCOA3 gene|NCOA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MYC gene|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ovarian Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ATM gene|ATM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ethylene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TACSTD1 protein, human|EPCAM",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Mammary Tumor Virus, Mouse",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Transduction Pathways,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,maspin|SERPINB5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AFP gene|AFP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Psychological adjustment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,diagnostic procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FHIT gene|FHIT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Merozoite Surface Protein 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,APC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Micronutrients,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hexachlorobenzene,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Growth Factor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,High weight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,17-Ketosteroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"PTPN6 protein, human|PTPN6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Contraceptives, Oral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Microsatellite Instability,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTT1 gene|GSTT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Raloxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,impression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mismatch Repair,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Urokinase Plasminogen Activator Receptor|PLAU|PRAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transforming Growth Factor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,hydroxytamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogens,Carcinoma of Male Breast,Hormonal Factors,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,Venoms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pre-Eclampsia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Fatty Acids, Essential",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Progestins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Somatotropin-Releasing Hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oncogenes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Curative Surgery,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,methylurea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oestrogen deficiency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thromboembolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,beta catenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dieldrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,leukemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Butyric Acid,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,fascin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Retinoblastoma Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polychlorinated Biphenyls,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Sausage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cofactor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Apoptosis Inhibiting Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Li-Fraumeni Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phytic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Intrinsic factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GGCT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,anastrozole,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,DNA Sequence,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Conjugated Equine Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EGFR gene|EGFR,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Amines,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,"Etiology, operative procedure, as cause of",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,estrone sulfatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beer intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,trilostane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein Kinase C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nutrients,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vitamins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epithelial Cell Proliferation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Development of the breasts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transgenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Feeding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,B-pyridine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mastodynia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PGR gene|PGR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTM1 gene|GSTM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NFKB1,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Vitamin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,AROMATICS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Symptoms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLK14,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tocopherols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53 gene|TP53,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Permeability,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Phytoestrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATP7B,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GGCT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TSG101 gene|TSG101,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Aromatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tryptophan|TYRP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Mastitis, associated with childbirth",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,trastuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SLC19A3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nutrients,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Primary carcinoma of the liver cells,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Bone Density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cellular Retinol Binding Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Down-Regulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYR61,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Raloxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LMO4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Peptidyl-Dipeptidase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Immunologic Adjuvants,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body Fat Distribution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNAI3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diphosphonates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thyroid Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mammary Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Spontaneous abortion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Mutation, Missense",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Soybean Oil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Abortion, Induced",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oestrogen increased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclooxygenase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NCOA3 gene|NCOA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PPIG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Contraceptives, Oral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polychlorinated Biphenyls,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Fatty Acids, Omega-3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Somatomedins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adhesions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,11q13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Unspecified Abortion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA Damage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Raloxifene,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Tumor Promoters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Somatomedins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,Other,0.0692,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vegetables,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic Stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Docosahexaenoic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Enzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,maspin|SERPINB5,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,cyclooxygenase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,protein kinase inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nuclear Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leptin|LEP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aneuploidy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Microcalcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Progestogen hormone therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERBB2|NEU1|NEURL1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Epidermal growth factor receptor inhibitor,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Kininogenase|KLK4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Oligonucleotides, Antisense",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infiltrating duct carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BONE MASS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BIRTHPLACE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Skin problem,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic breast density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Mutation, Nonsense",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Metals, Heavy",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Single Nucleotide Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary Fats,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mammary gland development,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,19p13.3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Leucine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Resonance Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EMSY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin-Like Growth Factor II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Folate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Diethylstilbestrol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MCM2 gene|MCM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESTROGEN USE,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Normal growth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin D3 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Environmental Pollutants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,genotoxicity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,stressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,connexin 26,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DDT (Insecticide),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stromal Cell-Derived Factor 1|CXCL12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,STK6 gene|AURKA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vitamin E,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Soy Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Somatomedins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Urokinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pollutant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcriptional Activation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gelatinase B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thromboembolic event,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to Screening for malignant neoplasm of breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SPRY2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LAG3 gene|LAG3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,protective factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Transduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogen Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Raloxifene,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,cyclooxygenase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oxidative Stress,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,Pharmaceutical Preparations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Transforming Growth Factor beta|TGFB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prenatal Exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diastolic blood pressure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Short menstrual cycle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CA9 gene|CA9,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Estrogen Receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytotoxin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Osteoporosis,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Dietary Carbohydrates,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CXCR4 gene|CXCR4,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cruciferous Vegetable,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coffee,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to genetic counseling,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogens,Breast Carcinoma,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Calcium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PGR gene|PGR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fruit,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Progestational Hormones, Synthetic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,isoflavonoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLC25A18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Juice,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Focal Adhesion Protein-Tyrosine Kinases,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,"Hemoglobin, Glycosylated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Granulocyte Colony-Stimulating Factor,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Estrogenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phytoestrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Isoleucine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolic Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carotenoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fat tissue increased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Contraceptive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,indole-3-carbinol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Isoflavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Abruptio Placentae,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SULT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fruit,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vegetable intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PTGS2 gene|PTGS2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Human papillomavirus 16,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MET gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cholesterol levels raised,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Postmenopause,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,caveolin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Androgen Receptor|AR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Female Breast Carcinoma,Carcinoma of Male Breast,Other,0.0174,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Lobular hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Prolactin|PRL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary restriction NOS,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polycyclic Hydrocarbons,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Li-Fraumeni Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen receptor positive tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Iron intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Hyperparathyroidism, Primary",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,migration stimulating factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic field,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Chemicals,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Obesity,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,sulforafan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERCC2 gene|ERCC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Monoclonal Antibody Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Arachidonic Acid,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Hyposensitivity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,decaffeinated coffee,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mammaglobin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ADAM12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Integrin beta3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,apolipoprotein D|APOD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Motility,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CDV3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"progesterone, micronized",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SR-2508,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PBRM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CISH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,rho GTP-Binding Proteins,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,NCOA3 gene|NCOA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adiponectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RETN gene|RETN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Adverse effects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,caspase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Soy Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cancer Promoting Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HIC1 gene|HIC1,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,hemagglutinin I,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,cytokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Menopause, Premature",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oestrogen therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Receptor Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fusion Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Molecular Fingerprint of Tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Impaired cognition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,APOA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Combined Modality Therapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,ATM gene|ATM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcription Repressor/Corepressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta-adrenergic receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nicotinamide adenine dinucleotide (NAD),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLC45A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ERBB2|NEU1|NEURL1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ETS1 gene|ETS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Exercise,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,S-Phase Fraction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HSF1 gene|HSF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biguanides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLLN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MLLT11,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Drink,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Indigotindisulfonate Sodium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Catechin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Garlic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TNF protein, human|TNF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,WISP3 gene|WISP3,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Estrogen Receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm Metastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Xeroderma pigmentosum, group C",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LAMR1 gene|RPSA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,osteosarcoma,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TWIST1 gene|TWIST1,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Ultrasonography,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Androgen therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erlotinib,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Sentinel Lymph Node Mapping,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAD50,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sedentary,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BLCAP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CpG Islands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,14q31,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RNA, Untranslated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RBL2 protein, human|RBL2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"2,5-dichloro-4-bromophenol",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SHFM1 gene|SEM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DUSP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,participation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA Repair Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Processed meat intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Receptors, Progesterone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Breast tenderness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNAs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,stress-activated protein kinase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MTHFR gene|MTHFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pharmaceutical Preparations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cardiovascular Diseases,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,gemcitabine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Screening mammography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Isoflavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pumpkin seeds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phytochemical,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,trastuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fruit intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Aromatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Angiogenesis Inhibitors,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Decreased translucency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,atorvastatin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Phosphoglycerate dehydrogenase|PHGDH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Collagen,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Topoisomerase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nitrate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Angiopoietin-2|ANG,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Neoplasm progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,receptor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Mucins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Folate intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phosphotransferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Contraceptive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Flavonoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Animal Feed,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRD7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body mass index,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Atypical hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Virus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRIP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Point Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lesion,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Hypoxia,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ERBB2|NEU1|NEURL1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MicroRNAs,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Vitamins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FOXP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Serine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,lycopene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pathogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SRSF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Nuclear Receptor Subfamily 4, Group A, Member 1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Leptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,paclitaxel liposome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin D intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alleles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AXL gene|AXL,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,JTB gene|JTB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Interferon Alpha, Human|IFNA1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,toxicant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Insulin, Long-Acting",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prolactin|PRL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Radiotherapy, Adjuvant",Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
DISRUPTS,Taxol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SPDEF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,equol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VEGFA,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,BRIP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Soy Foods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BEX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HIF1A gene|HIF1A,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Metabolic syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Transcription, Genetic",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atypical antipsychotic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Visual Accommodation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cancer prevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormone Receptor,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,CISH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Placental Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,METHYLATE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GPER1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,congener,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xanthine Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,progesterone analog,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Single Nucleotide Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epidermal Growth Factor Receptor|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CASP8 gene|CASP8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCOA3|ANIB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xenograft Model,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Progestins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Estrogen Receptor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glutathione S-Transferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BHMT gene|BHMT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCL12 gene|CXCL12,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,response,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Phytochemical,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Adducts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RASSF1A,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Thyrotropin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PTEN gene|PTEN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Candidate Disease Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HDAC9,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ESTROGEN USE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Gelatinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclooxygenase 2 Inhibitors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tumorigenicity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ITGA11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Small Nucleolar RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TOX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physically active,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Niacinamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein p53|TP53,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Repair Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epigallocatechin gallate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paravertebral anesthesia,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Matrix Metalloproteinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gene polymorphism,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Psychotherapy, Multiple",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MicroRNAs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TP53 gene|TP53,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Body Weight decreased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypertensive disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Bone Neoplasm,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Endocrine Disruptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cardiovascular Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN34A gene|MIR34A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fisetin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,systemic administration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GM2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,progesterone receptor positive,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR655,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,peoniflorin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphatidylethanolamine N-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cholesterol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SPRY1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epidermal growth factor receptor inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Choline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Depressed mood,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Vitamin D3 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Receptor Activation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Epidermal growth factor receptor inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fibronectins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lipopolysaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of lymph node,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,F3 gene|F3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RSU1 gene|RSU1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,3' Untranslated Regions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Induction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paget's Disease,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,curdione,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,14q24.1,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,GATA3 gene|GATA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclophosphamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SOAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Response Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HIF1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LOH11CR2A gene|VWA5A,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tumor Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary fiber intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PALB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTPN12 gene|PTPN12,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Extracellular Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atypical hyperplasia,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Functional RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXC1 gene|FOXC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ARNTL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infiltration,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Therapeutic agent (substance),Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm Metastasis,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,PORPHOBILINOGEN SYNTHASE|ALAD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperandrogenemia,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Histone Deacetylase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RAB8A gene|RAB8A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical activity,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Tubulin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ZYX gene|ZYX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MBTPS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCOR2 gene|NCOR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ethacrynic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF423,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,6q25.1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Exertion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Transcript,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRIM25,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,MIR520C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tetradecanoylphorbol Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C6orf106,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"MAPK14 protein, human|MAPK14",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Functional RNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Disease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Fibroblast Growth Factor Receptors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,UBE3A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Dehydration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Cell Invasion,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Pesticides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Receptors, Interleukin-1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Forkhead Transcription Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,G0S2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Phosphoric Monoester Hydrolases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Death (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,zoledronic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,F Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TFF3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Advance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa|RPS6KB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Metalloproteases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,vasodilator-stimulated phosphoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Curcumin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,anastrozole,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,PLAC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,docetaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transforming Growth Factor beta|TGFB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overweight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Neoantigen,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,TNFRSF6B gene|TNFRSF6B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XRCC3 gene|XRCC3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NF-kappa B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,prevention through information dissemination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Zinc,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metaplastic Breast Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lymph,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SETD7,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PIP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytotoxic Chemotherapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Fatty Acids, Omega-3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP27A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CA-15-3 Antigen,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,tumor growth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,P2RY6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,MAGI3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,diallyl disulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Performance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary Component,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcript,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Metabolites,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,stanniocalcin 2,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,Paclitaxel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Genes,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Aromatase Inhibitors,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,synaptotagmin I|RELA|SYT1|GORASP1|WNK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EPHB2|MAPK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Soluble ErbB-1|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transforming Growth Factor beta,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CYR61,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Primary Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Transduction Pathways,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,CAMK2B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HOXD10,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Honey,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Polymerase|ERVK-9|ERVK-19|ERVK-11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Synaptophysin|SYP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADIPOR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ISL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RUNX1 gene|RUNX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,hepatocellular carcinoma protein 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"RNA, Messenger",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Regulatory Element,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Granulocyte-Macrophage Colony-Stimulating Factor|CSF2|LAMC2,Breast cancer metastatic,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gelatinase B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIR gene|MLXIP|MYLIP|MARCH8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytotoxic T-Lymphocyte-Associated Protein 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Noninfiltrating Intraductal Carcinoma,Other,0.3988,0.0109890109890109,Female Breast Cancer
AFFECTS,Tocopherols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Anthocyanins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DMXL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Curcumin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,POU5F1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stromal Cell-Derived Factor 1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,OBSCN gene|OBSCN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,STAT5A gene|STAT5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WBP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,myricetin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Ethanol,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Ultrasonography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PITX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SUMO1P3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Autophagy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SOHLH2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Clomiphene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AKT2 gene|AKT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GPR1 gene|GPR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNAJB4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,discoidin domain receptor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PLAUR gene|PLAUR,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,SHH gene|SHH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,trastuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NEK6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,O-GlcNAc transferase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ACKR3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MicroRNAs,"cellular diagnosis, breast cancer",Other,0.0,0.0,Female Breast Cancer
AFFECTS,Cisplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,"Lung Diseases, Interstitial",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Cisplatin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dinoprostone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transcriptase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunity,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Reading,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,depolarization,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HRG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GATA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MERTK gene|MERTK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin B 12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Peptides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cyclic AMP-Responsive DNA-Binding Protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Thrombosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Variation (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Genes, X-Linked",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOXA1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,GAS5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GGN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SLC4A7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"PDGFA protein, human|PDGFA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Crisis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Calcitriol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,RICTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GACAT3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,preference,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,"Biological function, NOS",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Twin birth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP3A4 gene|CYP3A4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CXCL13 gene|CXCL13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PSMB4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Carcinoma, Non-Small-Cell Lung",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Small cell carcinoma of lung,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gefitinib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RAD51,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cruciferous Vegetable,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTHLH gene|PTHLH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FBXL14,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Topoisomerase Inhibitors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ERBB2 gene|ERBB2,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,BDE-99,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radionuclide Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Risedronate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,recessive allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclooxygenase 2,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,DNAJC2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HORMAD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Habits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EREG|ESR1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,N-Cadherins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,16q12.1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,C3|ERVK-2,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Hypothyroidism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,S100A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prognosis bad,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Cycle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,resveratrol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADAM17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,sunflower seed oil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sun Exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Raloxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oils,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TYMS gene|TYMS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytokeratin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KDM1A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Transcript,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,"sal protein, Drosophila",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Coffee,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RAP1A|RABGEF1|TERF2IP,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Mutate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gonadal Steroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,piperine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SPC24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endocrine substance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EGFL6 gene|EGFL6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tubulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MULTISECTION:FINDING:POINT IN TIME:BREAST:NARRATIVE:MRI,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NOTCH1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LSINCT5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,decaffeinated coffee,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,high-dose chemotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrosis,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oils,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,blood lipid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphotransferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00310,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Black tea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Premarin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESR2 gene|ESR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EPHB4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EIF4G1,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Inflammation Mediators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,baicalein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erbB-2 Receptor|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,racial differences,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histologic type,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Raloxifene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"UBD protein, human|UBD",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CDC16,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammary Tumorigenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ARHGAP9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogenic effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Membrane Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cell invasion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,lysophosphatidic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MMP9 gene|MMP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Postmenopausal syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hyperthyroidism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Compete,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Head circumference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Succinate Dehydrogenase|SARDH|SDHB|SDS,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,cell motility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen hormone therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Pleural Effusion, Malignant",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunologic Adjuvants,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SULF2 gene|SULF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARF6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Alcoholic Beverages,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Progestins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BAX gene|BAX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone replacement therapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Uterine Cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,health-related beliefs,Malignant neoplasm of breast,Ethical and Cultural Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoxia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ZD 6126,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"VEGF protein, human|VEGFA",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Mucins,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Tyrphostins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lactation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Organochlorine pesticide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lean body mass,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Somatomedins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,genetic aspects,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beta Carotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Osteoporosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Daily drinker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thinness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pain relief,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha-carotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Amitriptyline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Polyamines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Sulfuric Acid Esters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Somatomedins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,BNIP3,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Steroid hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Reexcision,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,"Endometriosis, site unspecified",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GSTT1 gene|GSTT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTP1 gene|GSTP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin Resistance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,celecoxib,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PRSS3P2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,VEGF gene|VEGFA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical activity,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,leptin receptor|LEPR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,sulfotransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progesterone Receptor Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ibandronate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RGS17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Behavior showing increased motor activity,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fever,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anthracyclines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Almond Nut,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Breast cancer invasive NOS,Other,0.3988,0.0099900099900099,Female Breast Cancer
AFFECTS,Up-Regulation (Physiology),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERCC5 gene|ERCC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of liver,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOXL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RHOA gene|RHOA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LGMN gene|LGMN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Enkephalins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antihypertensive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRKD1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Atypia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD55|TCN2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Waist circumference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Antigens, CD5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tibolone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Diagnostic Neoplasm Staging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pancreatectomy,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,MicroRNAs,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,MicroRNAs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,personal experience,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Choline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,syndecan 2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Selenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tumor Antigens,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Recreation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Angiogenesis,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Minipill,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiotensin-Converting Enzyme Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ablation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Detection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Energy Metabolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Aromatase Inhibitors,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Diseases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Sentinel Lymph Node Biopsy,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,8q24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Angiotensin-Converting Enzyme Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hydroxyestrones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Iron,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Antagonists,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IGFBP3 gene|IGFBP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RHOC gene|RHOC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Promoter Regions (Genetics),Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,DDT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Berries,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Peptidyl-Dipeptidase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Malignant Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,binge drinking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,17q12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antidepressive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fiber,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mammary tumor virus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"KLK15 protein, human|KLK15",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,response,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IL6 gene|IL6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Positron-Emission Tomography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRLR gene|PRLR|PTP4A3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LOC118430 gene,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FCER1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Endometrial Carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Exploration procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SHC1 gene|SHC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Free Radicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormone Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ELF3 gene|ELF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Fatty Acids, Saturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pesticides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stearoyl-CoA Desaturase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antidepressive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Recombinant Erythropoietin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prolactin Receptor|PRLR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,capecitabine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tocotrienols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BMP7 gene|BMP7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Complication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Low Dose Radiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,hemiplegia; ascending,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HPR gene|HPR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MUTYH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,soy protein isolate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine Disruptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beta-carotene intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pulse vegetables,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,claudin 6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,soy protein isolate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tretinoin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epirubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UQCRFS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pterostilbene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Folic Acid Deficiency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Duffy blood group phenotype,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Asthma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"NUP214 protein, human|NUP214",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCNE1 gene|CCNE1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sleep disturbances,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,argatroban,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Genes,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,taxane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,retinoic acid receptor beta 2,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Osteoporosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CLOCK gene|CLOCK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogene Proteins c-akt|AKT1,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,HERC4,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,responsibility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pulmonary complications,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,[X]Unspecified osteoporosis with pathological fracture,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mRNA Expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RHOA gene|RHOA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,OSU 03012,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fine needle aspiration biopsy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Methylenetetrahydrofolate reductase (NADPH)|MTHFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low glycemic index food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to In vitro fertilization,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ovarian cancer prevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Abdominal obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine therapy,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Transforming Growth Factor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Insulin-Like Growth Factor I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dimethyl Sulfoxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HGS gene|HGS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,research outcome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,hypercholesterolemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tomatoes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gross' disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mucin 1 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metastatic malignant neoplasm to brain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ductal Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,abnormal glucose tolerance test,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Functional RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ID1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Interstitial Collagenase|MMP1,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APOBEC3A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PPARG gene|PPARG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LOX gene|LOX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Human papilloma virus infection,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,3' Untranslated Regions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SULT1A1|SULT1A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast size,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FTO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cyclooxygenase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C-reactive protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TNF gene|TNF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinoembryonic Antigen|CEACAM5|CEACAM3|PSG2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast size,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Underweight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 Mutation,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,Adiponectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNF8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STN gene|EEF1A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Depressive disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ascorbic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Botanicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLF4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Weight fluctuates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carboplatin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Equine laminitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Thyroid dysfunction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NMU gene|NMU,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GAL3ST1|SLC35A1|CASZ1|CST12P,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diethylhexyl Phthalate,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypoxia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lymphedema,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Motion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTGS2 gene|PTGS2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,breast cancer diagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,tibolone,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Pharmacotherapy,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,"RNA, circular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Seizures,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Bendroflumethiazide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FLII,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,aurora kinase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Insulin|INS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KIF4A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ultrasonography,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Peanut butter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Strenuous Exercise,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diffuse Scleroderma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Symptoms,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Diet,Breast cancer recurrent,Behavioral Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,Metastasis Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Gastrin|GAST,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TLR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oral contraception,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypersensitivity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Organochlorine pesticide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Reduction mammaplasty,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Nephroblastoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Excision,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pork,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Transforming Growth Factor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary Fiber,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCND1 gene|CCND1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Zn-alpha-2-glycoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epithelial hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nuclear Hormone Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,resistin|RETN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Curcumin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vegetables,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Reflexology,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Inflammation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,vinorelbine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Willing,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S100A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KISS1 gene|KISS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protein Subunits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,MAP Kinase Kinase Kinase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CHD5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,zoledronic acid,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Caffeine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Tomography, Emission-Computed",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TWIST2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclophosphamide/fluorouracil/methotrexate protocol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Metals, Heavy",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,XRCC6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammography,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Migraine Disorders,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Histopathology,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRLR gene|PRLR|PTP4A3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgen Receptor|AR,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,"Diet, Mediterranean",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HIF1A gene|HIF1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fish intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,feral,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,5-Alpha reductase inhibitor,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Follistatin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Inflammatory Response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TGFB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Engine Exhaust,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dioxygenases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptor, Angiotensin, Type 1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclooxygenase 2,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Mass Screening,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microsatellite Repeats,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Sentinel Lymph Node Biopsy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,"Antidepressive Agents, Tricyclic",Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chinese cabbage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oncogene Proteins,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,anastrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Screening mammography,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Vitamins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Environmental Tobacco Smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mullerian-inhibiting hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,XRCC1 gene|XRCC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Defense Mechanisms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Expressed Sequence Tags,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Dissection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Red meat intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Skin necrosis,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,SOX10,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,XRCC2 gene|XRCC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Autoantibodies,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Dinoprostone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogens,Noninfiltrating Intraductal Carcinoma,Hormonal Factors,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,DNA Repair Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Non-Invasive Lesion,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PREDICTED,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,trastuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitality,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KMT5A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Blood hormone levels,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bicalutamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,oleuropein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ALKBH3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chemopreventive Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant Neoplasms,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cytochrome P-450 CYP1A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Progesterone,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Lesion,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Polymorphism, Genetic",Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GH1 gene|GH1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Untranslated Regions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Virus Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epidermal Growth Factor Receptor|EGFR,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Angiogenesis Factor,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SLC45A2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,25-hydroxyvitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sulfotransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA topoisomerase II alpha|TOP2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RHBDD1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gelatinase B|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN150 gene|MIR150,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,tibolone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adenosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Discrepancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Needle biopsy procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin-Dependent Kinase 10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of lung,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Medroxyprogesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,exemestane,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Invasive Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hot flushes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP2D6 gene|CYP2D6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GGT1|GGTLC5P|GGTLC3|GGT2|GGTLC4P,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Polychlorinated Biphenyls,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cyclin D3|CCND3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hormone Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Serotonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMAD3 gene|SMAD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USP11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ethanol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IRF4 gene|IRF4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Composition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Resonance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MAP2K3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP2D6 gene|CYP2D6,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,CXCR4 gene|CXCR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA Repair,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,P-Cadherin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Doxorubicin Hydrochloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,QUINTILE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mass of body structure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnostic radiologic examination,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Calcium Channel Blockers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Strenuous Exercise,Breast cancer invasive NOS,Behavioral Factors,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Environmental Estrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,receptor activator of NF-kappaB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Exposure to,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,collapsin response mediator protein-2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin D Deficiency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,equol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTT1 gene|GSTT1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cyclophosphamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin A intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hydroxymethylglutaryl-CoA Reductase Inhibitors,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Sentinel Lymph Node Biopsy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Red breast,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,endogenous steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Iron, Dietary",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hetastarch,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,White bread,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endometrial Hyperplasia,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,"1,4-dioxin",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lasofoxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"1,4-dioxin",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Noninfiltrating Intraductal Carcinoma,"Carcinoma, Ductal, Breast",Other,0.0692,0.0029970029970029,Female Breast Cancer
PREDISPOSES,XRCC3 gene|XRCC3,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MTA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Human Development,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,G-T mismatch-binding protein|MSH6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCL1 gene|CCL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STAT3 gene|STAT3,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,retinoic acid receptor beta 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ID2 gene|ID2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cullin 1|CUL1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ERBB2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,IARS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proteasome inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Functional RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genetic Markers,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic inflammatory disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DSCAM-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ORALIT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S100A7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PIK3CA gene|PIK3CA,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Trans Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Protein phosphatase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Trans Fats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Corticosterone,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tryptophan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,K-ras Oncogene|KRAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-8,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,DNA Sequence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GTP-Binding Protein alpha Subunits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TBX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HOXC6 gene|HOXC6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Body mass index procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Peptide Nucleic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,anastrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DANCR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Growth Hormone Receptor|GHR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Urokinase|PLAU|PRAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogene Proteins c-myc|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CYP1B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,survivin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primary idiopathic dilated cardiomyopathy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polysaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNORA7B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NanoGel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Positive Lymph Node,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Small Inducible Cytokine A18|CCL18,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,BRCA2 Mutation,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Serum Proteins,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Physiological stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anisotropy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,STAR gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Exons,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Genes, ras",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RPE65|UVRAG|TP63|CKAP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MAFG gene|MAFG,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TWIST1 gene|TWIST1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Self-Examination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARVA gene|PARVA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CBFB gene|CBFB|NFYA|NFYB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP1B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Arachidonic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Plant Preparations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Parabens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00968,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,leukemia,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Gastric Inhibitory Polypeptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tic disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biopsy,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,"RNA, Untranslated",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,CYP1B1,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,PLK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GALNT16,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease susceptibility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"CHEK2 protein, human|CHEK2",Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,taxane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Red meat,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Digital mammography,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,LINC00460,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CUL4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,honokiol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DNA Repair,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epstein-Barr Virus Infections,Breast Carcinoma,Herpetic Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TUFT1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Insulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glucocorticoid Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Cell Invasion,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Malignant neoplasm of lung,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SCUBE2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Anthracycline Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,trastuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"N',N''-diacetylspermine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aromatase|CYP19A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Receptors, Steroid",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Leptin|LEP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gelatinase A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Medication use,Carcinoma in situ of breast,Pharmacological Factors,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Vascular Endothelial Growth Factor Receptor-2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Electromagnetic Energy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Coffee,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NCAPD2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Radiotherapy, Adjuvant",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ginsenoside M1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Metformin hydrochloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Spermine Synthase|SMS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Gonadal Steroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hip circumference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PCB 180,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIRN34A gene|MIR34A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,silybin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM5B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ascorbic Acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Flavonoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,activated RNA polymerase II transcription cofactor 4|IFRD1|KRT6B|SUB1|PCSK4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methyl-CpG-Binding Protein 2|MECP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Androgen Receptor|AR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prognosis good,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Combined Modality Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sulforafan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRNCR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RHOA gene|RHOA,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,everolimus,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Functional assessment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR99A gene|MIR99A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stable weight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,27-hydroxycholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ATP8A2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,YAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CELF6 gene|CELF6,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Menstruation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Mitogen-Activated Protein Kinase 3|MAPK3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CGRRF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZMYND10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DNMT3B gene|DNMT3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNAs,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,RNA metabolic process,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Chemotherapy Regimen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dense breasts NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vascular Endothelial Growth Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low absolute lymphocyte count,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bilateral Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Paralogous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PAK6 gene|PAK6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00173 gene|LINC00173,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Angiogenic Process,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Positron Emission Tomography and Magnetic Resonance Imaging,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,clinical aspects,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,claudin 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypertriglyceridemic Waist,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PDZRN4 gene|PDZRN4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MK 2206,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,BRD7 gene|BRD7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM1A gene|KDM1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR451A gene|MIR451A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,LINC00993 gene|LINC00993,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,JAG1 gene|JAG1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"Leukemia Virus, Bovine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53 gene|TP53,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Breast-Conserving Surgery,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Menopause Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SFRP2 gene|SFRP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Exogenous Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Reproductive History,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Histamine H1 Antagonists,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,FNDC5 gene|FNDC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Family history,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CNN1 gene|CNN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,beta catenin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,citronellol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,osteopontin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOXK1 gene|FOXK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Variation (Genetics),Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,RNA Sequence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ITK protein, human|ITK",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ATP Binding Cassette Transporter, Sub-Family G, Member 2|ABCG2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Proteins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GSTM1 gene|GSTM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor size,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,sulforafan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Motifs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Mirn124a microRNA, human",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,SDHC gene|SDHC,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Vaccines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypersensitivity,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Gene Mutant,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,TFCP2 gene|TFCP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RWDD4 gene|RWDD4,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Discordance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Calcium-Sensing Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,tissue-factor-pathway inhibitor 2|TFPI2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,neoplasm-associated factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Escape,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High Level,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Signs and Symptoms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Subjective:Finding:Point in time:^Patient:Narrative,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOX10 gene|SOX10,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Aggressive behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Muscle Strength,Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,"MET protein, human",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CDYL2 gene|CDYL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Quintile,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FGFR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carotenoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinase 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stiffness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CBLB gene|CBLB|MMAB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic Breast Density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NES gene|NES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ribonucleotide reductase M2|RRM2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRDMT1 gene|TRDMT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical Inactivity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,brown adipose tissue uncoupling protein,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,daunorubicin liposomal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Suppressor Genes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bisphenol A,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Pharmacotherapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Aromatase Inhibitors,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TMPO-AS1 gene|TMPO-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,huaier,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Flavonoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prune Belly Syndrome,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Human Class I Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased risk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NUDT21 gene|NUDT21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,concise,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,NEK10 gene|NEK10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GPER1 gene|GPER1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,letrozole,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,YES1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CCL8 gene|CCL8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polygene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RUNX1,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Carbohydrate intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplastic Cell Transformation,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MCM3AP-AS1 gene|MCM3AP-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,interleukin-10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pathologic Response,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,antiporter,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,ELAVL2 gene|ELAVL2,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Genes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Neuropilin-1|NRP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Finding of body mass index,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fumigant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin B1|CCNB1,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,RNA Sequence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,calycopterin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,arctigenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrin fragment D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,pristimerin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"CD69 protein, human|CD69",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sedentary lifestyle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,kusunokinin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DAPK1 gene|DAPK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Late Relapse,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,risk factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FGFBP1 gene|FGFBP1,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,ZEB1 gene|ZEB1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TNF wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Puberty,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RIOK1 gene|RIOK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,magnesium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasms,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,IMPACT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,ergocalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD69 protein, human|CD69",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,naringenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Flavanones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metastatic malignant neoplasm to brain,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"RNA, Messenger",Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
CAUSES,wogonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BCL11A gene|BCL11A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcript,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,podofilox,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ERR1 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LIMK2 gene|LIMK2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Antimalarials,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MLF2 gene|MLF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MALAT1 gene|MALAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor size,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,sunitinib,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Hyperthyroidism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AMH gene|AMH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ACVR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Androgen Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CKLF gene|CKLF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Screening procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRKN gene|PRKN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,baicalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,simvastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Anti-Mullerian Hormone Receptor Type II, Human|AMHR2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Excessive dietary caloric intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genetic Polymorphism,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNAI1 gene|SNAI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADIPOR1 gene|ADIPOR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fibroblast Growth Factor Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APOBEC3B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Protein, Organized by Structure",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenic Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,tamoxifen,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Organophosphate pesticides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HER-2 protein|ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,water,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Response Modifiers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dna genetics,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"DNM1L protein, human|DNM1L",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GSTP1P1 gene|GSTP1P1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FANCM gene|FANCM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SNAI2 gene|SNAI2,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Sodium-Glucose Transporter 2 Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZFPM2-AS1 gene|ZFPM2-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BBOX1 gene|BBOX1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Uptake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Conventional Treatment,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant",Carcinoma breast stage I,Other,0.0,0.0,Female Breast Cancer
CAUSES,Injection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oils,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,TP53 gene|TP53,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,SERPINE1 gene|SERPINE1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,RASAL2 gene|RASAL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00922 gene|LINC00922,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,c-Mer Tyrosine Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Moderate risk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Processed meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,estrogens,Triple Negative Breast Neoplasms,Hormonal Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,HMGB1 gene|HMGB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"PDIA3 protein, human|PDIA3",Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,MIR30E gene|MIR30E,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor beta,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,MTOR gene|MTOR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score C,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RSPO3 Gene|RSPO3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Present,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,A2M-AS1 gene|A2M-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Progranulins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Thymidylate Synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SALL4 gene|SALL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Anthracyclines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KCNQ1OT1 gene|KCNQ1OT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,METTL14 gene|METTL14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoxia-Inducible Factor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cryptotanshinone,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,estrogen receptor-positive breast cancer,Other,0.3988,0.0089910089910089,Female Breast Cancer
AFFECTS,TUG1 gene|TUG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Neural Networks,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,mortalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Zearalenone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alternative Splicing,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,resistin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,bisphenol A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCAT7 gene|PCAT7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lamin B2,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,High Level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC01271 gene|LINC01271,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Elasticity Imaging Techniques,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"RNA, Untranslated",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Magnetic Resonance Imaging,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,hereditary factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTEN gene|PTEN,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,UBE3C gene|UBE3C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"IL2RB protein, human|IL2RB",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZNF670-ZNF695 gene|ZNF670-ZNF695,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATM gene|ATM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Risk Scores,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,OXER1 gene|OXER1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FBXO22 gene|FBXO22,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,selenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Uncertainty,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mullerian-inhibiting hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TINCR gene|TINCR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00665 gene|LINC00665,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bilateral mastectomy,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Pharmacotherapy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,iron,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Tumor Promotion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UCHL1 gene|UCHL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lactates,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,AGAP2-AS1 gene|AGAP2-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Psychosocial Intervention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Immune Checkpoint Blockade,Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SDHC gene|SDHC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MBD2 gene|MBD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Adiponectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Obesity, Abdominal",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leisure physical activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC01271 gene|LINC01271,malignant neoplasm of breast staging,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,calcium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,leptin receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Nutrients,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Calcium intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoxia,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,TP53 gene|TP53,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RNA, Circular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metric (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FZD2 gene|FZD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,gambogic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,"Breast Cancer, Familial",Other,0.3988,0.0,Female Breast Cancer
AFFECTS,hydroxyl group,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary Neoplasm,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CPT1A gene|CPT1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,calmodulin-dependent protein kinase III,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SENP3 gene|SENP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,elaidic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CDKN1A protein, human|CDKN1A",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATM gene|ATM,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Heterogeneous-Nuclear Ribonucleoprotein K,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,O(6)-Methylguanine-DNA Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ovarian failure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYTOR gene|CYTOR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunologic Surveillance,estrogen receptor-positive breast cancer,Immunological Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,COVID-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Inhibitor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Tumor Microenvironment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LRRC3B gene|LRRC3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,recreational activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hypoxia-Inducible Factor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Zinostatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Systemic Inflammatory Response Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ropivacaine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NF-kappa B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Body mass index procedure,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
AFFECTS,"PLK1 protein, human|PLK1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Prognostic Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FBXO32 gene|FBXO32,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ELF5 gene|ELF5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ENTPD1 wt Allele|ENTPD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDK15 gene|CDK15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcription Coactivator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Neoantigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adrenergic beta-Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ropivacaine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FADS1 gene|FADS1,Recurrent Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Recurrent Breast Cancer
DISRUPTS,hyaluronic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fetal valproate syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DPP6 gene|DPP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TWIST1 gene|TWIST1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Intronic Mutation,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,PADI1 gene|PADI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR599 gene|MIR599,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FANCA gene|FANCA,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,LOC100505851,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR638 gene|MIR638,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LOC105371267,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinoembryonic Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,receptor operated channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Graphene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hydroxymethylglutaryl-CoA reductase,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Thrombophilia,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,vitamin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ARHGAP1 gene|ARHGAP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WNT9B gene|WNT9B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VGLL1 gene|VGLL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Collagen Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR21 gene|MIR21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HAGLR gene|HAGLR,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,cytotoxicity,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,KIF23 gene|KIF23,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Consideration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"herstatin protein, human",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Xenograft procedure,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,CDKN2B-AS1 gene|CDKN2B-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,medication risk,Malignant neoplasm of breast,Pharmacological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Full Term Birth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,VCAN-AS1 gene|VCAN-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC01094 gene|LINC01094,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cerebrovascular accident,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,epithelial to mesenchymal transition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL27 gene|MYDGF|IL27,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Metals, Heavy",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hepatocyte Nuclear Factor 3-alpha|FOXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GLUT-1 protein,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,LINC01315 gene|LINC01315,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adhesions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coronary Arteriosclerosis,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,"Drug Resistance, Neoplasm",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,NEIL2 gene|NEIL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ursolic acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,bone morphogenetic protein 4|BMP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZBTB7A|AKIRIN2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnosis,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,fluorouracil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,LINC00922 gene|LINC00922,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cytokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,baicalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carbohydrates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stress,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HOXC10 gene|HOXC10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,New medications,Malignant neoplasm of breast,Pharmacological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcript,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"EIF4EL3 protein, human|EIF4E2",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"herstatin protein, human",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,"RNA, Small Interfering",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Mucin-1 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Problem,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MICAL2 gene|MICAL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TLR1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Endoplasmic Reticulum Stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,COVID-19,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,EHD1 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Fiber intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HSPA9 gene|HSPA9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,New Diagnosis Procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ergocalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,high weight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,2-(4-morpholinoanilino)-6-cyclohexylaminopurine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,High residue diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RBM38 gene|RBM38,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"herstatin protein, human",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Lactation established in non-human animal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDC20 gene|CDC20,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,granzyme B,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prieto X-linked mental retardation syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NFIL3 gene|NFIL3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,KRT19P3 gene|KRT19P3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PTEN gene|PTEN,Ductal Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Pathologic Complete Response,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"LATS1 protein, human|LATS1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CARD.RISK,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,"Genes, cdc",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,omega-3 fatty acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,liquiritigenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Autophagy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Vital activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,oxaliplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADRB2 gene|ADRB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"EZH2 protein, human|EZH2",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Antibody Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Agonist,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,hydrogen peroxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Obesity, Visceral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ultrasound scan finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SRP9 gene|SRP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tramadol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HTR1A gene|HTR1A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,LINC00466 gene|LINC00466,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,OPRM1 gene|OPRM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLK3 gene|KLK3,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,DDT (Insecticide),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Life Expectancy Less than Five Years,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARHGAP17 gene|ARHGAP17,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Duration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,tegaserod maleate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NEAT1 gene|NEAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Nutrients,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Sports,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoxia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Screening mammography,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Migraine Disorders,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,physiological aspects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NEDD4L gene|NEDD4L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR210HG gene|MIR210HG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD31 Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mRNA Expression,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,G-Protein-Coupled Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRIP13 gene|TRIP13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Keratin-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cisplatin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,RAB8A gene|RAB8A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PSAT1 gene|PSAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCR2 gene|CCR2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,RAB8A gene|RAB8A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epithelial ovarian cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SREBF1 gene|SREBF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Score,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolism,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Has difficulty doing (qualifier value),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"tropomyosin-related kinase-B, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,iron,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pediatric Obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCAPD2 gene|NCAPD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hyperactive behavior,Secondary malignant neoplasm of breast,Behavioral Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Players,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Endoplasmic Reticulum Stress,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,purinoceptor P2X4|P2RX4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Manipulation procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD274 protein, human|CD274",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GTSE1 gene|GTSE1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Field Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypersensitivity,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Human B-Lymphocyte Antigen CD20, human|MS4A1|KRT20",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,anhydroicaritin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical function,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Breast Self-Examination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC01287 gene|LINC01287,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Adipokines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Frailty,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Dietary Habits,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptor, PAR-1",Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,dietary fiber intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diabetes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATAD2B gene|ATAD2B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,FOXD3-AS1 gene|FOXD3-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Triglycerides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Post-mastectomy radiotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DDX21 gene|DDX21,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"protein TDP-43, human",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,si-wu-tang,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Comorbidity,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,folic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,benzene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydrogen Sulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,2-mercaptoethanesulfonic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gamma-Secretase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PSME2 gene|PSME2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ergocalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Helicobacter pylori,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,SCG2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Carcinogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZNHIT1 gene|ZNHIT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,GUSBP11 gene|GUSBP11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CUEDC2 gene|CUEDC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNA Recognition Motif,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TP53,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Florid red complexion (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Orthologous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CD47,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Aurora Kinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,intrinsic factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Claudins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PON1 gene|PON1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Eosinum, eosin, Homeopathic preparation",malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Androgen Binding Protein|SHBG|CCHCR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Sleep,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,catalpol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic Breast Density,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,Peptides,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Lymphatic Metastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Saturated fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00520 gene|LINC00520,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"RNA, Untranslated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,High grade serous carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PIK3CA Gene Mutation,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,TRANSCRIPTION FACTOR,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Rich food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RNA, Long Untranslated",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Colorectal Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antibody-Drug Conjugates,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogens,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,BVES gene|BVES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Diet, Paleolithic",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cardiac event,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Inhibitor,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,SLC1A5 gene|SLC1A5,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Parabens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,adenosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pharmaceutical Preparations,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,BRCA2 gene|BRCA2,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,SPATA25 gene|SPATA25,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metric (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pigment epithelium-derived factor,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,Intercellular adhesion molecule 1|ICAM1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,IGHG1 gene|IGHG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,agonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Screening procedure,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,GAS5 gene|GAS5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DDX11-AS1 gene|DDX11-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cerulenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Life Expectancy Less than Five Years,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,FTO gene|FTO,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Receptors, Progesterone",Advanced breast cancer diagnosis,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,arsenic trioxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Liposomes,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Diagnosis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"RAF Proto-Oncogene Serine/Threonine-Protein Kinase, human|RAF1",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Provisional,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,metformin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,tiliroside,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Programmed cell death ligand 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transection (procedure),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Drugs, Non-Prescription",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hypoxia Inducible Factor Family,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SMURF1 gene|SMURF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,genistein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,insulin-like growth factor 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,choline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Catechols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Microcalcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,methionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GNAO1 gene|GNAO1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,CCND1 gene|CCND1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,AXL,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,FOXO1 gene|FOXO1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,CCN1 gene|CCNA2|CYR61|PPP3CA,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Metabolic marker,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Transcription Factor AP-2 Beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIRT1 gene|SIRT1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,DANCR gene|DANCR,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Tumor Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,malignant disease,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,IGF2BP1 gene|IGF2BP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Pharmaceutical Preparations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"High Mobility Group Protein HMG-I, Human|HMGA1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta-arrestin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AKTIP gene|AKTIP,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Prolactin Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,green tea extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drug resistance,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,eriocalyxin B,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,HULC gene|HULC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USP13 gene|USP13,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,NLRP3 gene|NLRP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PHB2 gene|PHB2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,dietary fat intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Senility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,toosendanin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,VDR gene|VDR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Amino Sugars,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Meal (occasion for eating),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lactates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,clinical aspects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,eltrombopag,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,TTC17 gene|TTC17,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Atrial Fibrillation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Exogenous hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Amino Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,factor VII,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PKMYT1 gene|PKMYT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Specific antibody,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"DICER1 protein, human|DICER1",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,NUMB gene|NUMB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,COG2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ultrasonography,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Salpingo-oophorectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Microenvironment,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Sleep duration:Time:Pt:^Patient:Qn,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ursolic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hydroxy Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"SDHD protein, human|SDHD",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immune checkpoint inhibitor therapy,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lactates,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,"CTSH protein, human|CTSH",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Immune Checkpoint Proteins,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TYMS|PYCARD,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,CDK1 gene|CDK1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Epithelial proliferation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibronectins,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,COPS6 gene|COPS6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Life Expectancy Less than Ten Years,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KIF2C gene|KIF2C,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Severe (severity modifier),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIR326 gene|MIR326,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"HMGA2 protein, human|HMGA2",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,RNA-Binding Protein Musashi Homolog 1,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Non-Small Cell Lung Carcinoma,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,arsenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IPO7 gene|IPO7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ROR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Peripheral Nerve Sheath Neoplasm,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"TNF protein, human|TNF",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RNA-Binding Protein Musashi Homolog 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Peptides,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Biological Markers,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,PPP1R14B-AS1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,doxorubicin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,RNA-Binding Protein Musashi Homolog 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXP3 gene|FOXP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GATA3 gene|GATA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,palbociclib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 Gene Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Inflammasomes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,leptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,zinc,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HIPK3 gene|HIPK3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pre-miRNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metabolite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,alpha Catenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,YOD1 gene|YOD1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Obesity,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,SMYD2 gene|SMYD2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Cell Growth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TUSC2 gene|TUSC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GPX4 gene|GPX4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Circulating Tumor DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,interleukin-6,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,AURKA gene|AURKA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"CREB1 protein, human|CREB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cervical Cancer Screening,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protons,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ascorbic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Performance,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,zoledronate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Caspase-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,astragaloside IV,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mammaglobin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TMED2 gene|TMED2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary Neoplasm,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,HASPIN gene|HASPIN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Ferritin Light Chain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG14 gene|SNHG14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lymphatic Invasion,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Allele-Specific Oligonucleotide,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,beta catenin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,NR1D1 gene|NR1D1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mitosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,risk factors,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,estrogens,estrogen receptor-positive breast cancer,Hormonal Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,euphorbia factor L1,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,ketamine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXO3 gene|FOXO3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,andrographolide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NEK2 gene|NEK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Flavonoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pharmacologic Substance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,signaling cascade,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Phosphates,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,PAXX gene|PAXX,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Obesity,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Sesquiterpenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Colorectal Carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PIN1 gene|PIN1,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Trace Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FMO4 gene|FMO4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibroblast Growth Factor Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vacuum assisted biopsy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR223 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,taxane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inhibitor,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,hydroxypropylbetadex (0.58-0.68 MS),Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"POSTN protein, human|POSTN",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,TWIST1 gene|TWIST1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,chelidonine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Homologous Recombination Repair Gene,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,YBX1 gene|YBX1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Plasma Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,raloxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FBXO3 gene|FBXO3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Precision Medicine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,American College of Cardiology/American Heart Association Lesion Complexity Score A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chlordan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Shift worker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Stress, Psychological",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MTDH gene|MTDH,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,calcifediol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low Level,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,c-src Genes|SRC,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,HSP90 Inhibitor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Psychotic Disorders,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Ubiquitin-Conjugating Enzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Equilibrium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TIPARP gene|TIPARP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proliferative vitreoretinopathy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Complementary therapies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RAD51 gene|RAD51,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Duration,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,GALNT7 gene|GALNT7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MELK gene|MELK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leukotriene B4 Receptors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,GRB2 gene|GRB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LIAS gene|LIAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HER2/Neu Positive,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,SNORD16 gene|SNORD16,Early-Stage Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,clinical aspects,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,FBXO8 gene|FBXO8,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Fertility Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,icariin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Receptor Protein-Tyrosine Kinases,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,cadmium chloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oxidoreductase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ECM1 gene|ECM1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,SNHG1 gene|SNHG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Personal status - Adopted,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ORF74 protein, Human herpesvirus 8",Triple Negative Breast Neoplasms,Herpetic Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Tea Extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ubiquitin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNORD49B gene|SNORD49B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Healthy Lifestyle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,YAP1 gene|YAP1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"herstatin protein, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Clinical Significance,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,HOTAIR gene|HOTAIR,malignant neoplasm of breast staging,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Secondary Neoplasm,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Reactive Oxygen Species,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"ATP8A2 protein, human|ATP8A2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Menarche,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ABCB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alzheimer's Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pathogenic Variant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alzheimer's Disease,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Performance,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Obesity,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,UGT2B7 gene|UGT2B7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HIF1A gene|HIF1A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,O(6)-Methylguanine-DNA Methyltransferase|MGMT,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,baicalein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Biological Processes,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,GCKR gene|GCKR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PDP1 gene|PDP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Family,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FSCN1 gene|FSCN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,thiostrepton,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Hereditary Breast and Ovarian Cancer Syndrome,Other,0.0,0.0,Female Breast Cancer
AFFECTS,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CDK7 protein, human|CDK7",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NODAL gene,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,"Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6, human|CEACAM6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progranulins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Uridine Diphosphate Glucose Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Personal Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oligoribonucleotides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nitric Oxide Synthase Type II,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,FAS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TCF7L2 gene|TCF7L2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCOA1 gene|NCOA1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MLH1 gene|MLH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Motility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"GMNN protein, human|GMNN",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PAK1|PKN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methotrexate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Adenosine A1 Receptor|ADORA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aromatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammary Neoplasms,Carcinoma in situ of breast,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LSP1 gene|LSP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,indole-3-carbinol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TNFSF6 gene|FASLG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prevention,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,bortezomib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NME1 gene|NME1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Amyloid beta-Protein Precursor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,survivin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Connexins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Compound V,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bacterial Endocarditis,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,activating transcription factor 3|ATF3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Immune Cell Activation,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD47 gene|CD47,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Interleukin-17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MMP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,bone morphogenetic protein 6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AR gene|AR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NTRK2 gene|NTRK2,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,PITPNM1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IGKC gene|IGKC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CIP2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mammaglobin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BST2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin B6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor beta|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to genetic counseling,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,ethnic differences,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BMP2 gene|BMP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Free Radicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TNF protein, human|TNF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen receptor positive,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mullerian-inhibiting hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antineoplastic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Catenins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MYC gene|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genes, cdc",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,nitidine chloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"DNA, Mitochondrial",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BIRC4 gene|XIAP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Contraceptive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MC4R gene|MC4R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KIFC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Syndrome,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,PSMB6|YY1|DLL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNA-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cilostazol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FOXM1 gene|FOXM1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PAWR gene|PAWR,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,UBE2N,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,STMN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IQGAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,profilin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KISS1R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neuromedin U|NMU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mullerian-inhibiting substance receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor alpha|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR98,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CENPA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,isoliquiritigenin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Hormone Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Centchroman,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,MIRN21 gene|MIR21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RASAL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estradiol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ERBB2IP gene|ERBIN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RARRES3 gene|RARRES3,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Adenocarcinoma of large intestine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,dihydroxyacetone sulfate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,PALB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"RNA, Messenger",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leisure Time,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EPSTI1 gene|EPSTI1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Prodrugs,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NRIP1 gene|NRIP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,platelet-derived growth factor C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TIMP1 protein, human|TIMP1",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Estriol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclophosphamide,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Diethylstilbestrol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to genetic counseling,Contralateral breast cancer,Genetic Factors,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Thymidylate Synthase,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,APC gene|APC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin D1|CCND1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Urokinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,cyclooxygenase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast cancer invasive NOS,Malignant neoplasm of breast,Other,0.0587,0.3386613386613387,Female Breast Cancer
DISRUPTS,Orosomucoid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CTCF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TLR4 gene|TLR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sialoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Trace Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEK1 gene|CHEK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Organic Chemicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Leptin|LEP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XRCC4 gene|XRCC4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phosphotransferases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,estrone sulfate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glutamate Carboxypeptidase II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDH1 gene|CDH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KISS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"HGF protein, human|HGF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STAT5B gene|STAT5B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,transcription cofactor activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLF5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Supraventricular arrhythmia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Wiskott-Aldrich Syndrome Protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins c-sis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CA-125 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PFN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sodium Selenite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GRHL3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epigenetic Process,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Glutamic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,1-Phosphatidylinositol 4-Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Receptors, Tumor Necrosis Factor, Type II",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PELP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOX11,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Interleukin 4 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CMA1|SLC16A1|MCAT|MCTS1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Isoflavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polysaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,gamma-secretase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carboxypeptidase U,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atrial Fibrillation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Cancer of Rectum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TNFSF10 gene|TNFSF10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epstein-Barr virus antibody,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TSG101 gene|TSG101,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Neoplasm,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Epinephrine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Reserpine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Castration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIRN17 gene|MIR17,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"SHC1 protein, human|SHC1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,In complete remission,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aspartic Endopeptidases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Reproduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Up-Regulation (Physiology),Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,chromosome 17q,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Milk intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chronic inflammation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Caseins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Menstrual cycle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Androgens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Reserpine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,SRC gene|SRC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,OLFM4 gene|OLFM4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Circadian Rhythms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Virus,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,retinol acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Selenium intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vinyl Chloride,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,N-acetyltransferase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,retinyl methyl ether,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 gene|BRCA2,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Interleukin-13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,inhibitors,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Exogenous hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,calcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GPER1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RARB protein, human|RARB",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LEPR gene|LEPR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xeroradiography,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Bread,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,leptin receptor|LEP,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Exogenous hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cyclin E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogens,Breast cancer metastatic,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"CST6 protein, human|CST6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Metabolites,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Fatty Acids, Essential",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Puberty, Female",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vitamin D3 Receptor|VDR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,pyrrolidino-4-iodotamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcriptional Activation,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,valyl-valyl-valine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infusion procedures,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,20q13.2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Proto-Oncogene Proteins c-akt|AKT1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LOX,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Somatotropin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Progesterone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Fibroblast Growth Factor 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BONE MASS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Urokinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,No past history,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Candidate Disease Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Molecular Abnormality,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Indoles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estradiol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Immunotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Involution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cadherins,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Biopsy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Retroviridae,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Enzymes,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,EYA2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pill,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,neu Differentiation Factor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Reproductive History,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,parathyroid hormone-related protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hyaluronan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aromatic Amines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Dietary Fats,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,CA1|S100A10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Binding Sites,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Proto-Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Urea,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Melatonin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Fenretinide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Oncogene, HST|FGF4|HSF1",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Replacement Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Arginine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sterility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Benzanthracenes,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Absolute Alcohol,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Cytotoxic agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polyunsaturated fat intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Polyamines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,3-hydroxytamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PHENYL,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Termination of pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,adjuvant therapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Secondary malignant neoplasm of bone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,hormonal changes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fluorouracil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TAG 12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Term pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alkaline Phosphatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Breast Carcinoma,Malignant neoplasm of breast,Other,0.0166,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alkaline Phosphatase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Advance,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Athletics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EGF gene|EGF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Height / growth measure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ARGINASE,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Seizures,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Induction,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Malignant transformation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Thyroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tissue Polypeptide Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glycoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Malignant neoplasm of stomach,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Testicular Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammography,Breast Mucinous Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Haloperidol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hysterectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Medroxyprogesterone 17-Acetate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Ovariectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,v-H-ras Oncogenes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Prolactin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hair Dyes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neuromedin U|NMU,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
COMPLICATES,"Liver Failure, Acute",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Ovariectomy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Monoterpenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hydrocortisone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,melanoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Antagonists,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Neurotropism,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cystic Lesion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Contraction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Prostaglandins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,2-hydroxyestrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Hamartoma Syndrome, Multiple",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aminoglutethimide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antipyrine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Levamisole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,transglutaminase 1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hydrocortisone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PGR gene|PGR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Goserelin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Visual impairment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Scanning,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogenic,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Introns,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Flutamide,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CATHEPSIN D|CTSD,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,TP53 gene|TP53,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Dichlorodiphenyl Dichloroethylene,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Acetyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carrier of disorder,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,"(meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine)dichloroplatinum(II)",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mixture,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Human Chorionic Gonadotropin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Date of birth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Short stature,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin D1|CCND1,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Complex carbohydrate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SERPINB2 gene|SERPINB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Resonance Spectroscopy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTK2B gene|PTK2B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phenothiazines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,retinoic acid receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cyclic AMP Receptor Protein,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Maternal history,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vegetable Oils,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,6-pyruvoyltetrahydropterin synthase|SLC25A3|REG1A|PTPRU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Insulin-Like Growth-Factor-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Integrins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
COMPLICATES,Pathological fracture,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Enzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nulliparous,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mean blood pressure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,glypican 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Herpesvirus 4, Human",Breast Carcinoma,Herpetic Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,DNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"Smoking, Passive",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lhermitte-Duclos disease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BRCA2 gene|BRCA2,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CDKN2A gene|CDKN2A,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,NAT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overnutrition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcription Factor AP-2 Alpha|FABP4|GTF3A|TFAP2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SPO11 gene|SPO11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ultraviolet Rays,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GRB7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Premature Birth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Expression,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Mitogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Amplification,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,ras Oncogene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Invasive Carcinoma,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Fibroadenoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Receptors, Nuclear",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytochrome P450 3A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,estriol 3-sulfate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CHGA gene|CHGA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MDM2 gene|MDM2,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Vascular Endothelial Growth Factor Receptor-1|VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Disintegrins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NMU gene|NMU,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pre-Eclampsia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ovarian function,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogens,Breast Carcinoma,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Gross' disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Polycyclic Hydrocarbons, Aromatic",Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Vitamin E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Endostatins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,glutathione S-transferase M1|CHRM1|MRLN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,bone sialoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adrenal carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Encounter due to prophylactic surgery, unspecified",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Scanning,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,psychological stressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Opioid Peptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRCA1 Protein|BRCA1,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Depo-Provera,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Stress, acute",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,3MC,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Breast cancer metastatic,Other,0.3988,0.0279720279720279,Female Breast Cancer
CAUSES,Chemopreventive Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epoxy Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methylcholanthrene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Ibuprofen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Beta Carotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ESRRA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2 gene|ERBB2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,specific immunity,Breast Carcinoma,Immunological Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Repressor Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radioimmunotherapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TIE gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thyroid Hormone Receptor Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HDAC1 gene|HDAC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Androgen Receptor|AR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ATM gene|ATM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gelatinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,XRCC2 gene|XRCC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Kininogenase|KLK4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EGFR gene|EGFR,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Substance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ZHX2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Sporadic Breast Carcinoma,Malignant neoplasm of breast,Other,0.0365,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oleic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GTPase-Activating Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CHEK2 gene|CHEK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Telomerase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,COMT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth-Factor-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Estrogens, Synthetic",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Guanosine Triphosphate Phosphohydrolases,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Apple,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Hydrocarbons, Chlorinated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,parathyroid hormone-related protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Female genital tract problem,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fatty food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Embolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CHEK2 gene|CHEK2,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Carcinoma of Male Breast,Malignant neoplasm of breast,Other,0.0253,0.3386613386613387,Female Breast Cancer
DISRUPTS,"SKIL protein, human|SKIL",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ADAM23,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"retinoic acid binding protein II, cellular",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CANADIAN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mass in breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Carcinoma, Lobular","Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Medroxyprogesterone 17-Acetate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Lignans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 Mutation,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,Prolactin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mammary Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BIRC5 gene|BIRC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Creatinine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mammary Tumorigenesis,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Hepatocyte Growth Factor|HGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"JARID1B protein, human|KDM5B",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Receptiveness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pregnancy hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Recreation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,peptide I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IGKV2D-40,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carbohydrates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of prostate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hexachlorobenzene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HFE gene|HFE,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Methylcholanthrene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single-Stranded Conformational Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Emotional support,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WNT7B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Synucleins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Conjugated Equine Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta-ionone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgen therapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,death receptor-4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Iodides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tumor Protein p53 Binding Protein 2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Paroxysmal atrial tachycardia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endocrine Disruptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogenic,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Hyperglycemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Carcinogens, Environmental",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Thrombospondin 1|THBS1|CRISP2|PRSS55,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Increase in blood pressure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Convenience food,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,AKR1C1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EVL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogens,Breast cancer invasive NOS,Hormonal Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,"Contraceptives, Oral",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Fibrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CHEST PATHOLOGY,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,CYP1A2 gene|CYP1A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transcription Initiation Site,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aggressive cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,connective tissue growth factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Dopamine Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WNT7B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cyclic Peptides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Spray,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,N-Cadherins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EGFR gene|EGFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HSP90 Heat-Shock Proteins|HSP90AA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dairy Products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLC25A18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcript,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Female Breast Carcinoma,Other,0.3988,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Climacteric discomfort,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Valine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microdochectomy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Molecular Chaperones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Trans Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Integrins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Diabetes, Gestational",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,intestinal bacteria,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prolactin level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm Metastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Suppressor Genes,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,ADRA1D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IRS1 gene|IRS1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pregnanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Valine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carbon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRL increased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Molecular Target,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTH gene|PTH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tocotrienols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biopsy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IGF1 gene|IGF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,E-Cadherin,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,allyl sulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP1B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tetanus Vaccine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Biological Models,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mouse Pancreatic Intraepithelial Neoplasia-1B,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"Estrogens, Catechol",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lymph Node Involvement,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Anti-Inflammatory Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Betaine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Platelet-Derived Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,gamma-Glutamyl Hydrolase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Integrins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Endocrine Disruptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD44 gene|CD44,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Matrix Metalloproteinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin B Complex,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,BRMS1 gene|BRMS1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Disclosure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,phospholipid-hydroperoxide glutathione peroxidase,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,alpha-Fetoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SIRT7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tea intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,CATHEPSIN D|CTSD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53 gene|TP53,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AUGMENTS,Metalloproteases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Diethylstilbestrol,Breast Carcinoma,Behavioral Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Coronary heart disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Serotonin Uptake Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Pesticides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Detectors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,XRCC1 gene|XRCC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Serine Protease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prolylarginine|ABL2|RERE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,Contralateral breast cancer,Genetic Factors,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Insulin|INS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cortisol level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 Protein|BRCA1,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,NEK3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,EGFR gene|EGFR,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Thrombospondin 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Aldosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anthracycline Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCNA2 gene|CCNA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer invasive NOS,Demographic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Estrogen Receptor beta|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Cell Invasion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,saturated fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NES gene|NES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRANSCRIPTION FACTOR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,NPY1R gene|NPY1R,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HGS gene|HGS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Ascorbic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FANCA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Actin bundling protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypermethylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oligonucleotides,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Metabolic syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PGR gene|PGR,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Cyproterone Acetate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Development of the breasts,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,PIN1,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Alpha tocopheryl succinate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Obesity,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,steroid hormone receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Guanosine Triphosphate Phosphohydrolases,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Alar,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANXA1 gene|ANXA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,estradiol-17 beta-glucuronide,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,NF1 gene|NF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, Notch",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ERBB2 gene|ERBB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Organic Anion Transport Polypeptides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nucleotides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polyomavirus Middle T Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thymidine Phosphorylase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Study models,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hyperthyroidism,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SLC25A4|CD5|IL1RL1|TRAPPC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CENPH gene|CENPH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erlotinib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,lapatinib,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Androgens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Carcinogens, Environmental",Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Telomerase,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,JAG2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,PARP1|COL11A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD27,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,"Estrogens, Catechol",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vanadium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer Treatment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SPN|DEAF1|PPP1R9B,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CLDN2 gene|CLDN2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Sex Behavior,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Antagonists,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TWSG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Enzyme variant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Development of the breasts,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,PIK3R1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CD24,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,dehydroepiandrosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Levonorgestrel,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,Epicatechin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vascular Endothelial Growth Factor C|VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SH3KBP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Double Strand Break Repair,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLC9A3R1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LEPR gene|LEPR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Mutagens,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Homeostasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESR1 gene|ESR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Migraine Disorders,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mastication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,2q35,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell physiology,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sphingosine-1-Phosphate Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nicotinic Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Insulin|INS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,8q24,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,src-Family Kinases|SRC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Microsatellite Repeats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased estrogen level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oxidation-Reduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNAs,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,B3GNT2|B3GNTL1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,FRAGMENTS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD44 gene|CD44,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,FOXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Elevated insulin-like growth factor I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,WWP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Calcium, Dietary",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,High Mobility Group Proteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Calgranulin B|S100A9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRAZILIAN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydroxide Ion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Angiotensin-Converting Enzyme Inhibitors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Adenosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAD51C gene|RAD51C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,6q22.33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NF-kappa B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,brightness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SPN|DEAF1|PPP1R9B,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,FHL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Leptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sodium Valproate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TOPBP1 Gene|TOPBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proteins,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,RPE65|UVRAG|TP63|CKAP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Somatomedins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epithelial to mesenchymal transition,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Enhancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phosphatidylethanolamine Binding Protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PTPN11 gene|PTPN11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cadherin 5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,METHYLATE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,1-Phosphatidylinositol 3-Kinase,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,soy protein isolate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SNAI2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,patient family history,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Tamoxifen,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Sirolimus (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNAs,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,Malignant neoplasm of cervix uteri,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"TNF protein, human|TNF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Cytoplasmic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MS4A1|BBS9|IGKV7-3|SPANXB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Very high,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paraffin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAB1B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PYRUVATE CARBOXYLASE|PC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Annexin A1|ANXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Integral Membrane Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Arthralgia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PIAS1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Chemotaxis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Lead compound,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,treatment method,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,betaine-homocysteine methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP4Z1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STAT3 gene|STAT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRICKLE1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transfer RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PROTEIN KINASE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Choline dehydrogenase|CHDH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-ras Genes|NRAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,saturated fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Extravasation,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IGF2BP2|IMMP2L|SPPL3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCG2 gene|ABCG2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,furanodiene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgen Receptor|AR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTEN gene|PTEN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,2q33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Tumor Necrosis Factor Receptor Superfamily, Member 10B",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,Other,0.0692,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vascular Cell Adhesion Molecule-1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,OTUD1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Neurofibromin 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA1 gene|BRCA1,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Annexin A3|ANXA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,galangin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Environmental Estrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Processed meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PALB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,tubeimoside I,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Sulindac,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PAQR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,G-Protein-Coupled Receptors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,RECQL gene|RECQL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Trans-Activation (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Biological Response Modifiers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pyrimidine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOX17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Carcinoma in situ of breast,Other,0.0,0.0019980019980019,Female Breast Cancer
DISRUPTS,"DICER1 protein, human|DICER1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,myristoylated alanine-rich C kinase substrate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Ovarian ablation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IKBKB,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of lymph node,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Osteopenia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Extracellular Matrix Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RHOBTB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SYF2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Enhancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CTSO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary cholesterol intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PK 11195,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TAF7L gene|TAF7L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL8RB gene|CXCR2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,NEUROD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Maternal history,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
DISRUPTS,Diphosphonates,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Solid tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KDM6A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Matrix Metalloproteinase Inhibitor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,butylbenzyl phthalate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Prolactin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Recombinant Interferon-gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRD7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Myosin Light Chain Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pain relief,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Magnetic field,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Curcumin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,STXBP4 gene|STXBP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Treatment Protocols,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Extracellular Matrix Proteins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,EGF gene|EGF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cyclopamine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GABPA|NFE2L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GTF2H1|SQSTM1|KHDRBS1|NUP62|DCTN4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,sphingosine 1-phosphate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRDM1 gene|PRDM1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Iodine-131,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,XRCC1 gene|XRCC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epigenetic Process,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Morphine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Triazoles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,recombinational repair,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,BMP4 gene|BMP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ADAMTS18,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MAS1 gene|MAS1,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Housekeeping Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Genes, Developmental",Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Birth length,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,beta catenin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Genes,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,WNT10B gene|WNT10B,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Helminths,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN200A gene|MIR200A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PVT1 gene|PVT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRF1 gene|ZFP36L1|BRF1|MST1L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RECQL4 gene|RECQL4,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,RAB11FIP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,molecular chaperone GRP78,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of stomach,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Sirolimus (substance),Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,TCP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibroblast Growth Factor Receptor 2|FGFR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vascular Endothelial Growth Factor C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EHMT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MST1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZEB2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,FGFR1 gene|FGFR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NF-kappa B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pertuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nelfinavir,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDK6-associated protein p18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Metastasis Suppressor Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cucurbitacin B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,imbalance,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Hypogonadism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WBP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Atenolol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic breast density,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,STX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Methylene blue,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EIF4G2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,epigallocatechin gallate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammary Neoplasms,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,SKP2 gene|SKP2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Reactive Oxygen Species,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HIF1A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,exemestane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BCYRN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chrysophanic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SRPK1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,capecitabine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body Weight decreased,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,SRD5A2 gene|SRD5A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Calcitriol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,proto-oncogene protein Spi-1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Factors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Neprilysin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,EIF4G1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cardiovascular event,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,resistin|RETN,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Monoclonal Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EZH2 gene|EZH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cereals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NF-kappa B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Suppressor Genes,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Estradiol,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,TCF4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UGT2B4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LATS1 gene|LATS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RNA, Small Interfering",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IQUB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SYVN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Sponges, Gauze",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,KLF5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LIMK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Luciferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PCDH17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CD8B1 gene|CD8B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,endogenous steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,POMC gene|POMC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DLG5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Quercetin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CDK14,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Does stand,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic agent (substance),Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,genetic locus,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PMS2 gene|PMS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TSLP gene|TSLP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53BP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ITGB2 gene|ITGB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BIBR 1532,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumorigenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,extracellular signal-regulated kinase 3|MAPK6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Extracellular Matrix Proteins,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,MFN2 gene|MFN2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Insulin-Like Growth Factor I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,brca gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,REST gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PKM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth-Factor Binding Protein 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNF5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Membrane Transport Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SPRY4-IT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"PER2 protein, mammalian",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,cytokine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Alkaloids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Eicosanoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vision,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADAM12,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,LINC01116,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TP53 gene|TP53,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,OIP5-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,polyphenols,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Blue light,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIR195,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,phenyl ether,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heparitin Sulfate,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Study models,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor II|CD74|GCNT2|TCN2|VIPR1|TAF8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAS gene|FAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hesperidin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mutagens,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PDK4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Garlic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Multiple Myeloma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anesthesia procedures,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Soybeans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclical mastalgia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NAT2 gene|NAT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Yogurt,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UGT8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nuclear Factor 45 Protein|ILF2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"DNA, Mitochondrial",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PSMD2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,antibody conjugate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTM2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sterol Regulatory Element Binding Protein 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chemokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,src-Family Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MYC gene|MYC,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Chicken Meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A7,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,CD24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYTH3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin-2,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,UGT1A1 gene|UGT1A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,2-chloroethyl ethyl sulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2 gene|ERBB2,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Signal Transduction,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Flavonols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Alcoholic Beverages,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Epidermal Growth Factor|EGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Depressed mood,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZFHX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Functional disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Intellectual functioning disability,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD247,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Epidermal Growth Factor Receptor|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transfer RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gene therapy,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,lysophosphatidic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Measles-Mumps-Rubella Vaccine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,agonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,THBS1 gene|THBS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Loss of Heterozygosity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WWOX,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Deoxycholic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polymorphic microsatellite markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,cytokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of endometrium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Menstrual cycle,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,dietary intervention,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Reliance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PSYCHIATRIC HISTORY,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Neoplastic Processes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibroblast Growth Factor Receptor 2|FGF7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RNA, Messenger",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"DNA, Complementary",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histamine H2 Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antipsychotic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hormones,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ESR1 gene|ESR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,interleukin-23,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CXCL1 gene|CXCL1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Acetaminophen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diphosphonates,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Malignant neoplasm of breast,Female Breast Carcinoma,Other,0.3988,0.0049950049950049,Female Breast Cancer
CAUSES,benzanthracene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GSTM1 gene|GSTM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,adjuvant therapy,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Disease Progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Strenuous Exercise,Carcinoma in situ of breast,Behavioral Factors,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,EGR1 gene|EGR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptors,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,"Insulin, Glargine, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Zinc,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,IL13Ralpha2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Ataxia Telangiectasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Analgesics,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Insulin Receptor|INSR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immune response,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Calcium Channel Blockers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alcohol effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Ovarian Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Female Homosexuality,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,delta-hexachlorocyclohexane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Manganese Superoxide Dismutase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Receptor Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DPF3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Personality Traits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Paraoxonase 1|PON1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydroxyestrones,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,checkpoint kinase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HMGB1 gene|HMGB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSD11B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Growth Factor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DNA Methylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF217 gene|ZNF217,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tenascin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IRS1 gene|IRS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXC Chemokines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Organic solvent product,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Simvastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bevacizumab,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammation Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Moderate Exercise,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Uniparental Disomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Rubidium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,19p13.1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Injection procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Plasminogen Activator Inhibitor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sitting height,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,JNK Mitogen-Activated Protein Kinases|JUN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,E2F3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,polyphenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Contralateral breast cancer,Genetic Factors,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,6/4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,capecitabine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Heme Oxygenase-1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pregnancy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Metric,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Insulin|INS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CpG Islands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RABGEF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,participation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,FLOT2 gene|FLOT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Behavior,Familial cancer of breast,Behavioral Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Thromboembolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,response,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,NBN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic lymphocytic inflammation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Organic Food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HFE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"APEX1 protein, human|APEX1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RRM2 gene|RRM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemotherapy-Oncologic Procedure,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Enrich,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Nipple discharge NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Symptoms,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Hair Dyes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Histopathology,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Renin-angiotensin system inhibition,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,MAP Kinase Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Autoantibody NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neutropenia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Decalcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Asthenia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Nicotine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sulfonylurea Compounds,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Protein-Serine-Threonine Kinases,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Cyclin D1|CCND1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Vitamin D-Binding Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ursolic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical activity,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,NANOG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breastfeeding performance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CHEK2 gene|CHEK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TRAN gene|TRA-TGC7-1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overweight,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Estrogens,Breast cancer metastatic,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Depressive Symptoms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,receptor for advanced glycation endproducts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anorexia Nervosa,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,crocetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AKT1 gene|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,delphinidin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Common wart,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,apolipoprotein D|APOD,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Inflammation,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,LAPTM4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,COPS5,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Breast Feeding, Exclusive",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,everolimus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xenograft Model,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Radiation-Induced Change,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stress,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Self-Examination,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Breast neoplasm screening,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Multiple alleles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Deficient knowledge,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CLCN3 gene|CLCN3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ethylmalonic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HTATIP gene|KAT5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Taurine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Menopausal Status,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Angiotensin-Converting Enzyme Inhibitors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Benzodiazepines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Untranslated Regions,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,LINC01585,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MGMT gene|MGMT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Natural Products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical activity,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Ibuprofen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Serine Protease,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Emergency contraception,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carbon ion,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prognostic Factor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chemical Exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,vitamin supplement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,coenzyme Q10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Verbal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PGR gene|PGR,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CCDC6 gene|CCDC6,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Personal Satisfaction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oligonucleotide Arrays,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hot water,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methotrexate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Consanguinity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Verbal,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Ions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BLM gene|BLM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tamoxifen,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,DMBT1 gene|DMBT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TBX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Multiple Sclerosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Positron-Emission Tomography,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Noninfiltrating Intraductal Carcinoma,Breast cancer invasive NOS,Other,0.0692,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Human Chorionic Gonadotropin|CGA|HTC2|CGB5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Steroidal Aromatase Inhibitor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Obesity, Morbid",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,perfluorooctanoic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,F2RL1|NR1I2|SLC52A1,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Arginine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Rheumatoid Arthritis,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,NFKB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,letrozole,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GHRL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MATP gene|SLC45A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRCA1 gene|BRCA1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Animal fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP19A1 gene|CYP19A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Dietary Carbohydrates,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,peroxiredoxin I|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GHSR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NBS1 gene|NBN|NLRP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrone sulfotransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Recombinant Interferon-gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,[V]Follow-up examination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Diphosphonates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breasts asymmetrical,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Long chain fatty acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Interleukin-2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HSD17B6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Positive Lymph Node,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XRCC5 gene|XRCC5,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Triglycerides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Membrane Glycoproteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Systemic Scleroderma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast composition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LHX1 gene|LHX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infection,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Life Style,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PGRMC1 gene|PGRMC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIWIL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANLN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ethnic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gynecomastia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NAT2 gene|NAT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WWC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adverse effects,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,pertuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Behcet Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carrier of disorder,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,"Polycyclic Hydrocarbons, Aromatic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Egg Food Product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Whole-Brain Radiotherapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Perceived comfort level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glutamate Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anovulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,phenylpyruvate tautomerase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ovarian Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FANCM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Invasive Malignant Neoplasm,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,tibolone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,chemokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,CCAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Levonorgestrel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Free testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mimicry,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,1-Phosphatidylinositol 3-Kinase|PI3,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vaccines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sclerosis,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,flavan-3-ol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast cancer invasive NOS,Noninfiltrating Intraductal Carcinoma,Other,0.0587,0.0109890109890109,Female Breast Cancer
CAUSES,MME gene|MME,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNAs,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Lignans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Galectin 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARK7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,alpha Tocopherol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Excision,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine therapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Protein Overexpression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen receptor negative,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,BRCA2 Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gall Bladder Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STAT5A gene|STAT5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTEN gene|PTEN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Calcium Channel Blockers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ionizing radiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor I|INS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Polyunsaturated Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Lignans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bleomycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MSH6 gene|MSH6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Suspensions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Coronary Arteriosclerosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcoholic Beverages,Breast cancer recurrent,Demographic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Maternal Mortality,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Reaction emotional,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sulfonylurea Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,KDM4A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cerebrovascular accident,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Undifferentiated carcinoma of ovary,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,glutathione S-transferase M1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,brca gene,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,MDM4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KPNA2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,cytotoxicity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Positive Finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MFG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diethylstilbestrol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,desires,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,bufadienolide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tamoxifen,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,PGK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinoembryonic Antigen|CEACAM5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ZNHIT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SEMA3C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta catenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Amino Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Little's Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ginsenoside Rk1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Physiological Processes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Pimozide,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ZNF423,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNA Sequence,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Antidiabetics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HIF1alpha protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adriamycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,caveolin 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ZNHIT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNHG7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MALAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOX8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MIRN106A gene|MIR106A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CXCR4 gene|CXCR4,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Epidermal Growth Factor Receptor|EGFR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Myocardial Ischemia,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,phthalates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Leucine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDC2 gene|CDK1|POLD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cancer-Predisposing Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,shikonin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,NFE2L3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,lysyllysine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,G3BP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CBX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Interleukin-4,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Monomeric GTP-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PPM1D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mitomycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Luteolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endocrine System Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cell motility,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,ataxia telangiectasia mutated protein|ATM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,glutathione S-transferase M1|GSTM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Xenobiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,9-deoxy-delta-9-prostaglandin D2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Liposomes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,activated RNA polymerase II transcription cofactor 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HGS gene|HGS,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Formaldehyde,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Natural Products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,preference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIK3R1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00339,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VIRMA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VIRMA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Compete,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Platelet-Derived Growth Factor beta Receptor|PDGFRB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"3,4-Methylenedioxyamphetamine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single Nucleotide Polymorphism,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Bariatric Surgery,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Integrin alphaVbeta3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IDO1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,kaempferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nephroblastoma,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Diphenylamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Homologous Gene,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SERPINI2 gene|SERPINI2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,centromere protein F,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Aging-Related Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,anillin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"PTTG1 protein, human|PTTG1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Poly(ADP-ribose) Polymerases|WDTC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FBXL19-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Treatment Protocols,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Polychlorinated Biphenyls,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TAGLN2 gene|TAGLN2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,gadoterate meglumine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCB 138,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antipsychotic Agents,Carcinoma in situ of breast,Demographic Factors,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,SLC4A11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antioestrogen therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UDP-Glucuronosyltransferase 1A1|SLC45A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pigment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mitochondrial Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Formance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHD4 gene|CHD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gambogic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RPS27 gene|RPS27,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,hippo signaling,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,BARD1 gene|BARD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cholecalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,food product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Functional RNA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Albendazole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Activator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Interleukin-17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydrogel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Glioblastoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Untranslated Regions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TTN-AS1 gene|TTN-AS1,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,"MMP14 protein, human|MMP14",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,RASAL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,small molecule,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Profilins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HAND2-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lipid Peroxides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pre-op diagnosis,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,HSPA5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SOX2 Transcription Factor|SOX2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Letter:Finding:Point in time:{Setting}:Document:{Provider},Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP27A1 gene|CYP27A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ENO1 gene|ENO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 Gene Mutation,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,rosemary extract,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormone use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RESF1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Integrin alpha3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PPEF1 gene|PPEF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HDAC5 gene|HDAC5,Malignant neoplasm of female breast,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Colorectal Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP7B1 gene|CYP7B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PAK2 gene|PAK2|PKN2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,socioeconomic differences,Malignant neoplasm of breast,Socio-economic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epigallocatechin gallate,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,FTSJ3 gene|FTSJ3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"SFRP1 protein, human|SFRP1",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Alternative Splicing,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,GACAT3 gene|GACAT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Adriamycin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SPRY4-IT1 gene|SPRY4-IT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KLK12 gene|KLK12,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"GOLPH3 protein, human|GOLPH3",Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Underlying,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microsatellite Instability,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,USP43 gene|USP43,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"CEACAM5 protein, human|CEACAM5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRIP6 gene|TRIP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,mica,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Detection,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERR1 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immune response,HER2-positive carcinoma of breast,Immunological Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,FOXN4 gene|FOXN4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Soluble fiber (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High expression,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,leptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MYCN gene|MYCN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transforming Growth Factor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,inhibitors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Genome,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,ATM,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,glypican 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTTG1 gene|PTTG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adipokines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CTCb regimen,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,lumican,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tissue-factor-pathway inhibitor 2|TFPI2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NEAT1 gene|NEAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXM1 gene|FOXM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Marital Status,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,MYC,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SLCO6A1|GSTK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gestational Diabetes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CERNA2 gene|CERNA2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"TP53BP1 protein, human|TP53BP1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,interleukin-4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ALKBH5 gene|ALKBH5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BET Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor alpha,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Diagnostic Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Integrin alpha5,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,IMPACT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ECE1 gene|ECE1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,lovastatin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Invasive Carcinoma,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,XRCC3 gene|XRCC3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenic Process,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,GKLF protein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,PRR14 gene|PRR14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GKLF protein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Equol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,hexane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNA-Binding Protein Musashi Homolog 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Account number:Identifier:Point in time:^Patient:Nominal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KIF15 gene|KIF15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,bisphenol A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,D Vitamin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,FZR1 wt Allele|CDH1,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,LINC00707 gene|LINC00707,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FGFR1 wt Allele|FGFR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Abnormal metabolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aquaporin 7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,COTL1 gene|COTL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GPX3 gene|GPX3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Herbicides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caspase-3|CASP3,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,"SLC16A3 protein, human|SLC16A3",Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Pivot,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NME1 gene|NME1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,erastin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Metastatic malignant neoplasm to brain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Anti-Inflammatory Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumor Progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TNIP2 gene|TNIP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,acetylglucosamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alternative Splicing,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,purpurin 18,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,hesperetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Geldanamycin Analogue,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XIST gene|XIST,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Flavonols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ado-trastuzumab emtansine|DMPK|IGHD1-7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dysbiosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Therapeutic Effect,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fatty-acid synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mucin-1 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,OIP5-AS1 gene|OIP5-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hyperlipidemia,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Sexual function,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnostic radiologic examination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CERNA2 gene|CERNA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diphosphonates,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,Viral Tumor Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"RNA, Circular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease Progression,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,CMTM5 gene|CMTM5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR22 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Serum Proteins,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,arbutin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diet high in saturated fats,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MSH2 gene|MSH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCNAP1 gene|PCNAP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOSL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00346 gene|LINC00346,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signaling Protein,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANGPTL4 gene|ANGPTL4,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Negative Regulation of Apoptosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD8A wt Allele|CD8A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,sunitinib,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,brazilin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,cyclooxygenase 2|PTGS2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAD21 gene|RAD21,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,DYRK2 gene|DYRK2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,leptin,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,TT genotype,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Water consumption,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vitronectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Product containing glucagon-like peptide 1 receptor agonist (product),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP27B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR100HG gene|MIR100HG,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,diethylstilbestrol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Biological Response Modifiers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sphingomyelins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infiltration,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,Thyroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acetylserotonin N-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Sleeve,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Rheumatoid Arthritis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNA 205-5p,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Cyclin-Dependent Kinase Inhibitor p16|CDKN2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,periodate-oxidized adenosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acidosis,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Intercellular adhesion molecule 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KIF15 gene|KIF15,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Erythropoietin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,K-ras Oncogene|KRAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Imaging Reporting and Data System,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnosis,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Circulating Tumor DNA,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,ciclesonide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cisplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NRG1 gene|NRG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ryanodine Receptor 3|RYR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PPP2R2B gene|PPP2R2B,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,FN1 gene|FN1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,patient characteristics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Weight decreased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,amygdalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GPM6B gene|GPM6B,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,HHEX gene|HHEX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Copy Number Polymorphism,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
DISRUPTS,SOY ISOFLAVONES,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,verteporfin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Apoptosis Inducing Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BTF3 gene|BTF3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Metastatic malignant neoplasm to brain,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,butein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ST8SIA6-AS1 gene|ST8SIA6-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,si-wu-tang,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"ITK protein, human|ITK",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,A2M-AS1 gene|A2M-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Matrix Metalloproteinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MIR22HG gene|MIR22HG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bilateral mastectomy,Unilateral Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,27-hydroxycholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,paclitaxel,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Detection,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,DSCAM-AS1 gene|DSCAM-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PGK1 gene|PGK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neuropeptides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor size,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,EZH2 gene|EZH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Diphosphonates,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,interleukin-10,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,"WFDC2 protein, human|WFDC2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proliferation (morphologic abnormality),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMAD2 gene|SMAD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IL6ST gene|IL6ST,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,COVID-19,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,TRIM6 gene|TRIM6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"UBASH3A protein, human|UBASH3A",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PALB2 gene|PALB2,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,YY1 gene|YY1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LAGE3 gene|LAGE3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00885 gene|LINC00885,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,CCL5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,ZNF385B gene|ZNF385B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pain relief,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Connexin 43|GJA1,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,CHFR gene|CHFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,pristane,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ruthenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,tripterine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Trans Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL20RA gene|IL20RA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Health behavior,"Breast Cancer, Familial",Behavioral Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Functional Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphatidylinositide 3-Kinase Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AQP5 gene|AQP5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00511 gene|LINC00511,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MDM2 gene|MDM2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,OLFML2A gene|OLFML2A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Basis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gene Mutant,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High Level,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Volatile Organic Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USP6NL gene|USP6NL,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Transcription, Genetic",HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Tumor Microenvironment,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,HOXB5 gene|HOXB5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gamma-glutamyl transferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Therapy,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,MTUS1 gene|MTUS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SF3B3 gene|SF3B3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,cytokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IMPACT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"LCN2 protein, human|LCN2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ATP5F1B gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Cancer Prognostic Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Discoidin Domain Receptor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,polyphenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Photochemotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoantigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diuretics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Transcript,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,arsenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Matrix Metalloproteinases,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Pills,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Autoimmune Diseases,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,paracrine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Radiation,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ferroptosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Candidate Disease Gene,Recurrent Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Recurrent Breast Cancer
AFFECTS,Central Serous Chorioretinopathy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,triclosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAD51 gene|RAD51,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"HIF1A protein, human|HIF1A",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,high density lipoprotein binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HOXB7 gene|HOXB7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pathologic Complete Response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,paclitaxel,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Tobacco smoking behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infiltration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIR gene|PIR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDC25C gene|CDC25C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CLEC2D gene|CLEC2D,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,sirolimus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"MEN1 protein, human|MEN1",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Brominated Diphenyl Ethers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ACSL4 gene|ACSL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Flap Endonuclease-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IDO1 gene|IDO1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Immune response,Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,>40 years,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin-Dependent Kinases,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,DPP3 gene|DPP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,niclosamide,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,PQBP1 gene|PQBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antihypertensive Agents,HER2-positive carcinoma of breast,Demographic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Responsive Disease,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,CEP295 gene|CEP295,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tissue polypeptide specific antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,beta catenin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,PBXIP1 gene|PBXIP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pyroptosis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Duration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Axillary node METASTASIS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR655 gene|MIR655,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LOC105371267,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ITGA2B wt Allele|ITGA2B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pathogenic Variant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"E2F1 protein, human|E2F1|UBE2L3",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,phthalates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CATHEPSIN D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Possible,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,IL27 gene|MYDGF|IL27,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AZD4547,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gene Mutant,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GANT 61,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MARCHF5 gene,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GLI1 gene|GLI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LGALS8-AS1 gene|LGALS8-AS1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Body mass index procedure,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Liposomes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drug resistance,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,HOXD9 gene|HOXD9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immunologic Adjuvants,Noninfiltrating Intraductal Carcinoma,Immunological Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Genome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,POTEH-AS1 gene|POTEH-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STAT3 gene|STAT3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,FAM111B gene|FAM111B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Growth Differentiation Factor 15|PAEP,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,AR gene|AR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Decreased translucency,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Performance,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TSPAN1 gene|TSPAN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,astaxanthin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Hypoxia-Inducible Factor 1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Elevated Expression,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,KLF5 gene|KLF5,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,SETDB1 gene|SETDB1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"RNA, Circular",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"TNFSF10 protein, human|TNFSF10",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"WNK1 protein, human|WNK1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ENPP1 gene|ENPP1,Recurrent Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Recurrent Breast Cancer
AFFECTS,METTL14 gene|METTL14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NDUFV1 gene|NDUFV1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hydrogel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NOLC1 gene|NOLC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Resistance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AMACR wt Allele,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,ADRB2 gene|ADRB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"SEP15 protein, human|SELENOF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HOXC-AS3 gene|HOXC-AS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mutant Proteins,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,AA genotype,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Architectural Distortion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,EPB41L4A-AS1 gene|EPB41L4A-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genomic Instability,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Consideration,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Circulating Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Elevated Expression,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,KCNQ1OT1 gene|KCNQ1OT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,endosulfine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Hormone Receptor,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
PREDISPOSES,fusion transcript,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,erbB-2 Receptor|ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Protein Subunits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,COVID-19,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,PPP1R14C gene|PPP1R14C,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Ovarian hyperstimulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,brazilian,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Cancer Therapeutic Procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Healthy Lifestyle,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,choline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NFIB gene|NFIB,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Pathogenic Variant,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
AUGMENTS,fluvastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RAC2 gene|RAC2,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,interleukin-6,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,GSDMB gene|GSDMB,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Immune,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypercholesterolemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LINC00092 gene|LINC00092,Invasive Ductal Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,"Sleep Apnea, Obstructive",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HMMR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Agent,Triple Negative Breast Neoplasms,Demographic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Organic solvent product,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,DDX5 gene|DDX5,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Pharmacologic Substance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,1 time,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,secretory protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MDM2 gene|MDM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,"IL17A protein, human|IL17A",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00472 gene|LINC00472,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diffusion Kurtosis Imaging,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CCNB2 gene|CCNB2,Stage 0 Breast Cancer AJCC v6 and v7,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Adenocarcinoma in Situ,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Carcinoma, Lobular","Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
AFFECTS,anastrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD69 protein, human|CD69","Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
AUGMENTS,RBMS1 gene|RBMS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tea without milk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,genetic risk factors,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infantile Neuroaxonal Dystrophy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,doxorubicin liposome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,sigma-2 receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNHG3 gene|SNHG3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HMGB1 gene|HMGB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Processes,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Gene Silencing,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,False Positive,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Multifactorial,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MEDAG gene|MEDAG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Post-mastectomy radiotherapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,PIK3CA gene|PIK3CA,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,"Antibodies, Bispecific",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,FBXW7 gene|FBXW7,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,CCL3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mitochondrial mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Basis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MIR191 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GLI4 gene|GLI4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Convenience food intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer Therapeutic Procedure,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PEDS1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Monoclonal Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,fluoxetine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,canagliflozin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PAFAH1B1 gene|PAFAH1B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proto-Oncogene Protein c-kit,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CCDC102B gene|CCDC102B,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,RACK1 gene|RACK1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Imbrication (procedure),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,catalpol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"RNA, Untranslated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Score,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Transsexual (finding),Secondary malignant neoplasm of breast,Demographic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Responsive Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"IL17A protein, human|IL17A",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,ZNF276 gene|ZNF276,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Antioxidants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anabolism,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,TIMM8A gene|TIMM8A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrus,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,METTL3 gene|METTL3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FER1L4 gene|FER1L4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vitamin D Deficiency,Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,UBE2C gene|UBE2C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,diltiazem,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,resveratrol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FRG1 gene|FRG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NF2 gene|NF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Observation parameter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Emodin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Clinical Significance,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"PIK3CB protein, human|PIK3CB",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,METTL14 gene|METTL14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,N-acetyltransferase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Selective Estrogen Receptor Down Regulator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,water channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diffusion weighted imaging,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,ARL11 gene|ARL11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,MIR217 gene|MIR217,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 Overexpression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXN3 gene|FOXN3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ellagic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Retinol-Binding Proteins, Cellular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cancer-Related Death,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Cell-Free DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Duration,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Risk Scores,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Present,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,1-Phosphatidylinositol 3-Kinase,HER2-positive carcinoma of breast,Hormonal Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,"neoisoliquiritin, (E)-isomer",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphotransferases,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinase 9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HDAC7 gene|HDAC7,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,IGF2BP2 gene|IGF2BP2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,BCL2A1 gene|BCL2A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Cycle Arrest,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GNAS gene|GNAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,arginylproline|ABL2|RERE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,hexanoic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antipsychotic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tripe,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RMI2 gene|RMI2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Candidiasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SCAMP3 gene|SCAMP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SPC25 gene|SPC25,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RNA, Circular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KDM4A gene|KDM4A,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Treatment Protocols,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Neuregulin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,LBH589,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CBX7 gene|CBX7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRAF2 gene|PRAF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histone H3 Lysine 27,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low Level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,paclitaxel,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Malignant neoplasm of breast,Secondary malignant neoplasm of breast,Other,0.3988,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Genetic Loci,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANTXR1 wt Allele|ATR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,FKBP12-rapamycin associated protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ROS1 wt Allele|ROS1,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Mitophagy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"FABP1 protein, human|FABP1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,gamma-aminobutyric acid,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Mouse mammary tumor virus infection,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chaperone-mediated autophagy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dairy Products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen receptor positive,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,KAT7 gene|KAT7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anxiety,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,stanniocalcin 2|STC2,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,RNF43 gene|RNF43,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Secondary Neoplasm,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,F-Actin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,CPVL gene|CPVL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vegetarian diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TMEM105 gene|TMEM105,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,SIRT7 gene|SIRT7,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Biological Response Modifiers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RHD gene|RHD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MYC,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,STAT1 gene|STAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Axillary node METASTASIS,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SNRPC gene|SNRPC,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,HHEX gene|HHEX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,polyphenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Kanglaite Injection,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SIRT7 gene|SIRT7,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,SDC1 gene|SDC1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"RNA, Long Untranslated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Marital Status,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CARD.RISK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Agent,Carcinoma breast stage IV,Demographic Factors,0.0,0.0,Female Breast Cancer
CAUSES,human papillomavirus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,kaempferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,dydrogesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Ribonucleoprotein, U1 Small Nuclear",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,USP29 gene|USP29,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Galanin peptides, human (123 aa, ~13 kDa)",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NDC80 gene|NDC80,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammatory Response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLF2 gene|KLF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Luteolin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"PDCD1 protein, human|PDCD1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Magnetic Resonance Imaging,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,copper,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VEGFA gene|VEGFA,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Negative Surgical Margin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Agonist,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GAS5 gene|GAS5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NUCB2 gene|NUCB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mouse mammary tumor virus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oligonucleotides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Betaretrovirus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,stanniocalcin 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Methylnitrosourea,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,epithelial to mesenchymal transition,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CDH12 gene|CDH12,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
CAUSES,Invasive Ductal Breast Carcinoma,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,RNA-Binding Protein Musashi Homolog 2,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,16 alpha-hydroxyestrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,hydrocortisone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ectonucleotide pyrophosphatase phosphodiesterase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,oxybenzone,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Menstrual period late,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pediatric Obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lysine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NR2F1-AS1 gene|NR2F1-AS1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,MCM6 gene|MCM6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Psoriasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAP7D3 gene|MAP7D3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,DEGS1 wt Allele|DEGS1,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Pharmacotherapy,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,polyphyllin D,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,tocopherol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SPDEF gene|SPDEF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FAM171A1 gene|FAM171A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,olive oil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Poly(ADP-ribose) Polymerase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HNRNPA2B1 gene|HNRNPA2B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EYA4 gene|EYA4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Parafibromin|CDC73,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RHOV gene|RHOV,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,LINC01140 gene|LINC01140,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Progression,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,"TNFSF10 protein, human|TNFSF10",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,TYMSOS gene|TYMSOS,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Mutation,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,Glycoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ligands,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CD69,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Life Expectancy Less than Five Years,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Decreased Expression,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Phenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,medroxyprogesterone acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SEMA3B-AS1 gene|SEMA3B-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Anti-HER2 Monoclonal Antibody|ERBB2,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,C-reactive protein,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,MIR122 gene|MIR122,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAF1 gene|MAF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Toll-Like Receptor 1, human|TLR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,perfluorooctanoic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oncogenes,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,CD82 gene|CD82,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Biological Markers,Stage 0 Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinases,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Carbohydrates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ketogenic Diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNA Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PSMD14 gene|PSMD14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00702 gene|LINC00702,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phytochemicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNPH1 gene|DNPH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IMPA2 gene|IMPA2,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,FBXO3 gene|FBXO3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Cell Survival,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,OLT1177,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Neuroleptic Malignant Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Proto-Oncogene Proteins c-akt|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,beta catenin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Crohn Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HMGB3 gene|HMGB3,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Tumor Markers,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"COPEB protein, human|KLF6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary Neoplasm,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cardiorespiratory Fitness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PIK3CB protein, human|PIK3CB",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Radiation-Sensitizing Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STMN1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Waist Circumference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,olaparib,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Mammographic Breast Density,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,PALMD gene|PALMD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,1+,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NOTCH3 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ferroptosis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CELSR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WASF3 gene|WASF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Rhythm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thrombospondin 1,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Dormancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR203A gene|MIR203A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lutein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of liver,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Macrophage Activation Syndrome,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnosis,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Mouse Model,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,post surgery radiation therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pathogenic Variant,Hereditary Breast and Ovarian Cancer Syndrome,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Cell Death,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Plasma Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARHGAP6 gene|ARHGAP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ELAVL1 gene|ELAVL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FRY gene|FRY,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IDO1 gene|IDO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CLEC11A protein, human|CLEC11A",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Polynucleotide Adenylyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,idebenone,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Tenascin, human|TNC|TNNC1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Fibrocystic Disease,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,OGG1 gene|OGG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PDZK1 gene|PDZK1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MTCH2 gene|MTCH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infiltration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KLRK1 gene|KLRK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC01572 gene|LINC01572,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Dickkopf-Related Protein 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RAMP2-AS1 gene|RAMP2-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TLR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA1 gene|BRCA1,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,SLCO1B1 gene|SLCO1B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ezetimibe,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,NR2F2 gene|NR2F2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Nanotubes, Carbon",Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Follistatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AGRN gene|AGRN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NKAIN1 gene|NKAIN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mitochondrial calcium uniporter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ononin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,tanshinone II A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,S14 gene|PSMD8|RPS14|THRSP|LOC107228383,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TCF7L2 gene|TCF7L2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,oncostatin M receptor|OSMR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anthocyanins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prostaglandins,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin used,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TAL1 gene|TAL1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Tumor Markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNMT3B gene|DNMT3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,resveratrol,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,RHOC gene|RHOC,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Human plasma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,glycosylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Antagonists,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,CA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Steroid 17-alpha-monooxygenase|CYP17A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adenosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EZH2 gene|EZH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cardiovascular morbidity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IKZF2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Interleukin-24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Necrosis Factor Ligand Superfamily Member 6|FASLG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TAZ gene|TAZ,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Benzoic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estrogen Receptor alpha,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,SMARCA4 gene|SMARCA4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radioisotope scan of lymphatic system,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,RHOA gene|RHOA,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Folic acid supplementation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Acrylamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESTROGEN USE,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,recombinational repair,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KDM5B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Menopause, Premature",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,APC2 gene|APC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CETN1,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Aging,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Metaplastic carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Suicide Gene Therapy,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Combined Modality Therapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GATA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDX2 gene|CDX2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DUSP4 gene|DUSP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Selenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FLT1 gene|FLT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Menstrual migraine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant transformation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Eclampsia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nucleic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,APOBEC3B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immunologic Adjuvants,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Whole Cell Vaccine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XBP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer Model,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Calcium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytochrome P-450 CYP1A1|CYP2B6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,High fiber food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Breast Carcinoma,Other,0.3988,0.0279720279720279,Female Breast Cancer
AUGMENTS,MAP3K3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,UDP-Glucuronosyltransferase 1A1|SLC45A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NANOG,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CADMIUM EXPOSURE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TISSUE TRANSGLUTAMINASE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glycoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TLR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Quinones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progestins,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Therapeutic agent (substance),Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VEGF gene|VEGFA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,[D]Nausea and vomiting NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,JAG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Fatty Acids, Saturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,8q22,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,transcription factor PEA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TLR4 gene|TLR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Genes, Homeobox",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Deferoxamine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogens,Carcinoma of Male Breast,Hormonal Factors,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,PCAF gene|KAT2B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Specimen from breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR27B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BIRC5 gene|BIRC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RUNX1|MECOM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ANKRD12|ANKRD11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Interleukin-8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNASE3L gene|DROSHA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RHOBTB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53 gene|TP53,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Estrogen excess,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,ID1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,cyclooxygenase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Leptin|LEP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MULTISECTION:FINDING:POINT IN TIME:BREAST:NARRATIVE:MRI,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Transferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Quantitative Trait Loci,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MRPS30,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genes, Homeobox",Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BIRC7 gene|BIRC7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Annexin A2|ANXA2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ATR gene|ATR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fatty-acid synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TSLP gene|TSLP,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Endostatins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SH3KBP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,S100A9 gene|S100A9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nitrite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Cancer Treatment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ARF6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Extracellular Signal Regulated Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunoglobulin G,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gonadal Steroid Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CTNNB1 gene|CTNNB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antiperspirants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EGFR gene|EGFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signaling Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,asparaginylendopeptidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Soy Foods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,20q,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,STAT3 gene|STAT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CXCR3 gene|CXCR3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTPN11 gene|PTPN11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of endometrium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Interleukin 7 Receptor|IL7R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Livebirth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease Outcome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BMPR1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sulfuric Acid Esters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BMPR2 gene|BMPR2,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,Antineoplastic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Laminin Receptor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Protein-Serine-Threonine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Resonance Imaging,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Environmental Effects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ACR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolic Rates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CATHEPSIN D|CTSD,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Antibodies, Anti-Idiotypic",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Carotenoids,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Growth Factor Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Fibroadenoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Insulin-Like Growth Factor Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cDNA Library,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrous Cycle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Toxic effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Irregular menstrual cycle NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Pregnancy, Multiple",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TACSTD2 gene|TACSTD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cystic Breast Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 gene|BRCA1,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,LAMR1 gene|RPSA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fulvestrant,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,BCAS1 gene|BCAS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSD17B4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nifedipine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mechanics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MDM2 gene|MDM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body mass index,Carcinoma in situ of breast,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,LRRC32,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cysteine Proteinase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Pathways,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,salinomycin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,mutant gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Reconstructive Surgical Procedures,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Prostaglandin-Endoperoxide Synthase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GALNT14,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,mammary tumor virus,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Cadherins,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,Medroxyprogesterone 17-Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Manganese Superoxide Dismutase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Genes,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Tretinoin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Medroxyprogesterone,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Para 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dessert,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Trihalomethanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZNF121,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paraffin,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Retroviridae,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cytologic finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GATA3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,hybrid gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CCND1 gene|CCND1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Etoposide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Collagen,Ductal Breast Carcinoma,Demographic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,activity level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Trans-Activators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SHBG gene|SHBG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Athletic Training,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aromatic Amines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Androgens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Anovulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha-Lactalbumin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FGF3 gene|FGF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Prolactin Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Serum Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Photosensitivity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tamoxifen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Female Breast Carcinoma,Malignant neoplasm of breast,Other,0.0174,0.3386613386613387,Female Breast Cancer
AFFECTS,Electromagnetic Fields,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphotransferases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DNA biosynthesis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TFF1 protein, human|TFF1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Hypercalcemia,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"serine repeat antigen, Plasmodium",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pharmaceutical Preparations,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Animal protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogene Proteins p21(ras)|HRAS,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Estrogen Antagonists,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,FGF3 gene|FGF3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,international differences,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Genes, Suppressor",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Hydrocarbons, Aromatic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,onapristone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Paraffin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Monoclonal Antibodies,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Debrisoquin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gonadorelin|GNRH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Urea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Burden,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Dimethyl Sulfoxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BCL-2 Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,beta-hexachlorocyclohexane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gamma-glutamyl transferase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Interferons,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Bromocriptine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,IGF2 gene|IGF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,methylurea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of bone,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pathogenesis,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prognostic Factor,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Advanced cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ascorbic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Antigens, Viral",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AFP gene|AFP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Antipsychotic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HRAS gene|HRAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antineoplastic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Breast cancer invasive NOS,Noninfiltrating Intraductal Carcinoma,Other,0.0587,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PIP,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Wound Healing,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Lymph node excision,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Genes, Regulator",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High income,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lutein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radionuclide Imaging,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,X-Pro dipeptidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,New finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CATHEPSIN D|CTSD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tissue-factor-pathway inhibitor 2|PPP5C|TFPI2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fever,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,alpha-Linolenic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MLH1 gene|MLH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,regular physical activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ELK3 gene|ELK3|KCNH8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transfection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NBEAL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Linoleic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoma in Situ,Lobular carcinoma in situ of breast,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,C2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BUB1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glucagon|GCG,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Fatty Acids, Unsaturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MFT 279,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estradiol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GATA5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ETS Variant Gene 6 Protein|ETV6,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,folligen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cyclin D1|CCND1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Genes, Regulator",Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,sodium-iodide symporter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prolactin|PRL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Indomethacin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased body mass index,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Integrins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Insulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Decapeptyl,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Radium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interstitial Collagenase,Breast cancer invasive NOS,Demographic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,MYC gene|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HIV Infections,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Allelic Imbalance,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,response to hormone stimulus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,glycosylation,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Polyamines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Communication,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Electromagnetic Energy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Chronic Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein Overexpression,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CDC25A gene|CDC25A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,checkpoint kinase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Passive smoker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypokinesia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Isotopes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Sterol Regulatory Element Binding Protein 1c,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Psychometrics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,I Kappa B-Alpha,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Antioxidants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Triethylenemelamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fluorodeoxyglucose positron emission tomography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lymphoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NFKBIA gene|NFKBIA,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Fibroblast Growth Factor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chromosome abnormality,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Kininogenase|KLK4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CLARITY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ral Guanine Nucleotide Exchange Factor|RALGDS,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,letrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcription Coactivator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Retroviral Vector,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Serine Protease,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Saturated fat intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"N,N-dimethyl-4-anisidine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 gene|BRCA1,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,skills,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EMSY,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Family history of breast cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Amino Acid Substitution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Reproductive Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERCC4 gene|ERCC4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Venous Thrombosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,VEGF gene|VEGFA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Quantitative Trait Loci,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prempro,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PGR gene|PGR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,maspin|SERPINB5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Dehydroepiandrosterone Sulfate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphotransferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Micronutrients,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Retinoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ID-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Polypeptides,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MPO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Soy bean product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cancer-Predisposing Gene,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,Angiogenic Switch,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ID1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cryptococcus,Cancer en cuirasse,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Infertility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,EEF1B2P2|BHLHE22,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Decreased density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CD82 gene|CD82,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein Kinase C Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NQO1 gene|NQO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,apomucin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NELFB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm Metastasis,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,repair enzyme,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Orthologous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogen Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CASP1 gene|CASP1,Lobular carcinoma in situ of breast,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,TNFRSF1B gene|TNFRSF1B,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Granulocyte Colony-Stimulating Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tamoxifen,Carcinoma in situ of breast,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,cyclooxygenase 2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IL8 gene|CXCL8,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Steroidal Estrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Fibroblast Growth Factor 7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MFG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Catechol O-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperprolactinemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aromatase Inhibitors,Noninfiltrating Intraductal Carcinoma,Treatments,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,CAV1 gene|CAV1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tamoxifen,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Estradiol,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,Lignans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lariciresinol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Single Nucleotide Polymorphism,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Raloxifene,Carcinoma in situ of breast,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Anovulatory,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sore to touch,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gegenhalten,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CLCA2 gene|CLCA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Xanthine Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,pleiotrophin|PTN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,epigallocatechin gallate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta catenin,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,WISP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glutathione S-Transferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endopeptidases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,anti-apoptosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Environmental stimuli,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Asparagine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HPSE gene|HPSE,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Steryl-sulfatase|STS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cytochrome P450 3A4|CYP3A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Signaling Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polyphenols,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Estrogen Receptors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Breast Cyst,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Retinoblastoma Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mannose Binding Lectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Stanolone,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,YBX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ghrelin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ovarian Cysts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adaptor Signaling Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor alpha|EREG|ESR1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Fertility Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Thrombospondins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Catecholamines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oxytocinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Apolipoprotein E|APOE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Isoflavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to puberty,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CXCL12 gene|CXCL12,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PLAT gene|PLAT,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TSPYL5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIPA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PPAR gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CXCR4 gene|CXCR4,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Vitamin E,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Walking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCC11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCL12 gene|CXCL12,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Primary Prevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Antibodies, Anti-Idiotypic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SHFM1 gene|SEM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thrombolytic Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,14q24.1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NRP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MTNR1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"PSMD10 protein, human|PSMD10",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MTNR1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, Progesterone|PGR",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Titanium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gastric Adenocarcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,mTOR Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Clonal Expansion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acetyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADH1B gene|ADH1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SULT1A1|SULT1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Potato,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast tenderness,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,TNFSF11 gene|TNFSF11,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Phytoestrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transfection,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Autoimmune thyroiditis,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,OPN1LW|CRCP|RAB11FIP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,K-ras Oncogene|KRAS,Ductal Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,Carcinogenesis,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gene polymorphism,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,PREDICTED,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Interleukin-15,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NEK8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cigarette smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Sulfatases|ARSH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,estrogen receptor gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PALB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single Nucleotide Polymorphism,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,TRANCE protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KL gene|KL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCDC88A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Retinoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Receptors|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Agent,Breast cancer metastatic,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"Fatty Acids, Omega-6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SP1 gene|SP1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,G-Protein-Coupled Receptors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Diabetes Mellitus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carbon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Somatomedins,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Hypermethylation,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Phototherapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Granulocyte Colony-Stimulating Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,IL8 gene|CXCL8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UTS2R|SLC14A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANP32B gene|ANP32B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Compete,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Magnesium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Calgranulin A|S100A8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytochrome P450,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERR1 protein|ESRRA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ETV4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Bone Morphogenetic Proteins,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PTH protein, human|PTH",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Minisatellite Repeats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Anabolic steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PPAR gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NOTCH4 gene,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,S100A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Growth retardation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CYP1A1 gene|CYP1A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Niacin intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SIX1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,EGFR gene|EGFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Arrestins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BACH1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,chromosome decondensation factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PHB2|SIL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Advance,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MAPK14 gene|MAPK14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protein Isoforms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DNA Adducts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLX4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tetradecanoylphorbol Acetate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,amsonic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcoholic Liver Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AKT1 gene|AKT1,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Catechol O-Methyltransferase|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MRE11,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,protein-tyrosine kinase c-src|SRC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,vasodilator-stimulated phosphoprotein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,hesperetin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BRIP1,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,ING5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Angioendotheliomatosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphatidylethanolamine Binding Protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Aromatase Inhibitors,Breast cancer recurrent,Treatments,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Pharmaceutical Preparations,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,"2,3-bis(3'-hydroxybenzyl)butyrolactone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRCA1 gene|BRCA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BCL6 gene|BCL6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paclitaxel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,RPRD1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,XPO5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"TNF protein, human|TNF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Natural menopause,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MYC gene|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,sphingosine kinase-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KLF9 gene|KLF9,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,NKD1,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Hyperbaric Oxygenation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,USP21 gene|USP21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hexachlorobenzene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CRHBP gene|CRHBP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Myeloid Leukemia, Chronic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,benzyl isothiocyanate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Oxides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ABCB10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SMAD3 gene|SMAD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"20-hydroxy-5,8,11,14-eicosatetraenoic acid",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,shikonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KLF4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,fucoidan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PROTEIN KINASE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,letrozole,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Cyclin E,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,"Lupus Erythematosus, Systemic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Steroids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 gene|BRCA1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Lipogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant meningitis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Folic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NBAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Promoter Regions (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SULF2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,arctigenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,xanthohumol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interstitial Collagenase,Breast cancer metastatic,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,BVES,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,POU5F1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MSI2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANXA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,curcumol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,iron ion homeostasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oxygen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transferrin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Phosphotransferases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,pomegranate juice,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LRRC3B gene|LRRC3B,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,MET gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,YAP1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ITGB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,discoidin domain receptor 2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,protein tyrosine phosphatase 1B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Heat Shock Protein 27,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Complement 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HVCN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IGKV6D-21,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fertility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cell invasion,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Tenascin|TNC,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Heightened perception,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,C1GALT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bone remodeling,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,caveolin 1|CA5A|CAV2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Functional RNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Sporadic Breast Carcinoma,Other,0.3988,0.0,Female Breast Cancer
AFFECTS,Malignant tumor of colon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PGR gene|PGR,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Serotonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANG gene|ANG,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CALCA gene|CALCA,Ductal Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Lactate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Agent,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Diabetes,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,bakuchiol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dyslipidemias,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TFF3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pregnane X receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm Metastasis,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,OGG1 gene|OGG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MT2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine therapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,isoalantolactone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LEF1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Raloxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HIST2H2AC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epithelial antibody,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"BCAR1 protein, human|BCAR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fluoxetine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,sinomenine hydrochloride,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Interleukin-17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TARDBP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin B6 intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fibroblast Growth Factor Receptors,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,exemestane,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Adenocarcinoma of esophagus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADAM33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Homologous Recombination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,TP53 gene|TP53,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,hepatocellular carcinoma protein 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,HOTAIR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VTCN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RELN gene|RELN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Urine protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FCRL3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PARP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Interleukin-1 beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Antibodies, Anti-Idiotypic",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Enzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,intervention program,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,PTEN gene|PTEN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SHARPIN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,methyl 4-azidophenylacetimidate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Total estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PGR gene|PGR,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Polycomb,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,S1PR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SP7,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CD44,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCL20 gene|CCL20,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ITK gene|ITK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RNU4-2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,meleagrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Brown rice,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AR gene|AR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD29 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Forkhead Transcription Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcriptase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,salinomycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANKLE1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,skills,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AUGMENTS,sigma-1 receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAPT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Orthologous Gene,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Polysaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TGFBR1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,NBS1 gene|NBN|NLRP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Apoptosis Inhibiting Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,sphingosine kinase-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ischemia,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,S100A4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cervix carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Stem cell transplant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,progesterone receptor negative,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Soybean preparation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRD7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,CDC42 gene|CDC42,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Multiple malignancy,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,SENP2 gene|SENP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SUCLA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,CDCA7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,diallyl disulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Relaxin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GEN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,4-chlorophenyl methyl sulfide,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
CAUSES,H2AFX gene|H2AFX,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,CDH1 gene|CDH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Difficulty sleeping,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRI-2191,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Collagen,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CXCR4 gene|CXCR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Toremifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MSH6 gene|MSH6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCND2 gene|CCND2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GLS gene|GLS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Dietary Component,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-1 beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Isoprostanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TXNIP gene|TXNIP,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,WWC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,phenidone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,MALAT1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,fibulin-3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Chitosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MAPK8 gene|MAPK8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ZEB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"PER2 protein, mammalian",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"9,10-Dimethyl-1,2-benzanthracene",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"RNA, Satellite",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LGALSL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aloperine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CD80 gene|CD80,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein Precursors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydrogels,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2 gene|ERBB2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Adverse effects,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Estradiol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Test Result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TAZ gene|TAZ,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer cachexia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibrosis,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Membrane receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glycine Hydroxymethyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,beta catenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Luteolin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,TLN2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Gelatinase B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,disease stage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,midkine|MDK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pregnane X receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cigarette Smoking,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,BITTER MELON,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BCAR3 gene|BCAR3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,crystalloid,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,genetic locus,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHI3L2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,3MC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AR gene|AR,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,FGFR2 gene|FGFR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMEM25,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLK10 gene|KLK10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD247,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,YAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oncogene Proteins,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MLL gene|KMT2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDH1 gene|CDH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antineoplastic Agents,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cyclin D1|CCND1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Axillary Lymph Node Involvement,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,"TNF protein, human|TNF",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mutation,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CATHEPSIN D|CTSD,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Skim milk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epidermal Growth Factor Receptor|EGFR,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Dissection,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Symptoms,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Atypical lobular hyperplasia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Hexachlorobenzene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,personal responsibility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,beta-hexachlorocyclohexane,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Growth,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,receptor expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Generalized obesity,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RHCE|FIP1L1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Ischemic stroke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Malignant disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Aromatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tamoxifen,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,CD27,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SALL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cathepsin K|CTSK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,paxillin|PXN,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Metformin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CTHRC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CTHRC1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Hydroxyl Radical,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,DDT (Insecticide),Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Medication use,Malignant neoplasm of breast,Pharmacological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Depo-Provera,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Composition,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Ductal Breast Hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,prednisolone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,5-hydroxymethyl-2'-deoxyuridine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diabetic Retinopathy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Depressive disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SYK gene|SYK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DHFR gene|DHFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2|NEU1|NEURL1,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,Genes,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,IGF1 gene|IGF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aspirin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Dairy Products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Maternal status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PAX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vascular Endothelial Growth Factor Receptor-1|FLT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Paclitaxel,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,OR10J3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IRS2 gene|IRS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fine needle aspiration biopsy,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Therapeutic regimen,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,CYP1B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Allelic Imbalance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Soy Foods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,2-hydroxyestrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MTHFR gene|MTHFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Early Diagnosis,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Lobular Neoplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ultrasonography,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,small molecule,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Noscapine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S100A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,response,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,SLCO1B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD40 gene|CD40,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Acquired Immunodeficiency Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Systemic Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KISS1 gene|KISS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,osteopontin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Zeranol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF365,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leg length,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Worried,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Calgranulin B|S100A9,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CCNE1 gene|CCNE1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Suppressor Genes,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Progesterone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MIRN27A gene|MIR27A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,B3GNT2|B3GNTL1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,coping resources,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DDX5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aberrant DNA Methylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aldehyde dehydrogenases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"ribosomal protein S6 kinase, 70kD, polypeptide 2|RPS6KB2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A9 gene|S100A9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ORAI1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,XRCC3 gene|XRCC3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Creatinine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Speech reception threshold,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin-17,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,osteopontin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Therapeutic procedure,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,SOD2 gene|SOD2,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Metaplastic Breast Carcinoma,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Testosterone,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Free Radicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Berberine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Squamous cell carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,AG 14361,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Functional disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Amenorrhea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Biological function, NOS",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fluoxetine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SMARCE1 gene|SMARCE1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PTEN gene|PTEN,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,GSTT1 protein|SLC25A4|CD5|IL1RL1|TRAPPC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTT1 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oral form estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microinvasive carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,beta Sitosterol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Pharmaceutical Preparations,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Estradiol acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell fusion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM3A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,May-Hegglin anomaly,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Invasive Malignant Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MMP9 gene|MMP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,trastuzumab,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,crocin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PGR gene|PGR,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Rare Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PGRMC1 gene|PGRMC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,meningioma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Deferoxamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bread,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Rifabutin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Supplementation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Diabetes Mellitus, Insulin-Dependent",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,XIST,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glucocorticoids,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,RNASEL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Arsenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,oncostatin M|OSM,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Not significant,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,"Metals, Heavy",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinogens,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MIRN223 gene|MIR223,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TERT gene|TERT,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prophylactic immunotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,RNA I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fertility problem,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HTATIP2 gene|HTATIP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL10 gene|IL10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cyclooxygenase 2|XK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,S-Adenosylmethionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperparathyroidism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,household cleaner,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Behavior,Breast cancer recurrent,Behavioral Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,LUM gene|LUM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Extravasation of lymph,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CAV1 gene|CAV1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast surgery,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PRKDC gene|PRKDC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ethanol Metabolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCB1 gene|ABCB1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BAX gene|BAX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,acadesine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIRN21 gene|MIR21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclooxygenase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NR4A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol interaction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Angiography, Digital Subtraction",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Malaise,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDK2AP1 gene|CDK2AP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD28 gene|CD28,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Disease Outcome,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Primary tumor size,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,S100A9 gene|S100A9,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,breast cancer prevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SPSB1,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,TNFRSF1B gene|TNFRSF1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammatory Breast Carcinoma,Malignant neoplasm of breast,Other,0.0177,0.3386613386613387,Female Breast Cancer
DISRUPTS,Aromatase Inhibitors,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cytochrome P450,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fertilization in Vitro,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ligands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cookie and/or cracker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Heregulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Kininogenase|KLK4,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"TERT protein, human|TERT",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Conjugated Equine Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Uterine hemorrhage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,steroid sulfate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Clinical Protocols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beef,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNA Interference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Saponins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,glutathione S-transferase M1|CHRM1|MRLN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Plasminogen Activator Inhibitor 1|SERPINE1|SERPINB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Saponins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Maximum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,versican|VCAN,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Regional Disease,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Glucocorticoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Unreported,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Total cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Chlorogenic Acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SGCB|APOBEC3B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AANAT gene|AANAT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,4-hydroxy-2-nonenal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Contraceptives, Oral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD2 gene|CD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PROCR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SELPLG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic breast density,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,TIAM1 gene|TIAM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Examination of breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Detection,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,CDKN1C gene|CDKN1C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,8-oxo-7-hydrodeoxyguanosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carboplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chemoprevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DAND5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cosmic Radiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,loss; bone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,lobaplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Peptide Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,zoledronic acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,DMBT1 gene|DMBT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,arginylarginine|ABL2|RERE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Female Breast Carcinoma,Malignant neoplasm of breast,Other,0.0174,0.3386613386613387,Female Breast Cancer
AUGMENTS,ABCG2 gene|ABCG2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adaptation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Toll-like receptor 9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adenocarcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Atypical lobular hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,kinase inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AR gene|AR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Not significant,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Hemoglobin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Propranolol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cosmetic surgery,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Paget's Disease,"Carcinoma, Ductal, Breast",Demographic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,NF-kappa B,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,MIRN107 gene|MIR107,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Breast cancer recurrent,Other,0.3988,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Thioctic Acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mammaplasty,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fat graft,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Regulatory Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ESR1 protein, human|ESR1",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Initiative - finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,tumor growth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Iron,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Calcium Channel Blockers,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Adverse effects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,autoimmune thyroid disease,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Injectables,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogenes|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Local Anesthetics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thymine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Puberty,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Tumor Markers,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Absorptiometry, Photon",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Osteocalcin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Alendronate,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,KDM4A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,phthalate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TINCR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KRT19 gene|KRT19,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,DDT EXPOSURE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Benzanthracenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vimentin|VIM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Latent Virus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of breast,Breast Carcinoma,Other,0.3988,0.0279720279720279,Female Breast Cancer
AUGMENTS,phospholipase C beta2|NEUROD1|TUBB4B,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Folic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Steroid hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EVI1 gene|RUNX1|MECOM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATG9A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MUTYH,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Periodontal Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,K-ras Oncogene|KRAS,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Morphine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00339,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MKNK1,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,nicotinamide phosphoribosyltransferase|NAMPT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Induction,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,VEGFA,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Little's Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HOXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fluphenazine Hydrochloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen receptor negative,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Naloxone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glucosides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOXP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNORA7B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnesium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CASC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fatty acid glycerol esters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infiltration,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Small Inducible Cytokine A18|CCL18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,beta catenin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LINC01857,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tissue Model,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Schizophrenia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antisense RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CASC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,glycogen synthase kinase 3 beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NR0B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,schisandrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Antigens, Fos-Related|FOS",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Treatment Protocols,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,RFP2 gene|TRIM13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Green Fluorescent Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FSIP1 gene|FSIP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SIRT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,racial differences,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,COPB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Binding Sites,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,tropomyosin-4|TPM4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Steroid 17-alpha-monooxygenase|CYP17A1,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Estrogen receptor positive,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,saikosaponin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of lung,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RHPN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic inflammation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00460,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,UBE2D2 gene|UBE2D2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RASSF1A|RASSF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TGFB1 gene|TGFB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP24A1 gene|CYP24A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SATB1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ENOLASE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ACSF3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Red Meat Consumption,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,E2F1 gene|E2F1|UBE2L3,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Estrogens, Conjugated (USP)",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ENO1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CUL5 gene|CUL5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BODY HEIGHT:LENGTH:POINT IN TIME:^PATIENT:QUANTITATIVE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Apocrine adenocarcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOSL1 gene|FOSL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mastitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ribosomal RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCB 153,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STIM2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,NBEAL1,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AUGMENTS,PCB 153,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,acetylacetone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,betulinic acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CYP24A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADCY4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AZIN2|GADL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCB 118,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,11-beta-Hydroxysteroid Dehydrogenase Type 2|HSD11B2|RNU1-4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Implantation procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,caspase-8|CASP8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Electromagnetic Energy,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,PALB2,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Polycystic Ovary Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neuropathy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GTPase-Activating Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,C11orf74|C17orf49,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,ATP8A2 gene|ATP8A2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Aromatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,regulatory loop,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Enrich (product),Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,CGRRF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,estrogens,estrogen receptor-positive breast cancer,Hormonal Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,GTPase-Activating Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor-Associated Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PPAR gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NAMPT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRDM2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Thrombospondin 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,MIR223 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Hepatolenticular Degeneration,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nuclear Receptor Coactivator 3|NCOA3|ANIB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MAP2K4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LHX1 gene|LHX1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,blood test result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MIR195 gene|MIR195,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,quinoline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Deoxyuridine,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,High Confidence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UGT2B7 gene|UGT2B7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,LINC02657 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZEB1-AS1 gene|ZEB1-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,thrombin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,prasterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Substance with phenol structure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,thymoquinone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cyclin D1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"TFF1 protein, human|TFF1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SETD3 gene|SETD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnostic Imaging,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,GADD45A gene|GADD45A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LSR gene|LSR,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,27-hydroxycholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,H19 gene|H19|HILS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Accumulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Radiopharmaceuticals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prognosis bad,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,DNA Minor Groove Binding Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Sex Hormone-Binding Globulin,Invasive carcinoma of breast,Demographic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,GSTT1 gene|GSTT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,mullerian-inhibiting hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NOP2 gene|NOP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,E2F3 gene|E2F3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gamma-linolenic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Adriamycin,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,PLSCR1 gene|PLSCR1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,glutathione S-transferase pi|GSTP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primigravida,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,MIR454 gene|MIR454,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Binge Drinking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Basaloid squamous cell carcinoma,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,apolipoprotein D|APOD,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IGFBP7|SFPQ,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Small Molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TXNIP gene|TXNIP,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,platinum,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"EIF2C2 protein, human|AGO2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,pioglitazone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,gonadorelin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A14 gene|S100A14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,LINC00261 gene|LINC00261,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Methyl-CpG-Binding Protein 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CTHRC1 gene|CTHRC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,rhein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"POU5F1 protein, human|POU5F1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR622 gene|MIR622,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TFEB gene|TFEB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Profilin 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aromatase,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Hypersensitivity,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,RB1CC1 gene|RB1CC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mitotic Activity,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,LMNB1,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,ESM1 wt Allele,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cereal intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aggressive cancer,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,LOXL4 gene|LOXL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Extensive Necrosis,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMPO wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"RNA, Messenger",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,MIR145 gene|MIR145,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HOPX gene|HOPX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,risk factors,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,CD163,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neurosurgical Procedures,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,LMNB1,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,3-methylquercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TMED3 gene|TMED3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GPC1 gene|GPC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcript,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Industrial fungicide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Factors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Negative,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,malignant neoplasm of breast staging,Other,0.3988,0.0,Female Breast Cancer
AFFECTS,NEAT1 gene|NEAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TAC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alleles,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
AFFECTS,Negative Regulation of S Phase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SALL4 gene|SALL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunoregulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IL31 gene|IL31,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,fos-related antigen 1|FOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclophosphamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SAMD4A gene|SAMD4A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,WWOX wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Treatment modification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMAD7 gene|SMAD7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Residual Tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Androgen Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low Density Lipoprotein Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Illness (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,UGT1A1 gene|UGT1A1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SKA3 gene|SKA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glucocorticoid Receptor,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Nucleotides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HOMER1 gene|HOMER1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Blood Proteins,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Hyperphagia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypomethylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytokine,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Synthetic glucocorticoid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HOTAIR gene|HOTAIR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,fructose,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,CYFIP1 gene|CYFIP1,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,HER2-negative breast cancer,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,"GPER protein, human|GPER1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Family history,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Deubiquitinating Enzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Family history,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"CRYAB protein, human|CRYAB",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"YAP1 protein, human|YAP1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DSCC1 gene|DSCC1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Benzo(a)pyrene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin-Dependent Kinase Inhibitor Proteins,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,ATXN8OS gene|ATXN8OS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Diabetes Mellitus, Non-Insulin-Dependent",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,CHPF gene|CHPF,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,palbociclib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,epithelial to mesenchymal transition,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Aurora Kinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC12A8 gene|SLC12A8,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Transferrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Deodorants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,beta catenin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Alleles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,thioguanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Copy Number Polymorphism,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,"Receptor, Transforming Growth Factor-beta Type I|TGFBR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GOLPH3L gene|GOLPH3L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cystathionine beta-Synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Color doppler ultrasound,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,KIF15 gene|KIF15,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,osthol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KIF3B gene|KIF3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DNA Methyltransferase Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,letrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Agent,Carcinoma breast stage IV,Demographic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,mitogen-activated protein kinase kinase kinase 11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KIF3B gene|KIF3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cathepsin L,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Squalene monooxygenase,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,osthol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Hormone Receptor Positive Breast Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ABCG2 protein, human|ABCG2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,PARP inhibitor therapy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ITM2A gene|ITM2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,thymoquinone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TOX3 gene|TOX3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR22 gene|MIR22,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,estradiol,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,saffron extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
PREDISPOSES,beta-2 Microglobulin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,small size,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SHISA3 gene|SHISA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSEC gene|GSEC,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Smoking,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,ST7-AS1 gene|ST7-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alleles,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,KIAA1109 gene|KIAA1109,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Aquaporin 1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ACTL8 gene|ACTL8,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Stimulation procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,2 times,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,interleukin-10,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Botanical,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"RNA, Small Untranslated",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,LGMN gene|LGMN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,research results,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLAMF7 gene|SLAMF7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Childbirth,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,calcium ion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,bisphenol A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fatty-acid synthase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,UGT1A7 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Modest-Temperature Hyperthermia,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,SRSF1 gene|SRSF1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PVR gene|PVR,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,E-Box Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Long Intergenic Non-Protein Coding RNA,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,FBXO5 gene|FBXO5,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SRSF1 gene|SRSF1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,CEP55 gene|CEP55,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Artificially Sweetened Beverages,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mood:-:Point in time:^Patient:-,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Crotoxin,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,jolkinolide B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antigen Processing,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DPP4 gene|DPP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary Intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Portal Hypertension,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR526B gene|MIR526B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Processes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heparin Binding Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EN1 gene|EN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoke Exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microcalcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IFI30 gene|IFI30,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EGR1 gene|EGR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DPP10 gene|DPP10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Glycosphingolipids,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,pyridine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,cyclin B2,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Xenograft procedure,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,ANLN gene|ANLN,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,LINC01089 gene|LINC01089,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Copy Number Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMUG1 gene|SMUG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNA modification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ataxia telangiectasia mutated protein|ATM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stilbenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,NOL10 gene|NOL10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TMEM238L gene|TMEM238L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drug Combinations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IMPACT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR155 gene|MIR155,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Monocyte Chemoattractant Protein-1,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Intravenous therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TCOF1 gene|TCOF1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,TBX15 gene|TBX15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,disorder control (procedure),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,H1-5 gene|HIST1H1B,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,caveolin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oils,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Breast Density,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Coronary Arteriosclerosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tRNA modification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA1 Mutation,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Normal weight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR4521 gene|MIR4521,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Periodontitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lead,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Polyunsaturated fatty acid intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Response to treatment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Parity,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,hyaluronic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LIG1 gene|LIG1|LRIG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ARHGAP9 gene|ARHGAP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mortalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RPS6KA3 gene|RPS6KA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Matrix Metalloproteinase 11,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Hypersensitivity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tanshinol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RTL8C gene|RTL8C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,JAM2 gene|JAM2|JAM3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,progesterone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SYVN1 gene|SYVN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Constitutive skin pigmentation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genetic Profile,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vitamin D3 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MALAT1 gene|MALAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FAM189A2 gene|FAM189A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,sinomenine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lipoxygenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VIRMA gene|VIRMA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TSHZ1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MRPS30-DT gene|MRPS30-DT,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Taxol,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,HOXC-AS3 gene|HOXC-AS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LPAR6 gene|LPAR6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Very Important,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Anti-Bacterial Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Injections, Intraperitoneal",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, KIR2DL4",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EIF6 gene|EIF6,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Rhythm,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,ANKDD1A gene|ANKDD1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MEOX2 gene|MEOX2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MIR660 gene|MIR660,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,UHRF1 gene|UHRF1,Invasive Ductal Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,mRNA Precursor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDC42,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,PDE5A wt Allele|PDE5A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pregnancy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"IL22 protein, human|IL22",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Homologous Recombination Deficiency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,inermin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,STAMBPL1 gene|STAMBPL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LINC00472 gene|LINC00472,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,GZMK gene|GZMK,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,CDK16 gene|CDK16,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Sulfatases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RNA, Untranslated",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Indicators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Protein p53|TP53,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,diallyl trisulfide,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Malignant Neoplasms,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,ATP6AP2 gene|ATP6AP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LMNB1 gene|LMNB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alleles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of bone,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
AUGMENTS,MARK2 gene|MARK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GATA3 gene|GATA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RBIS gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,corynoline,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Ovarian Stimulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,urokinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mouse mammary tumor virus,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,History of previous events,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Micelles,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,cytochrome b561,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,File Being Validated,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C17orf49 gene|C17orf49,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,docetaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,eribulin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MYC gene|MYC,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,RUNX2 gene|RUNX2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNHG14 gene|SNHG14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,intracellular protein transport,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WNT2 gene|WNT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,fulvestrant,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,"Food, Preserved",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Elevated Expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KIF11 gene|KIF11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Lactic acid dehydrogenase isoenzyme 5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ANLN gene|ANLN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,COL11A1 gene|COL11A1,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Melanocyte stimulating hormone,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ACTA2-AS1 gene|ACTA2-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"IRS1 protein, human|IRS1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Necrosis Factor Signaling Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IMPA1 gene|IMPA1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,LINC01194 gene|LINC01194,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,4 times,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,perfluorooctane sulfonic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sulfonic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Refractory Breast Carcinoma,Other,0.0,0.0,Other
AFFECTS,EGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,New medications,Malignant neoplasm of breast,Pharmacological Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MRPS7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ascorbic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sirolimus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Matrix Metalloproteinase 9|MMP9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Generalized obesity,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IMPA1 gene|IMPA1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider},Triple Negative Breast Neoplasms,Demographic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Membrane Transport Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,E2F6 gene|E2F6,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Androgen Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,homocysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TP53 gene|TP53,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ACBD3 gene|ACBD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GAS6-AS1 gene|GAS6-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SERPINA12 gene|SERPINA12,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,SEMA3B-AS1 gene|SEMA3B-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Calcinosis universalis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLC3A2 gene|SLC3A2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GLI1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,carbidopa,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,RYK gene|RYK,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,heparanase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinase 2|MMP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FRY gene|FRY,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ITK protein, human|ITK",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MUC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"ERCC5 protein, human|ERCC5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MYCL gene|MYCL,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CXCL14 gene|CXCL14,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,AURKB gene|AURKB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lipopolysaccharides,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,lidocaine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSPB2 gene|HSPB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Early Diagnosis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,RECQL4 gene|RECQL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EXO1 gene|EXO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF217,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ligands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mevalonate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunogenic Cell Death,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Pathogenic Variant,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Metabolite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,glutathione S-transferase pi|GSTP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00473 gene|LINC00473,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Inhibitor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,FOXA1 gene|FOXA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,glutathione,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BARRIER,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Antiplatelet Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Basis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,USP37 gene|USP37,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,PPARA gene|PPARA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vitamin D3 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,boswellic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,dihydrotanshinone I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOX8 gene|SOX8,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Low-Dose Aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,health knowledge,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00536 gene|LINC00536,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,panobinostat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CBX3 gene|CBX3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,arsenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Anti-Inflammatory Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interventional procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOAT2 gene|SOAT2,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,FRMD3 gene|FRMD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ENOLASE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,perfluorooctanoate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,thiamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IMPACT gene,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,SDC1 gene|SDC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Circulating MicroRNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TINCR gene|TINCR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,birth control pill use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MIR497HG gene|MIR497HG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Differential Diagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Responsive Disease,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,LAPTM5 gene|LAPTM5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CLDN6 gene|CLDN6,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,TAF15 gene|TAF15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RHOV gene|RHOV,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Transforming Growth Factor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sauchinone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Targeted Therapy,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GABRD gene|GABRD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MVP wt Allele|RPSA|LRP1|PTPRA|MVP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CBFB|NFYA|NFYB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SIRT7 gene|SIRT7,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,MicroRNAs,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,caspase-3,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Disease/diagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Energy Balance,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MYBL2 gene|MYBL2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Improved,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NOTCH1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,COMMD3 gene|COMMD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leisure behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NPY1R gene|NPY1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cyclic guanosine monophosphate-adenosine monophosphate,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Biological Markers,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Sugar-Sweetened Beverages,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cobalt dichloride,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Hexokinase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"herstatin protein, human",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"Adaptor Proteins, Signal Transducing",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PLPP4 gene|PLPP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TIPARP gene|TIPARP,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Metabolic Profile,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hexokinase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GJA1 gene|GJA1,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Pathogenic Variant,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Phytochemicals,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Pyrenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,C1QL4 gene|C1QL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Food Habits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Noninfiltrating Intraductal Carcinoma,Triple Negative Breast Neoplasms,Other,0.0692,0.0189810189810189,Female Breast Cancer
AFFECTS,fruit extracts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heat Shock Protein 27,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sulfhydryl Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IDO2 gene|IDO2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Players,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,NDC80 gene|NDC80,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,reproductive hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ADAR gene|ADAR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Liposomes,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,GPT2 gene,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Long Interspersed Nucleotide Element-1,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,PTCSC3 gene|PTCSC3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,histone deacetylase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SCRIB gene|SCRIB,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infiltration,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Microenvironment of Metastasis Density,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immune,HER2-negative breast cancer,Immunological Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,IRF7 gene|IRF7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HDAC1 gene|HDAC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ferritin Light Chain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypothalamic inhibiting factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,MED1 gene|MED1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Triple Negative Breast Neoplasms,Malignant neoplasm of breast,Other,0.0298,0.3386613386613387,Female Breast Cancer
AFFECTS,MAPK1 gene|MAPK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogenesis,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,xiaoyaosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gravidity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytochrome b561,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Suppressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Multiple tumors,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,agonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Thrombotic Microangiopathies,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Dynamic Contrast-Enhanced Magnetic Resonance Imaging,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Alkaloids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ZNF831 gene|ZNF831,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MC1R gene|MC1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,estrogens,estrogen receptor-positive breast cancer,Hormonal Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,pristane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Non-alcoholic Fatty Liver Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ginsenosides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ethanol,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,40-49,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,interleukin-6|IL6,Invasive Ductal Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,"estrogens, conjugated (USP)",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR429 gene|MIR429,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Interleukin-16, human",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,polyphyllin II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ATF2 protein, human|ATF2",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,FTO gene|FTO,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mahanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,trastuzumab deruxtecan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,doxorubicin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,KLF5 gene|KLF5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Perimenopause,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FZR1 wt Allele|CDH1,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
AFFECTS,Screening for malignant neoplasm of breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAM83D gene|FAM83D,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RACK1 gene|RACK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CXCL8,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,A1BG-AS1 gene|A1BG-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ANO6 gene|ANO6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AFF4 gene|AFF4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PROS1 gene|PROS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,testosterone,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Hemoglobin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,chemokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,butylbenzyl phthalate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lesch-Nyhan Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CAVIN1 gene|CAVIN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Receptors, Opioid, kappa",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,AMACR wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TDRKH-AS1 gene|TDRKH-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"IMP3 protein, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"MFGE8 protein, human|MFGE8",Invasive Ductal Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Organic solvent product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endometriosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TTPAL gene|TTPAL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXK1 gene|FOXK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR205 gene|MIR205,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Non-alcoholic Fatty Liver Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Implants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESR1,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
AFFECTS,FTO gene|FTO,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,GNAO1 gene|GNAO1,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Tobacco,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXQ1 gene|FOXQ1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tea,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,PARK7 gene|PARK7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PPARGC1B gene|PPARGC1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TPM2 gene|TPM2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pivot,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,RSRC2 gene|RSRC2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ERBB2,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
COMPLICATES,Sarcoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD69 protein, human|CD69",Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,Estrogen Receptor alpha,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Score,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
PREDISPOSES,SIK2 gene|SIK2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carney Complex,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"interleukin-1, beta",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,magnesium cation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplastic Cell Transformation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,pimozide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Movement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR205 gene|MIR205,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Androgen Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SLC7A11 gene|SLC7A11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Gene Expression,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,MT-RNR1 gene|RNR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAB5A gene|RAB5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CAT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Patient Derived Xenograft,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CCDC150 gene|CCDC150,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Male-to-female transsexual (finding),Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Autoantibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MXRA5 gene|MXRA5,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,claudin 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NF2 gene|NF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,humanin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,translation factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WWOX gene|WWOX,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EP300 gene|EP300,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Leucine-Rich Repeat Proteins,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,scopolamine,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
COMPLICATES,EYA2 gene|EYA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PKMYT1 gene|PKMYT1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ME1 gene|ME1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CACNG4 gene|CACNG4,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Upstaging,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,obeticholic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,CCL20 gene|CCL20,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MBD2 gene|MBD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"IL1A protein, human|IL1A",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL22 gene|IL22,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,taurine,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Multiple Sclerosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Targeted Therapy,HER2-positive carcinoma of breast,Treatments,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Bee Venoms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Human Class I Antigens,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,DNA Replication,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CCNB1 gene|CCNB1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Urolithin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protective Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pyruvate dehydrogenase kinase 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tissue texture abnormality,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Basal Diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC38A5 gene|SLC38A5,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,FGF11 gene|FGF11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,phosphatidylinositols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,4-aminohippuric acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZBTB10 gene|ZBTB10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Combination Chemotherapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Folliculin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nitric Oxide Synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,20q13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GRB7 gene|GRB7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CCL18 gene|CCL18,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,TBX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FAS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TIMM50,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stromelysin 1|MMP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EPHA10 gene|EPHA10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cancer-Predisposing Gene,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,MAP3K1 gene|MAP3K1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estrogens,Breast cancer metastatic,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Integrin alpha4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,intraoperative radiotherapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Menopause,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,BRMS1L,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CYP1A1 gene|CYP1A1,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,"WBSCR22 protein, human|BUD23",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,11q13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Environmental Estrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cyclin D1|LMOD1|BBS9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Renal Cell Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cyclin A1|CCNA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oxygen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Pollutant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tangeretin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Enhancer Elements (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Glutamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Heregulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN143 gene|MIR143,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RAD51C gene|RAD51C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,AATF gene|AATF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta catenin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,STF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Selective serotonin re-uptake inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC39A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTGS2 gene|PTGS2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,8-Oxoguanine DNA Glycosylase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Annexin A1|ANXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Organized pneumonia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Methotrexate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IFNB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Suppressor Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, Opioid, delta",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL18 gene|IL18,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Androgen Receptor|AR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Pads,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Hypoxia,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Autophagy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Genuineness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BAG3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Carcinoma, Ductal, Breast",Malignant neoplasm of breast,Other,0.0396,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNAI1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytotoxicity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NOP14,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Rectal hemorrhage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NRIP1 gene|NRIP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Activins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Microtubule-Associated Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphoglycerate dehydrogenase|PHGDH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WRAP53,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epidermal Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,STC1 gene|STC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Environmental Pollutants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNAI1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TRIM62,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Wound Healing,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,ERBB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,osteoblast cadherin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Congestive heart failure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,octylphenol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ir Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADGRF5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Salts,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FH: Father NOS,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,carnosol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin-Like Growth Factor Receptor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ADRA2A gene|ADRA2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"1,4-dioxin",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,icariin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Expression Regulation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR200A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"ST13 protein, human|ST13",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PIK3R1|PIK3R2|ARHGEF7|CBFA2T2|PPP1R13B|PPP1R12C,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Physical activity decreased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,anthracene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FABP5 gene|FABP5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Follicle Stimulating Hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PRLR gene|PRLR|PTP4A3,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,GSTA1 gene|GSTA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,retinyl methyl ether,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PIK3CA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytokine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,High Vegetable Diet,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Levodopa,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,receptor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oncogenes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor I,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Clomiphene,bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
CAUSES,Viral Tumor Antigens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,mammaglobin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Diphosphonates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,glycosyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Brachytherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nifedipine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytokine,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Central Nervous System Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dichlorodiphenyl Dichloroethylene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ukrain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin D1|LMOD1|BBS9,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Human papillomavirus 16,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant mixed salivary gland tumor,Cancer en cuirasse,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,"Receptors, Progesterone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Human Platelet Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,reproductive hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TARBP2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Alcohol consumption,bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
CAUSES,Agent,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MAPKAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CTTN gene|CTTN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Atypical proliferation,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Tumor Antigens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Edema,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Voluntary,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Sulfones,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Polyunsaturated Fatty Acids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CD44 gene|CD44,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Herpesviridae,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Microsatellite Repeats,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Fatty Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Z-alpha-chlorochalcone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PRLR gene|PRLR|PTP4A3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LALBA gene|LALBA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,R-38486,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of breast,Breast cancer invasive NOS,Other,0.3988,0.0099900099900099,Female Breast Cancer
AFFECTS,Cyclophosphamide,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"TFF1 protein, human|TFF1",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Carotenoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MENSTRUAL STATUS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Common Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Menopausal Status,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,Mechlorethamine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Goiter,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Epidermal Growth Factor Receptor|EGF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,OK-432,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tall stature,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,dehydroepiandrosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Caloric Restriction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Esters,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Hodgkin Disease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"Carcinogens, Environmental",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atrophic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Excessive self-esteem,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Confident,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Dinoprost,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,cDNA Library,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,FGF4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrosing adenosis,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Epoprostenol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RBBP1L1 Protein|ARID4B,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,FGF4 gene|FGF4,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pregnancy review,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Zuclomiphene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,EMD 16795,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Silicones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Malignant Carcinoid Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ergocornine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Cisplatin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,2-Acetylaminofluorene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hypolipidemia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Retinoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tamoxifen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hormone manipulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transgenes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Microsatellite Repeats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adipositas,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drink,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Replacements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,ATM gene|ATM,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Noninfiltrating Intraductal Carcinoma,Breast cancer invasive NOS,Other,0.0692,0.0099900099900099,Female Breast Cancer
AFFECTS,TP73|ARHGAP24,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,thermography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Calcium Glucarate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Psychological Impact,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,p65|RELA|SYT1|GORASP1|WNK1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dietary Fats,Breast Carcinoma,Behavioral Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PPARBP gene|MED1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin-Like Growth Factor I,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,whey protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53 gene|TP53,bilateral breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Osteoclastic resorption,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SYK gene|SYK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microsatellite Instability,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,2-chloroethyl ethyl sulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Jogging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TFF1 gene|TFF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Postmenopausal Hormone Replacement Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pregnenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,casein kinase II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overweight,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Tumor Angiogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,matrix metalloproteinase 26,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,8-hydroxy-2'-deoxyguanosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,glutathione S-transferase pi|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Germ-Line Mutation,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Integrin alphaV,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha-Fetoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BIN1 gene|BIN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BIRC5 gene|BIRC5,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to Unspecified general medical examination,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ERBB2|NEU1|NEURL1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SLC39A6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Diet,Breast Carcinoma,Behavioral Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Pollutant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Parkinson Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Menopausal hot flushes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD82 gene|CD82,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Tumor Suppressor Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Amphiregulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TNFSF10 gene|TNFSF10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transforming Growth Factor alpha|TGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumor Suppressor Genes,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,"Diagnosis, Computer-Assisted",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,estrone sulfatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABL2|RERE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bone Resorption,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phytoestrogens,Breast cancer recurrent,Hormonal Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,SNCG gene|SNCG,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Fatty Acids, Monounsaturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,H-ras Genes,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Carcinoembryonic Antigen,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,REL gene|REL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Selenium,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Ethylnitrosourea,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"N,N-dimethyl-4-anisidine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tamoxifen,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
CAUSES,"BCAR1 protein, human|BCAR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AKT3 gene|AKT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Surgical biopsy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Technetium Tc 99m Sestamibi,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Hexestrol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Opioid Peptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,stanniocalcin 2|STC2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Early menarche,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,8-hydroxyguanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Fatty Acids, Omega-6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Anti-Inflammatory Agents, Non-Steroidal",Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptor, Melatonin, MT1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Antidepressive Agents, Tricyclic",Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LIG4 gene|LIG4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antineoplastic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNCG gene|SNCG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mitotic Activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tamoxifen,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Alpha heavy chain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"1,2-dibromo-3-chloropropane",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRCA2 gene|BRCA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Suppressor Genes,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,BRCA1 Protein|BRCA1,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Soy Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Slow acetylator status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ibandronate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"NOS2A protein, human|NOS2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,3' Untranslated Regions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinoma in Situ,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PTEN gene|PTEN,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Glutathione S-Transferase|SLCO6A1|GSTK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Embolism, Tumor",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Therapeutic regimen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Myocardial Infarction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,ATP12A|HK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogenic effect,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,FGF3 gene|FGF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,P-Cadherin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Prenatal Exposure,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,BAG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Eicosapentaenoic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytokinesis of the fertilized ovum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,adjuvant therapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Phosphorylcholine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fatty-acid synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dydrogesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Calgranulin B,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,SPOCK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RUNX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obstruction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,8q24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,Folate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cold temperature,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,helicase|HFM1,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Epithelial Cell Proliferation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Radiation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Fanconi's Anemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atypia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Monocyte Chemoattractant Protein-1|CCL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TNF,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,RANTES|CCL5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Recombinant Interleukin-8|CXCL8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Angiotensin Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,E-Cadherin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Apigenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Palmitic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"STK6 protein, human|AURKA",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,AROMATICS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-6 fatty acid intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tanshinone II A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of prostate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Puberty, Precocious",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chronic Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oxidoreductase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TNFSF6 gene|FASLG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Delayed menopause,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB3 gene|ERBB3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Testosterone,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,PPAR gamma|PPARG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogen Receptor Modulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MERTK gene|MERTK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ASAP1|MYCBPAP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glycol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PARP1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Oncogenes,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,polyphenon E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemopreventive Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Activins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RNA, Small Interfering",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Plants, Edible",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Analgesics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Disintegrins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Carbon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prohibitin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phosphatidylinositols,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Conjugated Equine Estrogens,Breast cancer invasive NOS,Hormonal Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,leucylproline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Carbon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Antihormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Connexins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,podocalyxin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HIVEP2 gene|HIVEP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Platelet-Derived Growth Factor Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Non-esterified cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERbetacx,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Insulin-Like Growth Factor Binding Protein 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, Cell Surface",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GSDME,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Norgestrel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,reproductive hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IFNG gene|IFNG,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Amphiregulin|AREG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,bone morphogenetic protein 2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Epidermal Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body mass index,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Specific antibody,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CHEK2 gene|CHEK2,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,RAD50,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Alleles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CA-125 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Expression,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,EGLN2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MTHFR gene|MTHFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glutathione S-Transferase|SLCO6A1|GSTK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CD24,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STK11 gene|STK11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,anti-apoptosis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogen Receptors,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Cell Communication,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,ERBB2 gene|ERBB2,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,CTCFL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LIN28A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Compound Q,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Simvastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Human Chorionic Gonadotropin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,protein tyrosine phosphatase 1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HMMR gene|HMMR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD70,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,TRANSCRIPTION FACTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,OTP gene|OTP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Janus kinase 2|JAK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MS2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histologic type,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Protein Expression,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,RUNX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP1B1 gene|CYP1B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,nuclear receptor coactivator 1|SRC,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Convenience food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Liposomes,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,KDM8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Cations, Divalent",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,HMMR gene|HMMR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Disulfiram,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LBX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IDO1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Molecular Fingerprint of Tumor,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,healthful behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"2,5-dichloro-4-bromophenol",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cullin Proteins,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Carbon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRMS1 gene|BRMS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PLXNB1 gene|PLXNB1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,RUNX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"SMO protein, human|SMO",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lemon extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,invariant chain|CD74,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,survivin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Cell-cell adhesion molecule,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Introns,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Apocrine adenocarcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FOXC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MYB gene|MYB,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Aluminum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RBBP7,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,quinoxaline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Germ-Line Mutation,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,YBX1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,isoflavonoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Spontaneous abortion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Receptors, Nuclear",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PLG gene|PLG,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,FASTK Gene,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,CYP2S1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A11 gene|S100A11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fenretinide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDC25A gene|CDC25A,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,MDM2 gene|MDM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AUSTRALIAN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UTS2R|SLC14A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RAD51,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,NRDC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S100A1|S100B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemoprevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Field crops,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Core needle biopsy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NOV,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TP53BP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATM gene|ATM,Contralateral breast cancer,Genetic Factors,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Pharmacologic Substance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Mammary Neoplasms,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,NCOA7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ALCAM gene|ALCAM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SPDEF gene|SPDEF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ESR1 gene|ESR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CXCR4 gene|CXCR4,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Receptors, Steroid",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta catenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SERPINE1 gene|SERPINE1,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Cancer Promoting Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolic Marker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CXCL10 gene|CXCL10,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,CBX7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caveolin 1,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,MMP9 gene|MMP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TIMP2 protein, human|TIMP2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BEX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Growth,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SOX18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAP Kinase Gene,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CD44 gene|CD44,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,intraoperative radiotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Gallic acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ATP2B2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KIT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAD51B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lipids,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,FBXW7 gene|FBXW7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,diindolylmethane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S Phase Arrest,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MALAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ASAP1|MYCBPAP,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,hypercholesterolemia,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,Functional RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,COX7A2L gene|COX7A2L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gelsolin|GSN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,F3 gene|F3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Primary Neoplasm,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,aurora kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCL22 gene|CCL22,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vascular Endothelial Growth Factor C|VEGFA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Primary carcinoma of the liver cells,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CRY1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CIP2A,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Berberine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vimentin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,IL2-inducible T-cell kinase|ITK|SLC22A3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KIF11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ATG4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chloroquine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMEM88,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumor Suppressor Genes,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,Proto-Oncogene Proteins c-myc|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cysteine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,RNA-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FGF1 gene|FGF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SFRP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PFN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alport's syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERCC1 gene|ERCC1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Diphosphonates,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Overweight,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,STAT3 gene|STAT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PARK7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Malignant neoplasm of prostate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,molybdenum disulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,OIP5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEST PATHOLOGY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,oleocanthal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neuromedin U|NMU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CASP9 gene|CASP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Angiopoietin-2|ANGPT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DEAE-Dextran,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Disaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LEPR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,docetaxel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Reproductive History,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,PIK3CA|PIK3CB|PIK3CD|PIK3CG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dieckol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Lovastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic Touch,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Smoking Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Phenformin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CCL13 gene|CCL13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Taxanes,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,teleocalcin,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,ligustilide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,C-terminal binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TNFAIP8L3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LGR5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immune response,Breast cancer metastatic,Immunological Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant neoplasm of urinary bladder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polyaromatic hydrocarbon,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,matrine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein phosphatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCR7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glucuronosyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,interleukin-17E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins c-akt|AKT1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MAGEA2,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genes, Regulator",Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Inactivation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Somatostatin Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC9A3R1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Docosahexaenoic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDX2 gene|CDX2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,RCCD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN34A gene|MIR34A,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,NBAT1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Neuropilin-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammation,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"kallikrein 5, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammation,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Endothelin-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast cancer invasive NOS,Breast cancer metastatic,Other,0.0587,0.0279720279720279,Female Breast Cancer
AFFECTS,Ethanol,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,FOXM1 gene|FOXM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Fatty Acids, Omega-3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NSUN2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Primary carcinoma of the liver cells,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lysine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cadherins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MTA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Membrane Transport Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Trichloroethylene,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
COMPLICATES,topical application,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"KLK5 protein, human|KLK5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Non-alcoholic fatty liver,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Age at menarche,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sleep behavior finding,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ESR2 gene|ESR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NOD2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCL4 gene|CCL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oligonucleotides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,receptor,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Antiepileptic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTM3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIRT7,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Neoplasm,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Progesterone level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Aptamer,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FABP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,E2F7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,zinc-binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Proliferation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Hydroxyestrones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KRT5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Isoprostanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coffee intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Choline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WWOX,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PPM1D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcriptional Regulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GATA4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,everolimus,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,decorin|DCN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epidermal Growth Factor Receptor|EGFR,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Dessert,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PHF5A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ITGA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,thymoquinone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cucurbitacin B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thyroid Hormone Receptor Alpha-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dronedarone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FOXC1 gene|FOXC1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Menarche,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,kaempferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Encounter due to prophylactic surgery, unspecified",Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,zileuton,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,APC,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Stanolone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Loops,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polycylic aromatic hydrocarbons-DNA adduct,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,XRCC1 gene|XRCC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fibronectins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"Neoplastic Syndromes, Hereditary",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,APOE gene|APOE,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ceramides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ATP phosphohydrolase|DNAH8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metabolic syndrome,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Angiogenesis,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Spectroscopy, Nuclear Magnetic Resonance",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiofrequency ablation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ANAPC15,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDC2 gene|CDK1|POLD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EZH2 gene|EZH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lapatinib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Apolipoprotein A-I|APOA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UGT1A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Integrins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CHES1 gene|FOXN3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NES gene|NES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A8 gene|S100A8,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Emodin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Raloxifene,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Neoplasm progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fasting,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TOB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fatty fish,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caveolin 1,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,RAD51C gene|RAD51C,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Anti-Anxiety Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Progesterone|EREG|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polyunsaturated Fatty Acids,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,P-Glycoprotein,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Hormone replacement therapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Recreation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,CDKN1A gene|CDKN1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Endopeptidases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,BRCA1 gene|BRCA1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Osteoporosis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogen Replacement Therapy,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,LACRT gene|LACRT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phenelzine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Oral Contraceptives, Low-Dose",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nortriptyline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overweight,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Diet,Breast Carcinoma,Behavioral Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Overoptimism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nonpuerperal mastitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Health promotion behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Binding Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"IGFBP2 protein, human|IGFBP2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Excision,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,somatotropin-binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Behavioral change,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoking,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Alkaline Phosphatase,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,RFC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Health-related behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Androgen Receptor|AR,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,phenylalanyl-glycyl-valyl-statyl-alanyl-phenylalanine methyl ester,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Aromatase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gonadotropins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,bilateral breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,CCND1 gene|CCND1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,bexarotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Serum Albumin,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Diastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antineoplastic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diabetes type,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ataxia Telangiectasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMEM131L,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MMP14 gene|MMP14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,16q12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Macrophage Colony-Stimulating Factor,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Cycle Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Goserelin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Air Pollution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biotinidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UBE2S,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Carcinoma, Ductal, Breast",Noninfiltrating Intraductal Carcinoma,Other,0.0396,0.0109890109890109,Female Breast Cancer
AFFECTS,Primary Lesion,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Mastectomy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Vincristine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Punctate calcium deposition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hodgkin Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary Supplements,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endotoxins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IRS1 gene|IRS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Valine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,STN gene|EEF1A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Excessive weight gain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Drinking pattern,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prunes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Thyroid Hormones,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cosmetic procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Drug Exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCL5 gene|CCL5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Autoimmune hypothyroidism,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nuclear Receptor Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcoholic Beverages,Female Breast Carcinoma,Demographic Factors,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,VASOMOTOR SYMPTOM,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,epigallocatechin gallate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,agonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tipifarnib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Activins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MUC4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Personal Satisfaction,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,PALB2,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,lapatinib,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Interleukin-8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Steroidal Estrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,trichostatin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLK5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Family history of breast cancer,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Rare Diseases,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,deceased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Telomere Maintenance Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cyclin-dependent kinase 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,conjugation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,overdiagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Sirolimus (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NR5A2|P2RX5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diabetes Mellitus,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,KRT20|C17orf97,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NR3C1 gene|NR3C1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Progesterone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,zeaxanthin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRCA3 gene|BRCA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,heparanase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CD40 Ligand|CD40LG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,interleukin-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Calgranulin A|S100A8,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Physical therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Red Meat Consumption,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Muscular Dystrophy, Facioscapulohumeral",bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Instability,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diabetes Mellitus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CSH2 gene|CSH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Actin bundling protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IL8 gene|CXCL8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KIF2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Apoptosis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MTHFR gene|MTHFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AKR1C4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ABCC10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCDC91,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ribonucleotide reductase M2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MT1A|MT1B|MT1E|MT1F|MT1G|MT1H|MT1JP|MT1M|MT1L|MT1X|MTNR1A|ALG1|MT1IP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cadmium Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,psychological distress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PALB2,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,HIF1A gene|HIF1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Alcohol products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammography abnormal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Copper,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,germin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoking,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,Hyaluronan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,diindolylmethane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disorder of pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sleeplessness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RRM2 gene|RRM2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Sirolimus (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Soluble ErbB-1|EGFR,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Silence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gene Family,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PELP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fertility care,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MMP11 gene|MMP11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic microcalcification,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,MIRN93 gene|MIR93|MIR9-3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Urokinase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Protein p53|TP53,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tumor Suppressor Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Rye flour,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Clusterin|CLU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gonadal Steroid Hormones,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Diffusion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Co-morbid conditions,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,regular physical activity,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,C-KIT Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MICE gene,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Mitotic/Spindle Checkpoint,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,claudin 6,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,NEK2,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Somatotropin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CHD5 gene|CHD5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glutamate-Cysteine Ligase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PERP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EGF gene|EGF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammaplasty,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Mammographic breast density,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Autoimmunity,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sunlight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PARD6A|PWAR6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cardanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,None|SLC16A3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoma in situ of breast,Breast cancer invasive NOS,Other,0.0304,0.0099900099900099,Female Breast Cancer
AFFECTS,Corn Oil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Zinc,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,UCA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CHEK1 protein, human|CHEK1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Non-Viral Vector,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aglepristone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,White bread,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Disability NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERCC2 gene|ERCC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,"Calcium, Dietary",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Fluorodeoxyglucose F18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-18,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,chemokine receptor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CCND1 Gene Amplification,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Integrin alphaV,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PROX1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Dioxins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cisplatin/cyclophosphamide/etoposide protocol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PINX1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,BST2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,aldehyde dehydrogenase 1|ALDH1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Membrane Transport Proteins,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
DISRUPTS,Tryptophan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Baresthesia,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Taurine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast arterial calcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FBXW7 gene|FBXW7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,palmitoleic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,LPO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Amphiregulin|AREG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PROTEIN KINASE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C14orf166 gene|RTRAF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EGFR Protein Overexpression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RPS6KA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FBXO31 gene|FBXO31,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FABP4 gene|FABP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Peroxisome Proliferator-Activated Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GATA3 gene|GATA3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Reexcision,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to breast augmentation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vimentin|VIM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GAS5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MAPK12 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,tacrolimus binding protein 4|FKBP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,COPS5,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,ZNF350,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Air Pollutants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Hyperostosis, Diffuse Idiopathic Skeletal",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,celecoxib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD151,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Fenretinide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Transduction Pathways,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Breast Cancer Model,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ellagic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FGFR1 gene|FGFR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunomodulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,HADHA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-acetyltransferase 1|EREG|ESR1,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Antiplatelet therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Receptor Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,TIMELESS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Annexin A2|ANXA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Work stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer Promoting Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RHBDD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Heparan Sulfate Proteoglycan|HSPG2|SDC2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,LAMTOR5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MALAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PGD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,"Diabetes Mellitus, Non-Insulin-Dependent",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"MAPK14 protein, human|MAPK14",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Estrogen Receptor Status,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,Liver Cirrhosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Brain Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Oranges,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Fatty Acids, Saturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Edema,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,SESTAMIBI,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Aspirin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Onions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lamins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Androstenedione,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body mass index,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,LINC00518,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DDT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overweight,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,ID2 gene|ID2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,thrombospondin 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Histone Deacetylase Inhibitor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,AQP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ranolazine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,mannuronic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KIF4A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,exemestane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Repeat Surgery,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PIP5K1C,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,KRT19 gene|KRT19,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Luteolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ectopic Expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOCS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AQP5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MFAP5 gene|MFAP5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCL20 gene|CCL20,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ENPP2|SMG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FTO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vitamin D3 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PDLIM2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SDC1 gene|SDC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gamma-Linolenic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Supportive care,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CD44 gene|CD44,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,RBMS3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,VIPR1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,triptolide,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,targeting,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Skin Lymphangiosarcoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coronary heart disease,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Metformin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Phosphorus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Rosacea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PUF60,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,YAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MAFG gene|MAFG,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,oncostatin M|OSM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dexamethasone,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Phthalimides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HDAC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VIM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CISH,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,ADAMTS1 gene|ADAMTS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Honey bee venom,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Antigens,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,C-Phycocyanin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NEAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,ATP-Binding Cassette Transporters|ATP8A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antisense RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNHG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mRNA Expression,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Anaplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SDC1 gene|SDC1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GLI3 gene|GLI3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tissue-Specific Gene Expression,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Egg Food Product,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Hyperglycemia,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Valproic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MDM4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins c-jun|JUN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MDM2 gene|MDM2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,E-Cadherin|CDH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pollutant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Medication use,Breast cancer invasive NOS,Pharmacological Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Chinese herbal medicine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TIMM13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"PER2 protein, mammalian",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cyclin-Dependent Kinase Inhibitor 2A|CDK4,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,silybin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PCB 138,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP2C8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN192 gene|MIR192,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Extracellular Matrix Proteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Phenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRIM44,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Quinoxalines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PXDNL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vitamins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TUFT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,transcription factor PML,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Silence,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Premenopause,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PTP4A3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDK12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinosarcoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor stage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Monocyte Chemoattractant Protein-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,JPH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcription Repressor/Corepressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UBE2V1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,RUNX2 gene|RUNX2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APRIN gene|PDS5B,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Chalcone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BMX gene|BMX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mitogen-Activated Protein Kinase 3|MAPK3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,everolimus,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Alternative Splicing,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,ethylene oxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FAM53A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microbicides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GABRA3 gene|GABRA3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,paclitaxel,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,HULC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Trans Fatty Acids,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,TGFB1 gene|TGFB1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,silence,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Promoter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"nuclear receptor subfamily 1, group H, member 2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR30A wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nance-Horan syndrome,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,intrauterine disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mercury,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CLDN11 gene|CLDN11,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
COMPLICATES,Secondary malignant neoplasm of bone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,RHPN1-AS1 gene|RHPN1-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA2 gene|BRCA2,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,ibrutinib,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Ubiquitin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Copy Number Polymorphism,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"Antibodies, Blocking",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TT genotype,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,opium alkaloids and derivative combination cough suppressants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tamoxifen,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,letrozole,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Mutation,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,SIRT4 gene|SIRT4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MIR221 gene|MIR221,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Invasive carcinoma of breast,Malignant neoplasm of breast,Other,0.0328,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00963 gene|LINC00963,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,29+,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Polyunsaturated fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Patient Derived Xenograft,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"TGFB1 protein, human|TGFB1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MIR221 gene|MIR221,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BHLHE40-AS1 gene|BHLHE40-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLX4IP gene|SLX4IP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,olaparib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Contrast enhanced spectral mammography,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
CAUSES,SFN,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,MTOR gene|MTOR,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,SOX21-AS1 gene|SOX21-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Detection,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,STAT1 gene|STAT1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AUGMENTS,Transcriptome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Macrolides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Gonadal Steroid Hormones,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Rheumatoid Arthritis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fiber,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunohistochemistry,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CISH protein, human|CISH",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NOP2 gene|NOP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SNHG3 gene|SNHG3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,MDC1 gene|MDC1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,FOXP1 gene|FOXP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UBE2M gene|UBE2M,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD44,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Iodides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MLKL gene|MLKL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,prolactin,Triple-Negative Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,subharmonic imaging,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,OSW 1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,STAT3 gene|STAT3,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,HER2-positive carcinoma of breast,Malignant neoplasm of breast,Other,0.0162,0.3386613386613387,Female Breast Cancer
AFFECTS,Second line treatment,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Hemangiosarcoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HEXIM1 gene|HEXIM1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Hormone Receptor Positive,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genes, Modifier",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proliferation (morphologic abnormality),Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Suppressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00160 gene|LINC00160,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,methanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOSB,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,KLHL22 gene|KLHL22,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Postmenopausal state,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytotoxic Chemotherapy,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,HSP90 Heat-Shock Proteins|HSP90AA1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,risk factors,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Cadherins,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Pathogenic,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,information seeking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RB1CC1 gene|RB1CC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RUNX3 gene|RUNX3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic resonance imaging of breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCR2 gene|CXCR2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,SIRT6 gene|SIRT6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ion Channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Eukaryotic Initiation Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Flavanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epigallocatechin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SIRT1 gene|SIRT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,apigenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AGR2,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Reactive Oxygen Species,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vitamin D3 24-Hydroxylase|CYP24A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BHLHE40 gene|BHLHE40,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epicatechin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"KRT10 protein, human|KRT10",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UBE2D2 gene|UBE2D2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CST3 gene|CST3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,P-Cadherin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRS gene|PRS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Easy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C8A gene|C8A,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Radionuclide Imaging,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
CAUSES,CTBP1-AS2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,silence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cancer-Predisposing Gene,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,NEAT1 gene|NEAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Caffeinated coffee,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,steroid glycoside,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,5-methyltetrahydrofolate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypertrophy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNAI3 gene|SNAI3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,lapatinib,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,rucaparib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FZD7 gene|FZD7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cisplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Kynurenine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,ZFPM2-AS1 gene|ZFPM2-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Visual Accommodation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mTOR Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
COMPLICATES,CTHRC1 gene|CTHRC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Crown-Like Structures of the Breast,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,UBR1 gene|UBR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NMU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,xanthomicrol,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Crown-Like Structures of the Breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"HLA Class I Histocompatibility Antigen, Alpha Chain G",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Adrenergic, beta-1|ADRB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,angiotensin converting enzyme 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"YAP1 protein, human|YAP1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polyphenols,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Lipids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,GPER1 gene|GPER1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,rasagiline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,JMJD6 gene|JMJD6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Regulatory Sequences, Nucleic Acid",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PPP2R2B gene|PPP2R2B,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,cisplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neutrons,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,HHEX gene|HHEX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ERRFI1 gene|ERRFI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary Alcohol,Invasive carcinoma of breast,Behavioral Factors,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,"CD9 protein, human|CD9",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZFAS1 gene|ZFAS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"CREB1 protein, human|CREB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mannose receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RCC2 gene|RCC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HER2-targeting Agent,HER2-positive carcinoma of breast,Demographic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Anti-Angiogenesis Effect,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Volatile Organic Compounds,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,gemcitabine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
COMPLICATES,Obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pulmonary Metastasectomy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Epidermal Growth Factor Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATM,Hereditary Breast and Ovarian Cancer Syndrome,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Neoplasms by Site,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Systemic Therapy,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,MST1 gene|MST1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol dehydrogenase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TRIM6 gene|TRIM6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tissue Inhibitor of Metalloproteinase-3|TIMP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,honokiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HNF1A-AS1 gene|HNF1A-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Low BMI,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"CD274 protein, human|CD274",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,human MUC1 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ethanol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GZMK gene|GZMK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,pembrolizumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,COL10A1 gene|COL10A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CHAF1A wt Allele|KAT2B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IFNG gene|IFNG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nicotinate-nucleotide pyrophosphorylase (carboxylating),Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,lipid mediator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High birth weight,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mean score,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,VPS35 gene|VPS35,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,water channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TNFRSF11A gene|TNFRSF11A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC01977 gene|LINC01977,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,vinorelbine,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,Cytochrome P450|CYP2B6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DEGS1 wt Allele|DEGS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atypical hyperplasia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Second line treatment,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,WNT7B gene|WNT7B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
CAUSES,Reactive Nitrogen Species,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Programmed cell death ligand 1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,CYTOR gene|CYTOR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin supplementation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR506 wt Allele,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NF-kappa B,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MTERF3 gene|MTERF3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,bisphenol A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lutein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GAS5 gene|GAS5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,estrogen receptor-positive breast cancer,Malignant neoplasm of breast,Other,0.0175,0.3386613386613387,Female Breast Cancer
CAUSES,voacamine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,GLUCOSE-6-PHOSPHATASE,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,atmospheric pollution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sphingolipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,directive therapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Pathologic Neovascularization,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"3,3'-diindolylmethane",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PFKFB4 gene|PFKFB4,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Interferon-alpha,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Biological Response Modifiers,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Metastatic malignant neoplasm to brain,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,Angiogenesis Inhibitors,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FABP4 gene|FABP4,Recurrent Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Recurrent Breast Cancer
PREDISPOSES,Imbalance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Candidate Disease Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Chlorpyrifos,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Treatment Protocols,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Agent,HER2-positive carcinoma of breast,Demographic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Androgen Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Long Intergenic Non-Protein Coding RNA,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Xenobiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRPV6 gene|TRPV6,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,MMP11 gene|MMP11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interstitial Collagenase,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,AMD1 gene|AMD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,E2F1 Transcription Factor|E2F1|UBE2L3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proton Pump Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,3F8 antibody,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased prolactin level,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,PET/CT scan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UBA5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DEAD Box Helicase p68|DDX5|KHDRBS1|POLD3|GATAD2B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Food, Organic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,rutecarpine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epstein-Barr virus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,bruceine D,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Breast Cancer Therapeutic Procedure,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TBX15 gene|TBX15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Kynurenine 3-monooxygenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ovary; insufficiency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PIM1 gene|PIM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Therapy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,AIFM2 gene|AIFM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZBTB7A|AKIRIN2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Trace Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MCM3AP-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RPPH1 gene|RPPH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"protein tyrosine phosphatase, non-receptor type 1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,estrogen use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metronomic Chemotherapy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,PALB2 gene|PALB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,kinase inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Adriamycin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,epithelial to mesenchymal transition,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Adverse Event Emergency Room Visit,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,SNHG3 gene|SNHG3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TUBA4A gene|TUBA4A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WDR43 gene|WDR43,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,AMIGO2 gene|AMIGO2,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,SNHG1 gene|SNHG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Intronic Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammaplasty,Stage 0 Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,"Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit 1, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,glucose high,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,aspirin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Elevation procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GATA3 gene|GATA3,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,TMEM130 gene|TMEM130,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,oleyloxyethylphosphorylcholine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Plasma Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RASSF1 gene|RASSF1,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,BNIP3 gene|BNIP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Overdiagnosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,erbB-2 Receptor|ERBB2,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
AFFECTS,fibroblast activation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Elevated Expression,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,COMT gene|COMT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"leptin receptor, human|LEPR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PTPN2 gene|PTPN2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,FGFR4,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,FERMT2 gene|FERMT2,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,"Receptor Tyrosine-Protein Kinase ErbB-4, human|ERBB4",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,atezolizumab,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Aromatase Inhibitors,Malignant neoplasm of female breast,Treatments,0.0,0.0,Female Breast Cancer
AFFECTS,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Parity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,limonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SHMT2 gene|SHMT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EIF3B gene|EIF3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MIR21 gene|MIR21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Suspensions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ultrasound Tomography,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Parallel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mRNA editing,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,Transcription Coactivator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lymphatic Invasion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Precision Medicine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
COMPLICATES,Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,IRAK1 gene|IRAK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TSPAN8 gene|TSPAN8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genetic Loci,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ergocalciferol,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
COMPLICATES,Lymphedema,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nicotinate-nucleotide pyrophosphorylase (carboxylating),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Confirmation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,cytokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ALDH2 gene|ALDH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,interleukin-21,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NTN4 gene|NTN4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CCL18 gene|CCL18,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,TLN1 gene|TLN1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Cell-Free DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low health literacy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TIMM8A,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Free triiodothyronine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HAUS5 gene|HAUS5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC01315 gene|LINC01315,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Targeted Therapy,Triple Negative Breast Neoplasms,Treatments,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,DLGAP1-AS2 gene|DLGAP1-AS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chromosomal translocation,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,SOX10 gene|SOX10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,lipid mediator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,terminal differentiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UBE2T gene|UBE2T,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Male fertility,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Intraoperative Radiation Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Uptake,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,GHET1 gene|GHET1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PGM5P3-AS1 gene|PGM5P3-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,exenatide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cancer care,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hereditary Breast and Ovarian Cancer Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Mortality, Premature",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZNF582-DT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Receptor, PAR-1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EBF1 gene|EBF1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Recurrent infections,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CENPW gene|CENPW,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GP5 gene|GP5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CYP2W1 gene|CYP2W1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Matrix Metalloproteinases,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,CDK6 gene|CDK6,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,MFNG gene|MFNG,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Amino Acids, Branched-Chain",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fast Foods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,asparaginylendopeptidase,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,MCM10 gene|MCM10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"SFN protein, human|SFN",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD44,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,tao hong si wu decoction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KDM4A gene|KDM4A,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Asbestos,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXF2 gene|FOXF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CENPW gene|CENPW,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,somatostatin receptor 1|SSTR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GJA1 gene|GJA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RNA, Long Untranslated",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MELK gene|MELK,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,TIMM8A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CASP9 gene|CASP9,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Blood group AB,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Cooking Practices,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mean score,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Phytochemicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PFKFB3 gene|PFKFB3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemicals,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
COMPLICATES,Acquired Immunodeficiency Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acute infectious disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLC6A14 gene|SLC6A14,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,RPS6KB1 gene|RPS6KB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SULT1A1 gene|SULT1A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dysbiosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alkaloids,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,medication use,Malignant neoplasm of breast,Pharmacological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chemokine CXCL12,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Oral intake,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,AMACR wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,calreticulin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CUEDC2 gene|CUEDC2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,NU 7441,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Prognostic Factors,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,Purinoceptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,sorafenib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,trichloroethylene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,estrogens,Advanced breast cancer diagnosis,Hormonal Factors,0.0,0.0,Female Breast Cancer
AFFECTS,"LATS1 protein, human|LATS1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KIF11 gene|KIF11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,nesiritide|NPPB,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,IRS2 gene|IRS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Expression,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Lymph-vascular invasion,Invasive Ductal Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,NR1H3 gene|NR1H3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,isoleucylvaline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"HMGB3 protein, human|HMGB3",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MTNR1B gene|MTNR1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Morbidity - disease rate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"DNA Breaks, Double-Stranded",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Observation - diagnostic procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Histone Demethylases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,maintenance of pluripotency,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Female Breast Carcinoma,Carcinoma of Male Breast,Other,0.0174,0.0049950049950049,Male Breast Cancer
AFFECTS,Tumor Microenvironment,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,MIR382 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hepatocyte Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SAFB2 gene|SAFB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,trichostatin A,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,MicroRNA 367-3p,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,selenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Flash,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Substance P Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Autophagy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,sauchinone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vascular Endothelial Growth Factors|VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PARP9 gene|PARP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sentinel node (disorder),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"interleukin-1, beta",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Prolactin Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer/Testis Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DDX3X gene|DDX3X,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,parecoxib sodium,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,PTPN13 gene|PTPN13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vigorous physical activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biomodulin T,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,KAT7 gene|KAT7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vigorous physical activity,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Ocular Cicatricial Pemphigoid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"RNA, Circular",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,IMPACT gene,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,IGF2BP1 gene|IGF2BP1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Chalcone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Degenerative polyarthritis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRMT2 gene|PRMT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PCAT19 gene|PCAT19,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,SFXN1 gene|SFXN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,glycyrrhetinic acid,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,TWIST1 gene|TWIST1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Psychosocial procedure,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,SFXN2 gene|SFXN2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proliferation (morphologic abnormality),HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,hydrochloride,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Reproductive tract infection,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Apolipoprotein A-I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Systemic Therapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOX9 gene|SOX9,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Anthropometric Measures:-:Point in time:^Patient:-,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,triclosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ETV7 gene|ETV7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Luteolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"FRAP1 protein, human|MTOR",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,New Target Lesion Identification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sirolimus,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,SMIM10L2A gene|SMIM10L2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Premenstrual Tension,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Secondary malignant neoplasm of breast,Other,0.3988,0.0029970029970029,Female Breast Cancer
AFFECTS,"CDK7 protein, human|CDK7",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,LINC02568 gene|LINC02568,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,morusin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Invasive carcinoma of breast,Noninfiltrating Intraductal Carcinoma,Other,0.0328,0.0109890109890109,Female Breast Cancer
DISRUPTS,quinacrine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,polyphenols,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Challenge:Type:Point in time:^Patient:Nominal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Emodin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,KCNQ1OT1 gene|KCNQ1OT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Angiotensin II receptor antagonist,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,propofol,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Cardiac dysfunction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG11 gene|SNHG11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mental disorders,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC7A11 gene|SLC7A11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tn antigen,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,TIPARP gene|TIPARP,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,pirarubicin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"TNK2 protein, human|TNK2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Lymph Node Metastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,glycosylation,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta-Glucans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,rebastinib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Indicators,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,MIR182 gene|MIR182,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,receptor for advanced glycation endproducts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATP2C1 gene|ATP2C1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,malignant disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,zoledronate,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Hypofractionated radiation therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,berberine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXA1 gene|FOXA1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Synapsin I,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,interleukin-8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,postmenopausal syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,thymidine kinase 1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIGLEC15 gene|SIGLEC15,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,formononetin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,MIDEAS gene|ELMSAN1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Amino Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,OTUB1 gene|OTUB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,leptin receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,High Density Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dried fruit intake,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,VEGFA gene|VEGFA,Invasive Ductal Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,LAYN gene|LAYN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIK3CB gene|PIK3CB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Raw vegetable,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,RHOT1 gene|RHOT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Inflammatory Response,Invasive Ductal Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,STAT3 gene|STAT3,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,polyphyllin II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SB 203580,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,hydnocarpin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,UHRF1 gene|UHRF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PAXX gene|PAXX,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Decreasing,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,venetoclax,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,doxorubicin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Consideration,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ANXA9 gene|ANXA9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SF3B1 gene|SF3B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chest asymmetry,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Positive Regulation of Oxidative Stress Process,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,CERS4 gene|CERS4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"MMP11 protein, human|MMP11",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"MAP3K8 protein, human|MAP3K8",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Androgens,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,takinib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Squalene monooxygenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RIN2 gene|RIN2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,G protein-coupled receptor kinase 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proteome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCB1,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,"Diet, Western",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,INSM1 gene|INSM1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"PTGS2 protein, human|PTGS2",Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,AZGP1 gene|AZGP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,directive therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CIB1 gene|CIB1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Carney Complex,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,NCBP1 gene|NCBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NEU1 gene|NEU1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,factor XIII,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ELAVL2 gene|ELAVL2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Breast-Conserving Surgery,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,momordicoside K,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Soybeans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,APOBEC3A gene|APOBEC3A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ROS1 gene|ROS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,SNORD49B gene|SNORD49B,Early-Stage Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,ezrin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Details of education,Malignant neoplasm of breast,Educational Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MYC gene|MYC,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,SIPA1 gene|SIPA1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"ORF74 protein, Human herpesvirus 8",Triple Negative Breast Neoplasms,Herpetic Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,RBM24 gene|RBM24,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,FOXO3 gene|FOXO3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,NT5DC2 gene|NT5DC2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CERNA2 gene|CERNA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PTPRG-AS1 gene|PTPRG-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgen Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Genes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SF3A2 gene|SF3A2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,SLC7A11 gene|SLC7A11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,PDK1 gene|PDK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Reproductive History,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Lipidome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BAIAP2L1 gene|BAIAP2L1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,Cell Cycle Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine System Diseases,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Viscosity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hormone Receptor,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,NUDT1 gene|NUDT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CONOTRUNCAL ANOMALY FACE SYNDROME,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Corticotropin-Releasing Hormone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,receptor for advanced glycation endproducts,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Intravascular Metastasis,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,MAPK8 gene|MAPK8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PDZK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tibolone,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,CpG Islands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PARP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CXCL12 gene|CXCL12,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,ATF3 gene|ATF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Soy Milk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRPM7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neuregulin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BCL-2 Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRAF4 gene|TRAF4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast cancer metastatic,Malignant neoplasm of breast,Other,0.0306,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estrogen Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic inflammation,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,EPHA10 gene|EPHA10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,STAT3 gene|STAT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTO2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"FRAP1 protein, human|MTOR",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"CYP2B6 protein, human|CYP2B6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LECT2,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,Selective Estrogen Receptor Modulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transferase Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA repair protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,p-hydroxycinnamaldehyde,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,maspin|SERPINB5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,arginylarginine|ABL2|RERE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Biosensors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NCOA1 gene|NCOA1,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,SRC gene|SRC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXD3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of lung,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARF6,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,GPER1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,arsenite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,catalpol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRANCE protein,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,pigment epithelium-derived factor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,AMOT gene|AMOT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Health behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,3' Untranslated Regions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Receptor beta|EREG|ESR1,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,CYP2C19 gene|CYP2C19,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NFKB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GIT1 gene|GIT1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,mammaglobin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Angiotensin II Type 1 Receptor Blockers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogens,Female Breast Carcinoma,Hormonal Factors,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,LIN28A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,25-hydroxyvitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diet good,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mdm2 protein|MDM4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BMP4|BMP4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Signal Pathways,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,YBX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,deferiprone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Medroxyprogesterone 17-Acetate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Detection,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,"Carcinogens, Environmental",Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,Genistein,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Noninfiltrating Intraductal Carcinoma,Malignant neoplasm of breast,Other,0.0692,0.3386613386613387,Female Breast Cancer
PREDISPOSES,3/4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXP2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Smoking,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,WWTR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Microcalcification,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Tungsten,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Botanicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HNRPM gene|HNRNPM,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,RAB22A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PARP1 gene|PARP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,docetaxel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BIRC7 gene|BIRC7,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,BCL2L11 gene|BCL2L11,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Squamous cell carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heme,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,fraxetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Seafood,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Animal fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GATA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Molecular Chaperones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lard,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic microcalcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MicroRNAs,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,"Genes, Suppressor",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Neoplasm,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Intercellular adhesion molecule 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Colorectal Cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S100 Proteins|S100A1|S100B,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,BRCA3 gene|BRCA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,S100A8 gene|S100A8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pteridines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Finding of antibody titer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hemorrhage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Evolution,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,PCSK6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Reserpine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin-6,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,MIRN10B gene|MIR10B,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CTSL gene|CTSL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERBB2 gene|ERBB2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,ERBB4 gene|ERBB4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Positive Test Result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Selective Estrogen Receptor Modulators,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Estriol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Serum Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Genome,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Detection,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Selenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nitric Oxide,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Aromatase Inhibitors,Breast cancer metastatic,Treatments,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Study models,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Prostate-Specific Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FABP7|MAS1L,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2 gene|ERBB2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Retinoblastoma Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,leukemia inhibitory factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phytochemical,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Lactoylglutathione Lyase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,Flap Endonuclease-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Gastrointestinal Neoplasms,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,TNFSF11 gene|TNFSF11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,E-Cadherin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,thymalfasin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Progestogen only oral contraceptive,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vegetables,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Technetium Tc 99m Sestamibi,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Potato,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Deletion Mutation,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Integrin beta3|EEF1B2P2|BHLHE22,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,NLRP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gynecomastia,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,DNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Fluorouracil,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mammary Neoplasms,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Chemopreventive Agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Arginine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Blind Vision,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,family background,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antispasmodics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Chromosome 11 Short Arm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Caffeine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Hydralazine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Skin problem,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,N-Acetylneuraminic Acid,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,cell motility,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Intraductal Hyperplasia,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Fibroadenoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant Neoplasms,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Milk Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ductal Carcinoma,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Buserelin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ASK Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinoma,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,benzanthracene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CHEST PATHOLOGY,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Thiotepa,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Milk, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibronectins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CEACAM5 gene|CEACAM5,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,HPR gene|HPR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mitoxantrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polyomavirus Middle T Antigens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,trastuzumab,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Peanut Agglutinin,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,PREMARIN USE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"VEGF protein, human|VEGFA",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Androsterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,limonene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histologic type,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Angiostatins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,sex hormone-binding globulin receptor,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leucine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Indicators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tumor Suppressor Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PBP gene|DOCK3|PEBP1|PKD1|MED1|PPBP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,rac-PK beta|AKT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Immunoconjugates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NME2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Glycoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,National origin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Candidate Disease Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antigens,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Fetal Growth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,tumor growth,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,alpha-Linolenic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Protease Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,formestane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Equine laminitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Protease Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cell Cycle Proteins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CD4 gene|CD4,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CA-15-3 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSPB8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Growth Factor Receptors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Androgens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Endometrial Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Telomerase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,perlecan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Amphiregulin|AREG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cyclin D1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Study models,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Vascular Endothelial Growth Factor Receptor-2|VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,riboflavin-binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progesterone increased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-18,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Brain Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Micronutrients,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Detection,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,c-myc Proto-Oncogenes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Therapy responder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis Factor,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Epithelial-Stromal Communication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunization,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Hydrocarbons,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NF-kappa B,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Punctate inner choroidopathy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,resveratrol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,17q23,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Preventive Services - Orthodontics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sphingosine kinase-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endopeptidases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Environmental Pollutants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EPSTI1 gene|EPSTI1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Brain hemorrhage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Molecular Pathology,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Thrombus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,response,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,AKT2 gene|AKT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transgenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Protein Kinase C|PRRT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Serpins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Cyclooxygenase 2 Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tamoxifen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Endocrine therapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Uterine activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Transcript,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,fulvestrant,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"CBFB protein, human|CBFB|NFYA|NFYB",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MSN gene|MSN,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Human Chorionic Gonadotropin|CGA|HTC2|CGB5,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Colony-Stimulating Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VEGF gene|VEGFA,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,BARD1 gene|BARD1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Renal tubular disorder,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Dinucleotide Repeats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Isothiocyanates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GADD45A gene|GADD45A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TSG101 gene|TSG101,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Fanconi's Anemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,progesterone analog,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mouse mammary tumor virus infection,Breast Carcinoma,Herpetic Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Abnormal digestive tract function,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LRRC15,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Angiotensinogen|AGT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Poland Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,STK11 gene|STK11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BIN1 gene|BIN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,4-nonylphenol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,P-Selectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CLSPN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Doxazosin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LZTS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dopamine Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IL6ST gene|IL6ST,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cell Adhesion Molecules,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Fibrinogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,adduct,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tomography,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Clusterin|CLU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hereditary Malignant Neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CASP8 gene|CASP8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acne,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Wine intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coumestrol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lymphoid neoplasm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pulmonary toxicity,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,"Xeroderma pigmentosum, group C",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IGFBP1 gene|IGFBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Membrane receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinogenicity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APOE gene|APOE,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pulmonary Embolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,5'-AMP-activated protein kinase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Transforming Growth Factor beta Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,E2F4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mucinous Neoplasm,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Paroxetine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,syndecan 1 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Recombinant Transforming Growth Factor-Beta 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PSMA5|AP5Z1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RHOC gene|RHOC,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,Neoplasm,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Body mass index,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,CXCR4 Receptors|CXCR4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Farnesyl Transferase Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antihypertensive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ethylene Oxide,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Cysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,catenin p120(ctn) protein|CTNND1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Homologous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTN gene|PTN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SCTR gene|SCTR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Complex Extracts,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Biopsy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Repetitive Region,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NBS1 gene|NBN|NLRP2,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL6R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Stromal Cell-Derived Factor 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SULT1A1|SLC45A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ethylene Oxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BEX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,steroid hormone receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,semapimod,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Excretory function,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,polyphenols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hamartoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Serum Folate Level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,of 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Nucleotide Excision Repair,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Plasmin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Focal Adhesion Protein-Tyrosine Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bone morphogenetic protein 5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tobacco smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammaplasty,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,PES1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transgenes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,INPPL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dyslipidemias,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PROTEIN KINASE|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,KL gene|KL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,nucleic acid inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KLLN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIWIL1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,chemokine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Estrogens,Sporadic Breast Carcinoma,Hormonal Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,CYP3A5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,adjuvant therapy,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Breast cancer metastatic,Malignant neoplasm of breast,Other,0.0306,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Medical care, unspecified",Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,Proto-Oncogene Proteins c-akt,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TWIST2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,estrogen receptor gamma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADIPOQ,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZNF703,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Progestins,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,PELP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAPK8 gene|MAPK8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FGFR2 gene|FGFR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Phosphotransferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,P-Glycoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sarcoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Annexin A6|ANXA6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Reactive Oxygen Species,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,thymidine kinase 1,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Chromosome 10 Short Arm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protein phosphatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD44 gene|CD44,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,CD24,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,butylbenzyl phthalate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transcription Factor 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAPK12 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Plasminogen Activator Inhibitor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A2 gene|S100A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,antiangiogenesis therapy,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Monocyte Chemoattractant Protein-1|CCL2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SIX1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Heat Shock Protein 27,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dipyridamole,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor Beta 2|NEUROD1|TUBB4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PARD6A|PWAR6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TUBB4A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,plumbagin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SIX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,6-bromo-2-naphthyl sulfate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"FRAP1 protein, human|MTOR",Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,beta catenin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,KLF9 gene|KLF9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin-Dependent Kinase 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FOXO3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TNFRSF10B gene|TNFRSF10B,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,corrigendum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Beta-glucuronidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CLDND1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Germ-Line Mutation,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dietary Supplements,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,plumbagin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Fibroblast Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ion Channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolic syndrome,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Evolution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Ceruloplasmin|CP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Promoter Regions (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,interleukin-22,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOX17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pyruvate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cholesterol levels raised,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,MC1R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Signaling Molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Inflammatory Breast Carcinoma,Other,0.3988,0.0009990009990009,Female Breast Cancer
AUGMENTS,Protein C Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dichlorodiphenyldichloroethane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nicotinamide adenine dinucleotide (NAD),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NR4A1 gene|NR4A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dexamethasone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TWIST1 gene|TWIST1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NUCB2 gene|NUCB2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Risk Reduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MSI2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Diethylstilbestrol,Noninfiltrating Intraductal Carcinoma,Behavioral Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,IL33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCL9 gene|CXCL9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRPV4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Berries,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Margarine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IGF1R gene|IGF1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GPR116 gene|ADGRF5,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Docosahexaenoic Acids,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Protein phosphatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Colorectal Cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GIT1 gene|GIT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA Adducts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chemoprotection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,RGS2 gene|RGS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ABCB6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NUP155,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,atorvastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Signaling Molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,kinase inhibitor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Adenomatous Polyposis Coli,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Reactive Oxygen Species,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glioma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm progression,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,UBE3A,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,CLDN2 gene|CLDN2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,NUMB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,liraglutide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRMS1 gene|BRMS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acute myocardial infarction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammography finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,radiosensitization,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP2B6 gene|CYP2B6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,membrane-type 1 matrix metalloproteinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thiamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PLAT gene|PLAT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor Status,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,TARDBP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Zinc,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PIWIL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MMP,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Hyperinsulinism,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,KLF17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SHARPIN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DACT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APBA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Benzoic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYC1 gene|CYC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Late pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,jatrophone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ABCG2 protein, human|ABCG2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thiazolidinediones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CISH,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,PPM1D,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,tumor growth,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,calmodulin-dependent protein kinase II|CAMK2G,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,calmodulin-dependent protein kinase II|CAMK2G,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Oncogenes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
COMPLICATES,Fibrosing adenosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BCYRN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FGF2 gene|FGF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KRAS gene|KRAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CXCL1 gene|CXCL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Amino Acids, Branched-Chain",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ALDH1A3 gene|ALDH1A3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prostaglandin-Endoperoxide Synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,nucleolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Arachidonic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vitamin D Analog,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,caveolin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anaphylaxis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Parabens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ARRDC3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MST1R gene|MST1R,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SENP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BCL2 gene|BCL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,grasp,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Endogenous Retroviruses,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCR7,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PRLR gene|PRLR|PTP4A3,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Esters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ESR1 protein, human|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lasso,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIK3R1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PTHLH gene|PTHLH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,uptake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Proto-Oncogene Proteins c-jun|JUN,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Collagen Type IV,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Recombinant Interferon-gamma|IFNG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GGN gene|GGN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADH1C|ADH5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CLOCK gene|CLOCK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARP9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATF4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Taxol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptors, LH",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Liposomes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tobacco use,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,BCAS3 gene|BCAS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,N NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sentinel Lymph Node Biopsy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,wogonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MCM10 gene|MCM10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glutamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Embryonic Development,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tobacco smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pentabromodiphenyl ether,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aromatase,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,OIP5-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Linoleic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TRANSCRIPTION FACTOR,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dietary Oils,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NF-kappa B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Rest,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ARNT2 gene|ARNT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Black tea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lysophosphatidic acid,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PTK6 gene|PTK6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,response,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,ESR1 gene|ESR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nuclease Sensitive Element Binding Protein 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NES gene|NES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,norethindrone acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IQGAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNAs,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Oxytocin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Galactosamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A9 gene|S100A9,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,NAMPT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIRN205 gene|MIR205,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Homeo Box Sequence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Viral Tumor Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Early Diagnosis,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,SNW1 Gene|SNW1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Carcinogens, Environmental",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RBX1 gene|RBX1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Apoptosis,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,CEACAM5 gene|CEACAM5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chromosome 15 Short Arm,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Superoxides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIP,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Immunoglobulin Fc Fragments,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Cytostatic Agents,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,vigilin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTPN13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FADS2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fish Oils,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vascular Endothelial Growth Factor Receptor-3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Atypical hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heat-Shock Proteins 70|HSPA4,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,stromelysin 3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Carrier of disorder,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,FMO5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endostatins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Loss of Heterozygosity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Optimistic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adrenergic Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Mammary Carcinoma, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Serine Proteinase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tumor Necrosis Factor Ligand Superfamily Member 6|FAS,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Atypical proliferation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,SULT1A1|SULT1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,C-Peptide,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Lecithin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BONE MASS,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,celecoxib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CAMP,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FOXM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Freund's Adjuvant,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PTGS2 gene|PTGS2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Low Birth Weights,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,letrozole,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Rh Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Total cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,High Density Lipoprotein Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SSM,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Contraceptives, Oral",bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Contraceptive methods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Multivitamin preparation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,letrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NAMPT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR519D,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Puberty stage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERCC5 gene|ERCC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Butter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Non-infiltrating lobular carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Heat-Shock Proteins 70|HSPA4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vegetable Oils,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Speaking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Weakly positive,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,adjuvant therapy,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Growth Factor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Breast Fibrocystic Change, Proliferative Type",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Transcription, Genetic",Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,poor health,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,nimesulide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Eicosapentaenoic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Flavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Resonance Imaging,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Adrenal Cortex Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,tibolone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Short Tandem Repeat Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Long chain fatty acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADRB3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Magnetic Resonance Spectroscopy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Biopsy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Specific antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GPR30 gene|GPER1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ill-at-ease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Detection,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,pterostilbene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PKP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Proto-Oncogene Protein pp60 (c-src)|SRC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ethanol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Contralateral breast cancer,Malignant neoplasm of breast,Other,0.0189,0.3386613386613387,Female Breast Cancer
AUGMENTS,GDI2 gene|GDI2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cadherins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Osteogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Klinefelter's Syndrome,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,Acetaldehyde,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ezrin|EZR,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,LIG4 gene|LIG4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Silence,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Hypertension induced by pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APOB gene|APOB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Asleep,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Interleukin-17,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,Estrogen Receptor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Gelatinase B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LPCAT3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic procedure,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Neoplasm progression,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CALML3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ODAM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MRE11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RPS6KB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Macrophage Chemotactic Factors,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytokine,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Vitamin B12 intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,butein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,heparanase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,estrone sulfate,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,atovaquone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CYP24A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemokine (C-X-C Motif) Ligand 1|CXCL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estradiol,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Computed Tomographic Colonography,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,VASOMOTOR SYMPTOM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Folic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,osteopontin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,cadherin 5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Steroid hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,aldehyde dehydrogenase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Connexin 43,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fruit intake,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,Interleukin-12,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,biological_process,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,ADAM29,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TYRP1 gene|TYRP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estradiol + norethindrone acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GAL3ST1|SLC35A1|CASZ1|CST12P,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Receptor alpha,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,HORMONE REPLACEMENT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemotherapy-Oncologic Procedure,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,EMSY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atypical hyperplasia,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Dinoprost,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant",Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Insulin Resistance,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Cytokeratin 18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Transforming Growth Factor beta,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Residual Cancer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interstitial Collagenase,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nickel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Feeding,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,BCCIP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHI3L1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antigens,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer recurrent,Demographic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Somatostatin analog|SST,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Interferon Type II|IFNG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Mixed Function Oxygenases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL1RN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin D1|CCND1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Breast Fibrocystic Change, Proliferative Type",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,S100A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,sake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Protein Family,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MDM4 gene|MDM4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cadmium,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Xq25,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XRCC5 gene|XRCC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,transduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Infectious Mononucleosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oils,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EGFL7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PROM1,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,DCSTAMP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,gefitinib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GLIS3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,trastuzumab,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,AXILLARY LYMPH NODE METASTASIS,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Sleep Apnea Syndromes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Water,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,regional differences,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,perfluorooctane sulfonate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Isoenzymes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Riboflavin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HP gene|HP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast cancer invasive NOS,Carcinoma in situ of breast,Other,0.0587,0.0019980019980019,Female Breast Cancer
AFFECTS,Second Primary Cancers,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Alcoholic Beverages,Breast cancer invasive NOS,Demographic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Infant feeding method NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Weight Gain,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Methionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DMD|BEST1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Localized Malignant Neoplasm,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Wine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical function,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Metaplasia,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Aldehydes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biopsy,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Estradiol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,snail transcription factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,phenethyl isothiocyanate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Black tea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Performance,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,oridonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,claudin 1 protein,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Alleles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,volatile substances,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Poultry Meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammography,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,CDKN2A gene|CDKN2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Diabetes, Gestational",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cognitive Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,high-dose chemotherapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Oxytocin Receptor|OXTR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,S100A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Does hit,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Fine needle aspiration biopsy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Large Neutral Amino Acid-Transporter 1|SLC7A5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Iodine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Monomeric GTP-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APEX1 gene|APEX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primary disease,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,pigment epithelium-derived factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Phyllodes Tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diphosphonates,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,SOSTDC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"EZH2 protein, human|EZH2",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,Blood Coagulation Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Catechin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Night sweats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Seeks information,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Carcinoma of Male Breast,Other,0.3988,0.0049950049950049,Male Breast Cancer
DISRUPTS,Flavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adverse event,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,hydroxytyrosol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,REXO1|ZFP42,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VEGFA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,FOLR1 gene|FOLR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Night Nurse,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL8RB gene|CXCR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NEK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Female,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Inflammation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Body Weight decreased,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Aminolevulinic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cerebrovascular accident,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Powerlessness, low",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diffusion Magnetic Resonance Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoglycemic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Echocardiography, Three-Dimensional",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pregnancy,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Atypical lobular hyperplasia,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Endothelin Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Polymerase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic breast density,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,ESTROGEN+PROGESTERONE RECEPTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Lasofoxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormones,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Mammography,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alkylating Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prevention,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,breast implant procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Analgesics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adenosine Triphosphate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Anti-Anxiety Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Mitoxantrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,PVT1 gene|PVT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RNA-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Solid tumor,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Homologous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,protopanaxadiol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CDCA4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SDCBP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTPN1 gene|PTPN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,no positive axillary nodes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gout,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sugar candy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tyrosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acetaminophen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRIM33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC50A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FUT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC01638,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIMREG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Interleukin-17,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,strictinin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,phenyl ether,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Plasma glucose result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,advanced disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atypical proliferation,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,SLC50A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ezrin|EZR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,beta catenin|CTNNB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Coal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNF115,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,S100B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SP1 gene|SP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,activated RNA polymerase II transcription cofactor 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Progesterone Receptor Status,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,HCP5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,nitric oxide receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RUSC1-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Glucocorticoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anticholesteremic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TSC1 gene|TSC1|CCL26,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Materials,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Pharmaceutical Preparations,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CHEK2 protein, human|CHEK2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Juvenile carcinoma of the breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease recurrence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TFF3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,HOTAIR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Collagen Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCB 180,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gold,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Excision Repair Protein ERCC-5|ERCC5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,XBP1 gene|XBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Burden,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Energy Balance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Immunity,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,HIF1alpha protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HAX1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,LARP4 gene|LARP4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"RNA, circular",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,angiotensin II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cedrelone,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Flavones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Catechol O-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phototherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SMAD4 gene|SMAD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant Neoplasms,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,Breast cancer stage III,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Nicotinamide Phosphoribosyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,LOXL1-AS1 gene|LOXL1-AS1,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,"2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,punicalagin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PAK4 gene|PAK4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAM83H-AS1 gene|FAM83H-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,folic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Late menarche,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,STARD8,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cream,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Protein Isoforms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,chalcomoracin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"PTGS2 protein, human|PTGS2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphoglycerate dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genome,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Hexokinase 2|HK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,insulin detemir,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"PKN1 protein, human|PKN1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ELF5 gene|ELF5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Mutant Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,apolipoprotein D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prophylactic treatment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TRANSCRIPTION FACTOR,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Fibromyalgia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KISS1R gene|KISS1R,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Genes,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,compromise,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Sentinel node (disorder),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Sleep Apnea, Obstructive",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chlorpyrifos,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CCL5,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,CTCb regimen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphoric Monoester Hydrolases,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,aluminum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLCO6A1|GSTK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insoluble fiber (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carbon Ion Radiotherapy,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,H19 gene|H19|HILS1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,risk factors,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Prolactin Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,BCL11A gene|BCL11A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,PPFIA1 gene|PPFIA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polybrominated Biphenyls,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PPFIA1 gene|PPFIA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PARP1 gene|PARP1,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,SOX9 gene|SOX9,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Primary care provider:Identifier:Point in time:Provider:Nominal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CBR3-AS1 gene|CBR3-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,limited use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polycystic Ovary Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNF111 gene|RNF111,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,steroid receptor coactivator AIB1|NCOA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,betaine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,risk factors,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Multiparametric Magnetic Resonance Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,new information,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Lyophilized powder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Blood Glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S-adenosylmethionine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Malignant Neoplasms,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Polypeptides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MNX1-AS1 gene|MNX1-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,removal technique,Stage IV Inflammatory Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,N-Myc Downstream Regulated Protein 1|NDRG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Dicarboxylic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,glycerin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ENC1 gene|ENC1,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,acetylcysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NORAD gene|NORAD,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Mammary Tumorigenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,CXCL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOX2 Transcription Factor|SOX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Genes,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CA10 gene|CA10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NME1 gene|NME1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MIR326 gene|MIR326,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Interferons,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,"Scoliosis, unspecified",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PART1 gene|PART1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erbB-2 Receptor|ERBB2,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,MIR451A wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,YTHDF3 gene|YTHDF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,leptin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,S100A14 gene|S100A14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Biopolymers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMPRSS13 gene|TMPRSS13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,nervous system disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,folate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRIO gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSD17B4 gene|HSD17B4,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Carcinoma of Male Breast,Malignant neoplasm of breast,Other,0.0253,0.3386613386613387,Female Breast Cancer
DISRUPTS,Luteolin,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,"CCND2 protein, human|CCND2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Piperlongumine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,thidiazuron,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,methylate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasms by Site,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Behaviorial Habits,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,UBR1 gene|UBR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCR5 gene|CCR5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Receptor Tyrosine-Protein Kinase ErbB-4, human|ERBB4",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CAVIN3 gene|CAVIN3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epithelial to mesenchymal transition,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,mitoxantrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"TFF1 protein, human|TFF1",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,Neoplasm Metastasis,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Polysaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,estrogens,Triple Negative Breast Neoplasms,Hormonal Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"WWTR1 protein, human|WWTR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transforming Growth Factor beta,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
COMPLICATES,contralateral breast cancer,Right-Sided Breast Neoplasms,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Systemic Therapy,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,PRMT5 gene|PRMT5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA replication checkpoint,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Fermented Foods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NF2 gene|NF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PLEKHA7 gene|PLEKHA7,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Ultraviolet B radiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,B3GNT2|B3GNTL1,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,STRN3 gene|STRN3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transcription factor genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZMYND8 gene|ZMYND8,Refractory Breast Carcinoma,Genetic Factors,0.0,0.0,Other
AUGMENTS,ZEB1 gene|ZEB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SOX6 gene|SOX6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RSPO2 gene|RSPO2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PEBP1 gene|PEBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thymidylate Synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Screening mammography,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,RARRES2 gene|RARRES2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,EIF4A1 gene|EIF4A1,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,CA13 gene|CA13,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Mouse Model,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Adverse event,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXK1 gene|FOXK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NUP43 gene|NUP43,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MYCN gene|MYCN,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,tamoxifen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,sanguinarine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HNRNPK gene|HNRNPK,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,ERRFI1 gene|ERRFI1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,STUB1 gene|STUB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S100A7 gene|S100A7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Clinical Significance,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Breast size,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Elevated C-reactive protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Triple Negative Breast Neoplasms,Malignant neoplasm of breast,Other,0.0298,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BTNL9 gene|BTNL9,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CDC25C gene|CDC25C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Profilin 2,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,HMGB1 Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Performance,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
DISRUPTS,PDCD4 gene|PDCD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,dendrophenol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MDM2 gene|MDM2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydrogel,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"Receptors, Opioid, kappa",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF132 gene|ZNF132,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pathogenic Variant,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Physical stress,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NRBP2 gene|NRBP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCAT1 gene|PCAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,metoclopramide,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Borg Category-Ratio 10 Perceived Exertion Score 5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TPT1-AS1 gene|TPT1-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KIAA1755 gene|KIAA1755,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,LINC00467 gene|LINC00467,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Therapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Homeobox Protein ARX,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tripterine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NORAD gene|NORAD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HAGLR gene|HAGLR,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins c-sis|PDGFB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Cycle Checkpoints,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inhibitor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Reaching,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,nucleoside diphosphate kinase A|NME1,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Antibodies,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Cytochrome P-450 CYP1A1|CYP19A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00894 gene|LINC00894,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR373 gene|MIR373,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Monoclonal Antibodies,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,BABAM2-AS1 gene,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Migration, Cell",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,melatonin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,docetaxel,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CXCL13 gene|CXCL13,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,METTL3 gene|METTL3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cigarette smoke (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oncogene Proteins,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,nucleolin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Benzimidazole derivatives, antinematodal",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,OVOL1 gene|OVOL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinase 3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Moderate risk,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,PTPN11 gene|PTPN11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,DPP9 gene|DPP9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STAU2 gene|STAU2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GATA3 gene|GATA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,peroxiredoxin I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,OMA1 gene|OMA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL17RB gene|IL17RB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Extraction,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Protein-Lysine 6-Oxidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypermethylation,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,RABIF gene|RABIF,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,calreticulin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,piperine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cultured Milk Products,Malignant neoplasm of breast,Ethical and Cultural Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Response Modifiers,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,NEIL2 gene|NEIL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hesperidin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,AKR1C1 gene|AKR1C1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC01094 gene|LINC01094,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Copy Number Polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Matrix,Triple-Negative Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,cannabinoid receptor,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,CASQ2 gene|CASQ2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Pharmaceutical Preparations,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,LRP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Platinum Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Very rare,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Raw Foods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CBR3-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TUBA1C gene|TUBA1C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,LINC02381 gene|LINC02381,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LGALS3BP,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Abnormality,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SH3BGRL gene|SH3BGRL,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,RGMA gene|RGMA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SARS-CoV-2 P.1 variant,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,SEMA6D gene|SEMA6D,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HSPA5 gene|HSPA5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mucin-1 Antigen,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,BARD1 gene|BARD1,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,NDRG2 gene|NDRG2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXP3 gene|FOXP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell secretion,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Inhibitor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,oleuropein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HSPA5 gene|HSPA5,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Pharmacotherapy,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ERBB2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Histological type,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BACH1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,monooxyethylene trimethylolpropane tristearate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LPAR6 gene|LPAR6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,interferon type II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PELI1 gene|PELI1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,KPNA2 gene|KPNA2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ZMIZ2 gene|ZMIZ2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,UBA6-AS1 gene|UBA6-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,calcitriol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nutritional status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MALAT1 gene|MALAT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,tanshinone,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,anhydroicaritin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,interleukin-10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 6|IGFBP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Agonist,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,kinase targeted therapy,Malignant neoplasm of breast,Treatments,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cancer-Predisposing Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ANKDD1A gene|ANKDD1A,Early-Stage Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,Inhibitor,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,BNIP3 gene|BNIP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Candidate Disease Gene,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,HCAR1 gene|HCAR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MED1 gene|MED1,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Environmental Estrogen,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,PROX1 gene|PROX1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Histone deacetylase inhibitor,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
AUGMENTS,perilipin 2,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,estradiol high,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stat3 protein,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Immune Checkpoint Inhibitors,Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,ZFR gene|ZFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNMT1 gene|DNMT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RUNX2 gene|RUNX2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Signal Transduction,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,dinaciclib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cholecalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HSPBP1 gene|HSPBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAP Kinase Kinase 5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mouse Model,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MSH2 gene|MSH2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,First relationship,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDK1 gene|CDK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tumor suppressor activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acute Promyelocytic Leukemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,B3GNT5 gene|B3GNT5,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Incomplete penetrance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pioglitazone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,quercetin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Tumor Suppressor Genes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Hydrogel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LINC00662 gene|LINC00662,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KIF4A gene|KIF4A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Inflammation Mediators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hypothalamic inhibiting factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,aucubin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Citrates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cyclin D1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC01234 gene|LINC01234,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Copy Number Polymorphism,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Therapeutic immunosuppression,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,polyethylene glycols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ryanodine Receptor 2,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,RAD51D gene|RAD51D,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ALYREF gene|ALYREF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Measurement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,perfluorononanoic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"POSTN protein, human|POSTN",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,RAD51B gene|RAD51B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PNO1 gene|PNO1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Oncogenes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,PIK3R1 gene|PIK3R1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNAs,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,OTUD6A gene|OTUD6A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MEG3 gene|MEG3|FAM129B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CXCL14 gene|CXCL14,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CDKN2A gene|CDKN2A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Immunoregulation,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Complement System Proteins,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Negative,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Large Neutral Amino Acid-Transporter 1|SLC7A5,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,plumbagin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MYC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Serum autoantibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00520 gene|LINC00520,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TPD52L2 gene|TPD52L2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glucosephosphate Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATP6AP1 gene|ATP6AP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR1294 gene|MIR1294,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Psychosocial Intervention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLC31A1 gene|SLC31A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RNase P,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,TGFB2-AS1 gene|TGFB2-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,inhibitor-of-apoptosis protein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MYCL gene|MYCL,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ERBB2,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,MDM2 gene|MDM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoxia,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,DIO3OS gene|DIO3OS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,centromere protein F,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N4BP3 gene|N4BP3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,SOD2 gene|SOD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF667-AS1 gene|ZNF667-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Free Energy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inhibitor,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,Parafibromin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RECQL5 gene|RECQL5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RBCK1 gene|RBCK1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Dietary Fatty Acid,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR506 gene|MIR506,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZSWIM1 gene|ZSWIM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vascular Endothelial Growth Factors|VEGFA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MIR21 gene|MIR21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PALB2 gene|PALB2,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Genes,contralateral breast cancer,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,MCF2L-AS1 gene|MCF2L-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Low Dose Radiation Therapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,"pregna-4,17-diene-3,16-dione, (17Z)-isomer",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Osteoporosis,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Histone deacetylase inhibitor|HDAC9,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,NR1H3 gene|NR1H3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Inflammation,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Aryl Hydrocarbon Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ALDH2 gene|ALDH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cytotoxic T-lymphocyte antigen 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PCSK1 gene|PCSK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drug Repositioning,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,YBX1 gene|YBX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Plasmids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00536 gene|LINC00536,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HNF1A gene|HNF1A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,CALML5 gene|CALML5,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,SOY ISOFLAVONES,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vimentin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RBCK1 gene|RBCK1,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,MYO6 gene|MYO6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Metric (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Clusterin,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Hydroxymethylglutaryl-CoA reductase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TLE5 gene|AES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Light Exercise,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Drinker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CREB1,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,bufalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Alanine Aminotransferase 1, human",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,cytidylyl-3'-5'-guanosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Snacks,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HAR1A gene|HAR1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TMED3 gene|TMED3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anaplastic carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,NUMB gene|NUMB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,internal risk factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fasting blood sugar result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CENPL gene|CENPL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BRCA2 gene|BRCA2,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,First line treatment,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Long Intergenic Non-Protein Coding RNA,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,glabridin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Toothache,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCAT19 gene|PCAT19,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Food antioxidant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,oleanolic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased risk,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EIF4A3 gene|EIF4A3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Antibody-Drug Conjugates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SOD1 gene|SOD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ANGPT1 protein, human|ANGPT1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Resistance Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caveolin 1,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,CYP1B1 gene|CYP1B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Global Longitudinal Strain,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Degenerative polyarthritis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coherent,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Matrix Metalloproteinase 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GPR141 gene|GPR141,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HFM1 gene|HFM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,tamoxifen,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,LGALS3 gene|LGALS3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Physiologic calcification,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,ZSCAN18 gene|ZSCAN18,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NNAT gene|NNAT,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Radioimmunotherapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Patient age,Triple Negative Breast Neoplasms,Demographic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,CREBZF gene|CREBZF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,OTUD1 gene|OTUD1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,HMMR gene|HMMR,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Natural Products,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,dihydroartemisinin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RNA Sequence,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Luteolin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Severe (severity modifier),Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,BCKDK gene|BCKDK,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Noninfiltrating Intraductal Carcinoma,Invasive carcinoma of breast,Other,0.0692,0.0089910089910089,Female Breast Cancer
PREDISPOSES,"Anesthetics, Inhalation",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Tumor Antigens,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,disulfiram,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Caffeic Acid Phenethyl Ester,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immune Tolerance,Secondary malignant neoplasm of breast,Immunological Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Menstrual status:Type:Point in time:^Patient:Nominal:Stated,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNAs,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,INSM1 gene|INSM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FUNDC2 gene|FUNDC2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Parafibromin|CDC73,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ubiquitin-protein ligase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,euphorbia factor L1,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Mammary Neoplasms,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,NOX4 gene|NOX4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stereotactic Body Radiation Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NT5E gene|NT5E,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,FOXQ1 gene|FOXQ1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2 Gene Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLRB1 gene|KLRB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,YTHDF1 gene|YTHDF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Micelles,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,MAPK1 gene|MAPK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,platinum,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CD160,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Polygenic Traits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transfer RNA,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,e protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,METTL3 gene|METTL3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Basis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,graphdiyne,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Collagen Diseases,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,DNAJA1 gene|DNAJA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMAD4 gene|SMAD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Obesity,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Biological Response Modifiers,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Hippo Signaling Pathway,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta sitosterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LRRC37A2 gene|LRRC37A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FZD8 gene|FZD8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF148,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Possible,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,quercetin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tumor Microenvironment,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,VASP gene|VASP,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Responsive Disease,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Clinical Significance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nail-Patella Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CREB3L1 gene|CREB3L1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DHP107,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PSME3 gene|PSME3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MDH2 gene|MDH2,Recurrent Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Recurrent Breast Cancer
PREDISPOSES,FZR1 wt Allele|CDH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PFKP gene|PFKP,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,RNF185 gene|RNF185,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Microenvironment,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,interleukin-1 alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RNA I,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Cheese intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,Invasive Ductal Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Oncogene Proteins,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,PARD3 gene|PARD3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,USP4 gene|USP4,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,STING1 gene,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Origin of Life,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tyrosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mitogen-activated protein kinase p38,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SLC38A3 gene|SLC38A3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,METTL7A gene|METTL7A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TNF protein, human|TNF",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,ASAH2 gene|ASAH2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DCTD gene|DCTD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malate dehydrogenase (decarboxylating),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AICARDI-GOUTIERES SYNDROME,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,dasatinib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,DNA Sequence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunogenic Cell Death,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Protein Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carboplatin/Etoposide/Melphalan Regimen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ST14 gene|ST14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RENBP gene|RENBP,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Cigarette smoke (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NAT10 gene|NAT10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pubertal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hypoxia,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,SNORD16 gene|SNORD16,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARID1A gene|ARID1A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,NUDCD1 gene|NUDCD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PKD2 gene|PKD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,phosphatidylethanolamines,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body composition measure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplastic Cell Transformation,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,ZMIZ1 gene|ZMIZ1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Emotional hypersensitivity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Withanolides,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,HER2-positive carcinoma of breast,Malignant neoplasm of breast,Other,0.0162,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KDM1A gene|KDM1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Triterpenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,nervous system disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRMT6 gene|PRMT6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,YY1 gene|YY1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,MIRN181A gene|MIR181A2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Huntington Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cyanidin 3-O-glucoside,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Rare Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,equol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,OGG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypoxia-Inducible Factor 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Ultrasonography,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,DYRK2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mitomycin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Leukotrienes,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Therapeutic agent (substance),Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,miltefosine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,FOXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Heparitin Sulfate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Ovulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoplasm Metastasis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,PSD4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gamma synuclein|SNCG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCAAT-Enhancer-Binding Protein-beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,camalexin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ESR1 gene|ESR1,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,CUL3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Streams,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TOX3,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,FLT1 gene|FLT1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Annexin A2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,ORAI3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fluvastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,KDM6B,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,"CRK protein, human|CRK",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Progestational Hormones, Synthetic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCR5 gene|CCR5,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,HOXD10 gene|HOXD10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRPV6,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,bexarotene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RAC-Alpha Serine/Threonine Kinase|AKT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,dihydroceramide desaturase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CIP2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Creatinine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Stearates,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Proteins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,PIK3CA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KLF8 gene|KLF8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Supplementation,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,methylcobalamin-coenzyme M methyltransferase|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Ubiquitin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Protein Family,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer recurrent,Demographic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Angiotensin II Type 1 Receptor Blockers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"TGFB1 protein, human|TGFB1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,anthracene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MYC Family Genes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RBBP8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Beverages,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HSP90 Heat-Shock Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fat graft,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,mitogen-activated protein kinase p38|CRK|MAPK14|MAPK1|AIMP2|GRAP2|AHSA1|POLDIP2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Ki antigen|PSME3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormone Receptor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Benzimidazoles,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IRAK4 gene|IRAK4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heart Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lysophosphatidylethanolamine,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Does hit,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cDNA Library,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Flavonoids,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,osteoblast cadherin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,HOXD@,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TFF3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Lovastatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EPHB2|MAPK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GTF2H1|SQSTM1|KHDRBS1|NUP62|DCTN4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AXILLARY LYMPH NODE METASTASIS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APOA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,genistin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GRPR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRIM62,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tau Proteins|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"NAT1 protein, human|NAT1|EIF4G2|SLC6A2|SLC38A3|SLC38A6",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tipifarnib,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,low protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,C-KIT Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Autophagy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LRIG1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,erlotinib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dimethyl sulfone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"TRIP10 protein, human|TRIP10",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SRD5A2 gene|SRD5A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Acetate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tumor Markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,XRCC2 gene|XRCC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Thrombospondin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCNA2 gene|CCNA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Proline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,icaritin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MDC1 gene|MDC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gene polymorphism,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Biopsy finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TWIST1 gene|TWIST1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"NOS3 protein, human|NOS3",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,GFRA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prolactin|PRL,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,dehydroepiandrosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Anti-Inflammatory Agents, Non-Steroidal",Breast cancer invasive NOS,Demographic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,formononetin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,8q22,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Effective communication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phospholipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ataxia Telangiectasia,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Common Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,DNA,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Stress,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,peptide hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,retinyl methyl ether,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PROTEIN KINASE,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Negative Finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aneuploidy,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,"technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Ethinyl Estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA Sequence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"SOD2 protein, human|SOD2",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,E-Selectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Neoplasm Metastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Exogenous hormones,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Fruit, Citrus",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ETV4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LMO7 gene|LMO7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antigens,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,Plasminogen Activator Inhibitor 1|SERPINE1|SERPINB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,peptide hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glutaminase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cheese,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Androgenic precursors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,HOXA1 gene|HOXA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dihydroxy-vitamin D3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Virus,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,spasmolytic polypeptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aminoglutethimide,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Monoclonal Antibodies,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,3-hydroxytamoxifen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Relate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histological finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Steroid Use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low-Density Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ESTROGEN USE,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Prednisone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Prolactin|PRL,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Caffeine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic Abortion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Fatty Acids, Nonesterified",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Augmentation mammoplasty,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Malignant neoplasm of breast,Contralateral breast cancer,Other,0.3988,0.0019980019980019,Female Breast Cancer
AFFECTS,MICE gene,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Smoking History,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sialyltransferases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CATHEPSIN D|CTSD,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Monoclonal Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Genes, vpr",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genome, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mucinous carcinoma-associated antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Polymerase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Dietary Fiber,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Insulin Receptor|INSR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Non-smoker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mixed Function Oxygenases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PCAF gene|KAT2B,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CCND1 gene|CCND1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Fluphenazine Hydrochloride,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SHBG gene|SHBG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Lymphoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NODULAR DENSITY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoembryonic Antigen,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Ionizing radiation,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Serine Protease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,SH Protease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Breast cancer recurrent,"Carcinoma, Ductal, Breast",Other,0.0174,0.0029970029970029,Female Breast Cancer
AFFECTS,3-hydroxytamoxifen,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Study models,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Glucagon,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Insulin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of liver,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Autologous bone marrow transplant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,cytokine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Histocompatibility Antigens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PGR gene|PGR,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,Epidermal Growth Factor|EGF,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,beta-Chemokines,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,PIN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vascular Endothelial Growth Factor C,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Signaling Molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microsatellite Instability,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Genes,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,DNA Polymerase I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZNF217 gene|ZNF217,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Laminin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,riboflavin-binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Raw vegetable,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinoma in Situ,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CDKN2A|CDKN2D|F9|REG1A|IL23A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EIF3S6 gene|EIF3E,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Inositol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SULT1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SAFB gene|SAFB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,Primary Carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Inositol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Differential Diagnosis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tumor Markers,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PRMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Folate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aneuploidy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Mitogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperlipidemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Bilirubin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,cyclin E2|CCNE2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SPARC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ID-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Germ-Line Mutation,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,Globo-H,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MYC gene|MYC,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Metformin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,"TACC1 protein, human|TACC1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Hydrocarbons, Halogenated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genetic syndrome,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hormones,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Platinum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EGb 761,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,celecoxib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nulliparity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,B-pyridine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pathologic Processes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ELF3 gene|ELF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Meal pattern NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diastasis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PLAUR gene|PLAUR,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Fumarate Hydratase|FH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vidal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thyrotropin-Releasing Hormone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,E-Cadherin|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AXIN2 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCL2 gene|CCL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fluoxetine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogen Receptor beta|ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bone sialoprotein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Thiazolidinediones,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,EZH2 gene|EZH2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,antireticular cytotoxic serum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERA-923,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CD151,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,restriction enzyme,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tretinoin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Multiparity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Tankyrase|TNKS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SEPT9 gene|SEPT9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Beans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Steroids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,betaIG-H3 protein|TGFBI,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,integrin-linked kinase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Tea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTHLH gene|PTHLH,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,T gene,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,zeaxanthin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Vitamin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Gonadal Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoking,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,CD109,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ERBB2|NEU1|NEURL1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IRS2 gene|IRS2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,SRC,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Small RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Heterocyclic Amines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PSIP1 gene|PSIP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Aromatic Amines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TBX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CA9 gene|CA9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Integrin alpha6beta1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Angiopoietin-2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,LMO4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antidepressive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IGF2 gene|IGF2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,SCTR gene|SCTR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fetus size,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogens,Sporadic Breast Carcinoma,Hormonal Factors,0.0,0.0,Female Breast Cancer
AFFECTS,"Shc1 protein, mouse|SHC1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERbetacx,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,multicatalytic endopeptidase complex,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Abnormal result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Environmental Estrogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Selective Estrogen Receptor Modulators,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PP5 protein-serine-threonine phosphatase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lesion,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,IGFBP3 gene|IGFBP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vascular Endothelial Growth Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-3 fatty acid intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cell invasion,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,TRANCE protein|TNFSF11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Genes, Homeobox|LBX1",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WISP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WWP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Water,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NDRG1 gene|NDRG1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Combination Drug Therapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Eating habit,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alanylalanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MUC5B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of bone,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,genetic element,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"DICER1 protein, human|DICER1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclophosphamide,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,"Nuclear Receptor Subfamily 4, Group A, Member 1",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Xanthine Dehydrogenase|XDH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NOTCH1 gene,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Bloody nipple discharge,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Adhesion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CCL18 gene|CCL18,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,trans-resveratrol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,phospholipase C beta2|NEUROD1|TUBB4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTK2B gene|PTK2B,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,ABCB1 gene|ABCB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytochrome P-450 CYP2D6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Transduction Pathways,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Prolactin Receptor|PRLR,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CCL2 gene|CCL2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Receptor Protein-Tyrosine Kinases,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,RGS Proteins|PITX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TNFSF11 gene|TNFSF11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRS gene|PRS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin D1|CCND1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,ADIPOR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bone remodeling,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ADRA1D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypoxia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"Receptors, Progesterone|EREG|ESR1",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pharmacotherapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,osteopontin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,cell fate determination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,N-Cadherins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LSP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stromal hyperplasia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gene Expression Alteration,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cessation of life,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,UNC45A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Human Papilloma Virus Vaccine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,JTB gene|JTB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CISH,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein Overexpression,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Systemic disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IGF1R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Candidate Disease Gene,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,artesunate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Adrenergic beta-Antagonists,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,Selectins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Paraffin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Extravasation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alkaline phosphatase isoenzyme,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,heparanase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Hormone Receptor Test,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Calcium, Dietary",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,denbinobin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Proline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AXL gene|AXL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FAT4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prophylactics use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD100 antigen|SEMA4D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TIAM1 gene|TIAM1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,HDAC9,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Tumor Suppressor Genes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ERBB2 gene|ERBB2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Stiff-Person Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TAZ gene|TAZ,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ethanol,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,COPS5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cigarette Smoking,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,CBX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,metabolic abnormality assessment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metabolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UHRF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ethacrynic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,asparaginylendopeptidase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Transcript,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,p21-activated kinase 1|CDKN1A|TCEAL1|NSG1|H3F3AP6,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,UHRF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sweet's Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,heparanase|HPSE,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTPN12 gene|PTPN12,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Antigens, CD25",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PLK1 gene|PLK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NUCB2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Fibroblast Growth Factor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Keratin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PER1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"EPIDERMAL GROWTH FACTOR, HUMAN",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Intercellular adhesion molecule 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,5'-AMP-activated protein kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Metals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Polyethylene Glycols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,flavanone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,WT1 gene|WT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acetaldehyde,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC2A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physiologic Responses,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,SMYD2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIRN96 gene|MIR96,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dimethylformamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PVT1 gene|PVT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Systemic poison,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Stereotactic radiotherapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Receptors, Progesterone|PGR",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CD47 gene|CD47,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mitogen-activated protein kinase 7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TGFBR2 gene|TGFBR2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Reactive Oxygen Species,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"ESR2 protein, human|ESR2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lard,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiotensins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CPEB4 gene|CPEB4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,triplet codon-amino acid adaptor activity,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Nicotine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,osthol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ginkgetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HOXD13,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,diallyl trisulfide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,citrate lyase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Breast cancer stage III,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,PPP2R1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Hydroxamic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADIPOR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor necrosis factor receptor 11b,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phospholipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin-1 alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Infrared radiation therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MMP12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"STC1 protein, human|STC1",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,DANCR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,baicalein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HMGA2 gene|HMGA2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Benzodiazepines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Breast cancer stage III,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Glycerol-3-Phosphate Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adhesions,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Neprilysin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,WBP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"MFNG protein, human|MFNG",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Placental Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Anthocyanins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mesothelioma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lipopolysaccharides,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Dysplasia, fibrous",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HGF gene|HGF,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RBBP1L1 Protein|ARID4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TERT gene|TERT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,hypercholesterolemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RETN gene|RETN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SYNJ2BP,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,phenylpyruvate tautomerase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LIMK1 gene|LIMK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Camellia sinensis extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutant Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Dioxygenases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SRCIN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Calcium-Sensing",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,17beta-HSD 7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RET gene|RET,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Immunotoxins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PNPLA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DNA,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,NRF1 gene|NRF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,L-2-amino-4-phosphonobutyrate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"8-oxoguanine-DNA glycosylase, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCDH10 gene|PCDH10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"NOS3 protein, human|NOS3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RUNX2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mitosis,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,NOTCH1 gene,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,CDK4 gene|CDK4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Riluzole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Androgens,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Prostaglandins E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CD4 gene|CD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tiron,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,TOLLIP gene|TOLLIP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CASP10 gene|CASP10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sorafenib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Paclitaxel,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Pharmaceutical Preparations,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cytochrome P-450 CYP2E1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CCNB1 gene|CCNB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dendritic Cell Vaccine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,cyclin B2|CCNB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,receptor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,atamestane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BARD1 gene|BARD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-(4-aminophenethyl)spiroperidol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GACAT3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Aspartate Transaminase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Therapeutic Intervention,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,UBAP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXC1 gene|FOXC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Bombesin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRIP1,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,Homologous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,indole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AKTIP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LMO4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alternative Therapies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIRT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,JAG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"NAT2 protein, human|NAT2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Acetylcysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Diet,Noninfiltrating Intraductal Carcinoma,Behavioral Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,LTB4R2 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fisetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dopamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,chemokine receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth-Factor-Binding Proteins|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 gene|BRCA1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,XPA gene|XPA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,rhodioloside,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HOXB5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nitric Oxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NES gene|NES,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,YBX1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,CDKN1B gene|CDKN1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,proteomic profiling,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mastectomy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,MIRN384 gene|MIR384,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNAI1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MFAP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MAL gene|CD8A|MAL|MKL1|TIRAP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hyperinsulinism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MTDH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diabetic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TRANCE protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Genistein,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CD24,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Breast hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,mixed drink,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mitogen-Activated Protein Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thrombospondin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hodgkin Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Diet,Breast Carcinoma,Behavioral Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CYP2A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Wound Healing,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Candidate Disease Gene,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Depo-Provera,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Hydrocortisone,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Estrogen receptor negative,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Malnutrition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Violence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Methotrexate,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,BP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Permeability,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Transplantation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CISH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor I,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SULT1A1|SULT1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tumor Promoters,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,tibolone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Indicators,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Menopausal Status,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,HYAL1 gene|HYAL1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Cell division,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SFRP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,letrozole,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,Genes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,SLC13A2|SLC13A5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sexual function,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bone metabolism,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Androgens,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Carcinoma in Situ,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,MIRN21 gene|MIR21,Ductal Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Lactate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,telomerase activity,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Seasoning,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinoembryonic Antigen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Atypia,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Test Result,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Pathologic stage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Janus kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PRL gene|PRL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,B VARIANT NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Shock,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RARA gene|RARA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antioxidants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gonadorelin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,progesterone receptor B|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,biological_process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Gelatinase B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MAP Kinase Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TGFB1 protein, human|TGFB1",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,VEGFA,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,soy protein isolate,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,"Polycyclic Hydrocarbons, Aromatic",Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,MED28,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,Selenium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immunoglobulin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MED28,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ARHI gene|DIRAS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,claudin 6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Superior Vena Cava Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,S100 Proteins|S100A1|S100B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Precancerous lesions,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,PLEKHF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Associated symptom,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,WNT5A gene|WNT5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,2q34,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fucoidan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,5-7-oxo-zeaenol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ESR1 protein, human|ESR1",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,EGFR|ENAH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,coactivator-associated arginine methyltransferase 1|CARM1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,ACKR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Chloroquine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa|UBASH3B",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Does play,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Weight maintenance regimen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RAP1GDS1|KIFAP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Methionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LPO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIP,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,ING1 gene|ING1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,proneurotensin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dehydroepiandrosterone Sulfate,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,PRKD1 gene|PRKD1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,EGb 761,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TIAM1 gene|TIAM1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,mortalin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTEN gene|PTEN,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,CACNA1A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,osteopontin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,biological_process,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,XIST,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CISH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin-6|IL6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,COX5B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adenoid Cystic Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AHNAK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MRPS18A gene|MRPS18A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,no positive axillary nodes,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Vitamin B2 intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,chitotriosidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PROSTATE SPECIFIC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adjuvant response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,E-Cadherin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Platinum salt,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Insulin Receptor|INSR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATM gene|ATM,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Mineralocorticoid Receptor|DHCR24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CREB3L1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Melatonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antilipemic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ITK gene|ITK,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CXCL10 gene|CXCL10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibroadenoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNAs,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,FANCM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,6/6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Thyroxine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,antibody therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gastrin|GAST,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Peanuts - dietary,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pancreatic carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KIF4A gene|KIF4A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Repair Gene,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Microcalcification,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Compete,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL1B gene|IL1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL4R gene|IL4R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Crystallins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MSX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,YBX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,valdecoxib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Mitomycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Enhancing Lesion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRRT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Sulfuric Acid Esters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EGFL7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CXCL13 gene|CXCL13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Contralateral breast cancer,Other,0.3988,0.0019980019980019,Female Breast Cancer
AUGMENTS,beta catenin,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,ERBB3 gene|ERBB3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LRRC3B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Nitric Oxide Synthase Type II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Thromboplastin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,Amyloid beta-Protein Precursor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CAPN9 gene|CAPN9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KIAA1199 gene|CEMIP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BMP1|PRCP|PGPEP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,baicalein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ACE gene|ACE,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha2HS glycoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PFAS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Microdissection,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VEGF gene|VEGFA,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Diet,Breast cancer invasive NOS,Behavioral Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,tibolone,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,collagenase 3|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Histopathology,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Chondroitin Sulfates,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Malathion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"VEGF protein, human|VEGFA",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Cholecalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,phenethyl isothiocyanate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Encounter due to breast reduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Detection,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,CYLD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TBX3,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Elongation Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOXC1 gene|FOXC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,H19 gene|H19|HILS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,patient retention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,gefitinib,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,USF1 gene|USF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oxytocin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WWOX gene|WWOX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,usnic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ferritin level,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Folic Acid Antagonists,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Norethindrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,toxicant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DACH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cacodylic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperinsulinism,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Venous Thrombosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WWOX,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USH2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cigarette smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,c-myc Genes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Antirheumatic Drugs, Disease-Modifying",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,PTH gene|PTH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NET1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SDC1 gene|SDC1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MXD1|MAD1L1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Flavonols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Pancreatic leak,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,TOP2A gene|TOP2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bilateral oophorectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Depo-Provera,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTM1 gene|GSTM1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Neck Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,gamma-Glutamyl Hydrolase,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,CATALASE,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Estrogen Receptor alpha,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Leeks (dietary),Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thromboembolic event,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Vasospasm,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,G-T mismatch-binding protein|MSH6,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Therapeutic Intervention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Response Modifiers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP2D6 gene|CYP2D6,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Micellar Paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oxalates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PHEMX protein, human|TSPAN32",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MED19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Performance,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,ECT2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,LINC00461,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USP1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DKK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIP5K1C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Abnormal protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Feeding and dietary regimes,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Malignant meningitis,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,ENPP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SMAD7 gene|SMAD7,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"NRIP1 protein, human|NRIP1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BITTER MELON FRUIT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD71 antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Factor VIII-Related Antigen,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PVR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Juice,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glucocorticoids,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CYGB gene|CYGB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Food,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,LRP6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Relapse,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclin-dependent kinase inhibitor 1B|CDKN1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Manual reduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"EPIDERMAL GROWTH FACTOR, HUMAN|EREG|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Natural Products,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,"RNA, Messenger",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Interleukin-6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Paraoxonase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Interleukin-1 beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PARVA gene|PARVA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZEB2-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CKS2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Anthracycline Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta-elemene,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,mammaglobin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lipocalin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caspase-8|CASP8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pancreatic Polypeptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"MPP3 protein, human|MPP3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL17F,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,claudin 6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gangliosides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Apolipoprotein A-I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AFAP1L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AMD3465,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CCAT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,shogaol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Osteoporosis, Postmenopausal",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Translocase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Taking medication,Malignant neoplasm of breast,Pharmacological Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-Acetylneuraminic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MicroRNAs,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,CYP2C8 gene|CYP2C8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EZR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Monoacylglycerol Lipases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABRAXAS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Heat-Shock Proteins 70,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,bone morphogenetic protein 2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,parathyroid hormone-related protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,HULC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARITY,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Proanthocyanidins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cell transformation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thyroid Hormone Receptor Beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Anthocyanidins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,26S proteasome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Macrophage Activation Syndrome,Invasive carcinoma of breast,Demographic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,LINC00665,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Enrich (product),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"interleukin-1, beta",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CEACAM5 protein, human|CEACAM5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neurophysiology - biologic function,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,rucaparib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,zoledronic acid,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Metaplastic carcinoma of breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fucoidan,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ERBB3 gene|ERBB3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,LINC00520 gene|LINC00520,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,TRIP6 gene|TRIP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Enzyme Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cholesterol hydroxylase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,anastrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Thromboplastin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,MIR182 gene|MIR182,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ROR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,COL10A1 gene|COL10A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CpG Islands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,chloroxoquinoline,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,ZNF10 gene|ZNF10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM5B gene|KDM5B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genome,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,bis(4-hydroxyphenyl)sulfone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sex Hormone-Binding Globulin,Noninfiltrating Intraductal Carcinoma,Demographic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PAQR4 gene|PAQR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZFP36L1|BRF1|MST1L,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hydrogel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,nobiletin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CALCIUM HOMEOSTASIS,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Targeted Therapy,Carcinoma breast stage IV,Treatments,0.0,0.0,Female Breast Cancer
AFFECTS,PTTG1 gene|PTTG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormones,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Epidermal Growth Factor Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"Breast Cancer, Familial",Malignant neoplasm of breast,Other,0.0171,0.3386613386613387,Female Breast Cancer
DISRUPTS,Aptamer,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xenograft type of graft,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ASAP1 gene|ASAP1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Genes, Essential",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Risk Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Graft acceptance,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,TRPM4 gene|TRPM4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNORA71B gene|SNORA71B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,marizomib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MARS gene|MARS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ergocalciferol,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Estrogen Receptor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transcriptome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Positive Transcriptional Elongation Factor B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ENO1 gene|ENO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SCUBE2 gene|SCUBE2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cell Proliferation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,AGR2,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,DLG3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mevalonate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MKI67 gene|MKI67,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,dinoprost,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epicatechin-3-Gallate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pathologic Response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"T-Cell Surface Glycoprotein CD4, human|CD4",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMEM165 gene|TMEM165,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Tumor-Associated Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PROM1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Contralateral Prophylactic Mastectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDC2 Protein Kinase|CDK1,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,MMP10 gene|MMP10,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Androgen Receptor,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,ENC1 gene|ENC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Xenograft Model,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cytologic atypia,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,"AGR3 protein, human|AGR3",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Smoked food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GA-Binding Protein Transcription Factor|GABPA|NFE2L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,platinum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HLCS gene|HLCS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Functional Food,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,UNC5B gene|UNC5B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ITPKC gene|ITPKC,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,cyclophosphamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stat3 protein,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Unlikely,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PART1 gene|PART1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SPRY4-IT1 gene|SPRY4-IT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cyclovirobuxine D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Salts,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Extranodal Extension,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADAMTS8 gene|ADAMTS8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Obstruction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fluid intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Periodontitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic Obstructive Airway Disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mammary gland involution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR100HG gene|MIR100HG,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,PALB2 gene|PALB2,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,MIR497 gene|MIR497,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,YY1 gene|YY1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"TRIM25 protein, human|TRIM25",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ganetespib,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Phosphoinositide Phosphatases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HAND2-AS1 gene|HAND2-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Expression procedure,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mastectomy,Stage IV Inflammatory Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Iodides,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,SRCIN1 gene|SRCIN1,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Eicosanoids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ciclesonide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adipose Tissue Deposition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PLEKHA7 gene|PLEKHA7,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,CDC25B gene|CDC25B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast normal,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Neoadjuvant Systemic Therapy,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,MKI67 gene|MKI67,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,estrogens,Invasive carcinoma of breast,Hormonal Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Ferritin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"RNA, Circular",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Transcription, Genetic",Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,HLA-F-AS1 gene|HLA-F-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Red Meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DSCAM-AS1 gene|DSCAM-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APLN gene|APLN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,heparanase,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,RING1 gene|RING1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,K-ras Oncogene|KRAS,Invasive Ductal Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Patient age,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Metabolic Process, Cellular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Digital Mammography,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,EIF3A gene|EIF3A,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,PFKL gene|PFKL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genes,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,"Sleep Disorders, Circadian Rhythm",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,No effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HMGA2 gene|HMGA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Insulin Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,leptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EPHA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,rutin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemotherapy Regimen or Agent Combination,Triple Negative Breast Neoplasms,Demographic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,ZEB1 gene|ZEB1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Long Interspersed Nucleotide Element-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Decreasing,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Heat shock proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MLN4924,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDKN2B gene|CDKN2B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin-Dependent Kinase 4,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Ataxia Telangiectasia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mutation,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,ACTL8 gene|ACTL8,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"CD274 protein, human|CD274",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,BCL6 gene|BCL6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary Modification,Noninfiltrating Intraductal Carcinoma,Behavioral Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,SIRT3 gene|SIRT3,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FOXO6 gene|FOXO6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pathologic Complete Response,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,"Neoplasm, Residual",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glucocorticoid Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,METTL3 gene|METTL3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"STK11 protein, human|STK11",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transferrin,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Transforming Growth Factor beta,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,KIF18B gene|KIF18B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PDLIM7 gene|PDLIM7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RFX5 gene|RFX5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,other medicated shampoos in ATC,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Nicotinamide Phosphoribosyltransferase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PUM1 gene|PUM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gene interaction,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prevention effectiveness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FGFR1 wt Allele|FGFR1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,AFAP1-AS1 gene|AFAP1-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,IMPACT gene,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Medical record number:ID:Pt:^Patient:Nom,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EEF1E1 gene|EEF1E1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Interleukin-12 Subunit p35,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,HIF1A gene|HIF1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Transformation, function",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Dovitinib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CASC16 gene|CASC16,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RNA, Messenger",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDC20 gene|CDC20,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,multidrug resistance-associated protein 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD9 protein, human|CD9",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,physiological aspects,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Possible,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,cell cycle regulator,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,MIR937 gene|MIR937,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,CBR3-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RAD54B gene|RAD54B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Luteolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"GPER protein, human|GPER1",Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,LRP6 gene|LRP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MEG3|FAM129B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Recurrent pregnancy loss,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pregnancy-Associated Plasma Protein-A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SCUBE2 gene|SCUBE2,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Physical function,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Disaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MORC2 gene|MORC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,G-Protein-Coupled Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ACTG2 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GATA3 Transcription Factor|GATA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Vascular Endothelial Growth Factor A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL18 gene|IL18,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABI1 gene|ABI1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,"BCAR3 protein, human|BCAR3",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Cell Growth,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,SHARPIN gene|SHARPIN,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,COVID-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrillar Collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antitumor Response,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"DKK3 protein, human|DKK3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Matrix Metalloproteinase 13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LIG3 gene|LIG3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphotransferases,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,WLS gene|WLS,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,collagen,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Positron-Emission Tomography,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,PLB1 gene|PLB1,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,USP41 gene|USP41,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,REPLETE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SMYD3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SP7 gene|SP7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"CDK7 protein, human|CDK7",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oligonucleotides,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,"CD69 protein, human|CD69",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Alkaloids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BCL6B gene|BCL6B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TWSG1 gene|TWSG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SPARC gene|SPARC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CTNNB1 gene|CTNNB1,Ductal Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,BCL6B gene|BCL6B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Whole Grains,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ergocalciferol,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Limonins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ipatasertib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MYD88 gene|MYD88,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Poly-L-lactic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,rosuvastatin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Hormone Therapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Reproductive Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TNFSF13 protein, human|TNFSF13","Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
CAUSES,"RNA, Long Untranslated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Markers,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogen Receptor Modulators,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Effective Communication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,glucose oxidase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,estradiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR10B gene|MIR10B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIR139 gene|MIR139,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,CDC20 gene|CDC20,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,1 time,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,"CTGF protein, human|CTGF",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"CD69 protein, human|CD69",Triple-Negative Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,paclitaxel liposome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TPI1 gene|TPI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acclimatization,Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
AFFECTS,imipramine,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,AMACR wt Allele,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,MKI67 gene|MKI67,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TPI1 gene|TPI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,limited use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CDK6 gene|CDK6,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,MAP1LC3C gene|MAP1LC3C,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Pathogenic Variant,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Pseudogenes,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,cyclin B2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TTYH3 gene|TTYH3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cyclooxygenase 2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Proliferation (morphologic abnormality),Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,HSPG2 gene|HSPG2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC01234 gene|LINC01234,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Individual Exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ELP3 gene|ELP3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Methylation Site,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Experimental Result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pneumocystis jiroveci pneumonia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DST gene|DST,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CYP2S1 gene|CYP2S1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High glycemic index food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RNA-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GTF2H1 gene|GTF2H1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Tomography, Emission-Computed",Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,ginsenoside Rg3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ULBP2 gene|ULBP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MEF2C gene|MEF2C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antioxidants,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,skill,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Plasma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,alpha Karyopherins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Mammary Carcinoma, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bioavailable testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SPOP gene|SPOP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Anthropometric Measures:-:Point in time:^Patient:-,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CUL4B gene|CUL4B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MMP13 gene|MMP13,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,TaqI POLYMORPHISM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Anthracycline Antibiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TIMM8A gene|TIMM8A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TRIM25 protein, human|TRIM25",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,inhibitors,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Pathologic Response,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,RET,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Contrast used,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNA 205-5p,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CLIC1 gene|CLIC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSPA8 gene|HSPA8,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,aflatoxin B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ZFP36 protein, human|ZFP36",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Decreased Expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,LINC00473 gene|LINC00473,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,clopidogrel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"3,3'-diindolylmethane",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Alkaloids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,vemurafenib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WBP2 gene|WBP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Histone deacetylase inhibitor,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,ezrin,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,microphthalmia-associated transcription factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WNT9B gene|WNT9B,Triple-Negative Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,beta-2 Adrenergic Receptors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Menopausal syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CXCR4 gene|CXCR4,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00667 gene|LINC00667,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation Abnormality,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lycorine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Performance,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Animal feed (substance),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SPON2 gene|SPON2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Mucosa-Associated Lymphoid Tissue Lymphoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,mannose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MTOR wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CRABP2 gene|CRABP2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,BTG4 gene|BTG4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Alanine Aminotransferase 1, human",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,ZSCAN1 gene|ZSCAN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USP20 gene|USP20,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,AFAP1-AS1 gene|AFAP1-AS1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,KMT2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PFKFB3 gene|PFKFB3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,treatment options,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"CD69 protein, human|CD69",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MCAM gene|MCAM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,hydroxybenzoic acid,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,20-40 years,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Retinoblastoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Treatment Protocols,Luminal B Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
CAUSES,Toxin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diesel Exhaust,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunoregulation,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Problem,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Singlet Oxygen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BARRIER,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bone Morphogenetic Protein Receptors,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,ZNF451 gene|ZNF451,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"Genes, env|ERVW-1|ERVK-20|ERVK-18|ERVK-32",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,taxifolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RAD52 gene|RAD52,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CCR7 gene|CCR7,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,macroautophagy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXXC5 gene|CXXC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Androgen Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Increased risk,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,TYMSOS gene|TYMSOS,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,systemic administration,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,cinobufagin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cancer Relapse,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased size (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IMPACT gene,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Axillary node METASTASIS,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,NR1D1 gene|NR1D1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD103|ITGAE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,anastrozole,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,risk factors,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,brusatol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hepatitis C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Menopause,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Suppressor,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,HLA-G gene|HLA-G,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,DLGAP5 gene|DLGAP5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,bruceine A,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,"IL5 protein, human|IL5",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,pimavanserin tartrate,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Histone deacetylase inhibitor|HDAC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Transformation, function",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,BCPR Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,hydroxypropylbetadex (0.58-0.68 MS),Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,VIRMA gene|VIRMA,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Piperlongumine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immune,Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Antigens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EZH2 gene|EZH2,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,BHLHE41 gene|BHLHE41,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,medroxyprogesterone acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SHC4 gene|SHC4,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,USP4 gene|USP4,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Diagnosis,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Anoikis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dichloroethylenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SRRM4 gene|SRRM4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Not significant,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,paraffin,Invasive Ductal Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,multicatalytic endopeptidase complex,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PTK2 gene|PTK2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Screening mammography,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,SKP2 gene|SKP2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,USP30 gene|USP30,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,thyme oil,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AIMP2 gene|AIMP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,maduramicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FOXO1 gene|FOXO1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,TWIST1 gene|TWIST1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,"PIK3CB protein, human|PIK3CB",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,cholecalciferol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TLR2 protein, human|TLR2",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,NSUN2 gene|NSUN2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXA2 gene|FOXA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FBXO8 gene|FBXO8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNORA73B gene|SNORA73B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Present,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,SCARNA4 gene|SCARNA4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PLK4 gene|PLK4,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MIR130A gene|MIR130A,malignant neoplasm of breast staging,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,fiber,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"membrane protein, SARS-CoV-2",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Mutant Proteins,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Bacteroides fragilis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epiberberine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,progesterone,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Benign foot rot,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Protease Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bloody nipple discharge,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,decanoylcarnitine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
COMPLICATES,Fibrous Dysplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RBMS3 gene|RBMS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Non-infiltrating lobular carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tegafur,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SF3A2 gene|SF3A2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Xenobiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,COL5A1 gene|COL5A1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Signs and Symptoms,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Score,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Multiple Sclerosis,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,NF-kappa B,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,MTA1 gene|MTA1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Increased risk,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,obeticholic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Hypolipidemic Agents,Triple Negative Breast Neoplasms,Demographic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cessation of life,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,ETNK1 gene|ETNK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antigens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Receptor, Melatonin, MT1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Steroids,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Protein Isoforms|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Behavior,Breast cancer invasive NOS,Behavioral Factors,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Folic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,protein-tyrosine kinase c-src|SRC,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Human Papilloma Virus Vaccine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Testosterone,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Warfarin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MAD2L1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Bicarbonates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinomatous peritonitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Deoxycytidine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,phosphatidylinositol 3-kinase gamma,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Fluorouracil,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PITPNM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Psoralens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RAI3 gene|GPRC5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRD4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Janus kinase 1|JAK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Metastasis Suppressor Genes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,exemestane,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,invariant chain|CD74,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,helicase|HFM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VIP gene|VIP,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,STK11 gene|STK11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,C-Peptide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogenesis,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GPR161,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IRF2 gene|IRF2,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,"Embolism, Tumor",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,DNA Methyltransferase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Brain-Derived Neurotrophic Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SOD3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Blood flow,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Pyrones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMAD2 gene|SMAD2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Transforming Growth Factor beta,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,BRCA2|BLID,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,neuropeptide Y|NPY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIX2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SMAD2 gene|SMAD2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"DNA, Double-Stranded",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SMAD3 gene|SMAD3,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,HIF1A gene|HIF1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogens,Carcinoma of Male Breast,Hormonal Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Systemic disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genes, Immunoglobulin",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TUNAR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,andrographolide,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Progesterone,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,HOXB13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DDX26 gene|INTS6|DDX56,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,UBE2I,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ADORA2B gene|ADORA2B,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Genes, env|ERVW-1|ERVK-20|ERVK-18|ERVK-32",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,chymotrypsin A,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Oral Solution,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Spironolactone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ceramides,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Nitric Oxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IGF1R gene|IGF1R,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutation,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,Adriamycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MIRN205 gene|MIR205,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATP6V1C1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Therapeutic procedure,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Red meat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fusion Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Hepatitis C virus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Invasive Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Eukaryotic Initiation Factor-4E|EIF4E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of gastrointestinal tract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN200B gene|MIR200B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TP53BP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pharmaceutical Preparations,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,Iron,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MAGEC2,Breast cancer metastatic,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thiopurine S-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATP1B2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NANOG,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pteridines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,combretastatin A-4 disodium phosphate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,MMP14 gene|MMP14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chronic heart failure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Tumor Necrosis Factor, Type II",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Ro 48-8071,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TAAR5|NR2E3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,FGF1 gene|FGF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lymphatic Diseases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Placebos,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VEGFC gene|VEGFC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of cervix uteri,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Oxidoreductase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DOCK1 gene|DOCK1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GAD2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Galactosyltransferases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,proteomic profiling,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Gynecologic Surgical Procedures,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta-cryptoxanthin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NDP,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,MIRN203 gene|MIR203A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Promoter Regions (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Multiple Myeloma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Cholesterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Norepinephrine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Tuberculosis, Pulmonary",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Retinoid X Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,aldehyde dehydrogenase 1|ALDH1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Prolactin|PRL,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Integrin beta3|ITGB3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CD29 Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Calcitonin Receptor|CALCR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PTHLH gene|PTHLH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prolactin|PRL,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogen Antagonists,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ABCC1 gene|ABCC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tamoxifen,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,KIF20A gene|KIF20A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glucosephosphate Dehydrogenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Leucovorin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MLLT11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 gene|BRCA2,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,WBP2 gene|WBP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Aspirin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,particle,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,6p12,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,E-Cadherin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Endobronchial metastases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Regulatory Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibrinogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mdm2 protein|SLURP1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Cholangiocarcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Sex Hormone-Binding Globulin,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Mutation,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Fruit,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,IGFBP7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diabetes Insipidus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"12-Hydroxy-5,8,10,14-eicosatetraenoic Acid",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Relationship problems,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of axilla,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Free Radicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLOPE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Calcitonin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Adrenalectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adriamycin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,16 alpha-hydroxyestrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estriol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Large Cell Lymphoblastic Lymphoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Caseins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Orchitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FCE 21336,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,leukemia,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TAG 12,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Body measure result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,S-Phase Fraction,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Idarubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha-Lactalbumin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Fucose,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,sterculic acid,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Nuclear Receptor Subfamily 4, Group A, Member 1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Difluoromethylornithine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Aflatoxin B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,fibrosarcoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Shock,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Enovid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Platinum,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ERVW-1|ERVK-20|ERVK-18|ERVK-32,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Interferons,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypophysectomy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Cellular Retinoic Acid Binding Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cerebellar degeneration,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Response Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,dromostanolone propionate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Stimulant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Trace Elements,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Familial cancer of breast,Other,0.3988,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Clinical finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BAG3,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
DISRUPTS,"Linoleic Acids, Conjugated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ductal Breast Carcinoma,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Telomerase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Readiness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FGFR1 gene|FGFR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Operative Surgical Procedures,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,blood lipid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,placental protein 11|ENDOU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTHLH gene|PTHLH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BRCA2 gene|BRCA2,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Immune status,Breast Carcinoma,Immunological Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Antihistamines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Pleural effusion disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,butyrate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NCOA3 gene|NCOA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Specific antibody,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Sulfhydryl Compounds,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,stanniocalcin 2|STC2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinogens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Genital Diseases, Female",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fluoranthene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,17q21,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Sterically Stabilized Liposome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Nitrosamines,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Early Diagnosis,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Small T-Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NME1 gene|NME1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Serine Protease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mutagens,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,sarcoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Prostate-Specific Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cyclin Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Immunotoxins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,RNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Histidine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Androgens,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Silicones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Tumor Suppressor Genes,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Somatropin|GH1|GGH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"VEGF protein, human|VEGFA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Radiation therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NRG1 gene|NRG1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Ether, Ethyl",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,cyclooxygenase 2,Carcinoma in situ of breast,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,c-myc Genes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nucleic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,small molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,factor C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Plants, Edible",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Raloxifene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,COMT gene|COMT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Genes, Homeobox",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Risk factor, cardiovascular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pregnancy History,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AR gene|AR,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,SHBG gene|SHBG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,telomerase activity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mutant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Amplification,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Watermelon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcriptional Repression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LTA gene|LTA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genomic Instability,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Nuclear Matrix-Associated Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSD17B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fibrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLC39A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neuropeptide Y Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AVP,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Chocolate milk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"ESR1 protein, human|ESR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,fulvestrant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coping Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Testosterone Propionate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Peptide Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,dominant allele,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Matrix Metalloproteinases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,SLIT3|SLIT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CTCFL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,5-lipoxygenase-activating protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thyroid Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Therapeutic procedure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tissue-Inhibitor of Metalloproteinase-1|TIMP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VEGF gene|VEGFA,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Metalloproteases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cheese,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Manganese Superoxide Dismutase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WNT5B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fluctuation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diagnostic radiologic examination,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Alanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CXC Chemokines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adhesions,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SLC3A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EP300 gene|EP300,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,PTN gene|PTN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phytoestrogens,Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of prostate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Ha-ras Oncogenes,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Gonadotropins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Testicular Diseases,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,Endopeptidases,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,"Receptors, Progesterone|PGR",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Tissue factor antibody,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Insulin-Like Growth Factor II|CD74|GCNT2|TCN2|VIPR1|TAF8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"LGALS3BP protein, human|LGALS3BP",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cysteinylglycine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aspirin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,myricetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin E,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Adriamycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prolyl-proline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hormone Receptor,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Heterocyclic Amines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Eating,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Siramesine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CALCIUM PHOSPHATE CRYSTALS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Quantitative Trait Loci,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LGI1 gene|LGI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BMI1 gene|BMI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,5-Trimethoxyamphetamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,5'-NUCLEOTIDASE|TRIM33,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ADAMTS4|ADAMTS3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,alpha 1-Antitrypsin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prolactin Receptor|PRLR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Benzodiazepine Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SKI gene|SKI,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,LFNG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Functional RNA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TNFSF11 gene|TNFSF11,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,gemcitabine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Encounter due to drug use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Receptors, Progesterone|EREG|ESR1",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Dancing,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,valylvaline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Toremifene,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,glypican 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Gelatinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,doxifluridine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Doxorubicin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Transient Receptor Potential Channels,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Phosphorylcholine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Fruit, Citrus",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stanolone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,4-octylphenol,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Aromatase Inhibitors,Contralateral breast cancer,Treatments,0.0,0.0019980019980019,Female Breast Cancer
CAUSES,RA 25,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pressure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,letrozole,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,GATA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AURKA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glucocorticoid Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AIP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogens,Breast cancer invasive NOS,Hormonal Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,MCAM gene|MCAM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SKP2 gene|SKP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IL2 gene|IL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PARP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TP53 gene|TP53,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Apigenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Histiocytoma, Malignant Fibrous",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cellular process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADIPOR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ALK gene|ALK,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Drug resistance,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,17q21,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BHLHE41,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"Cholesterol, Dietary",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HIF1A gene|HIF1A,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,arrestin3|ARR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LDL Cholesterol Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB4 gene|ERBB4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,versican|VCAN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Insulin, Regular, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,vinorelbine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HRAS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HOXB9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Retinoblastoma Genes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tumor Suppressor Genes,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Phosphatidylinositols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,thyroid microsomal antibodies|TPO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"DNA, Single-Stranded",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,bakuchiol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogens,Noninfiltrating Intraductal Carcinoma,Hormonal Factors,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,"9,10-Dimethyl-1,2-benzanthracene",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Herceptin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FABP7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLF10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epidermal growth factor receptor VIII,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis Inhibitors,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,GAPD gene|GAPDH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,HRG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oncogene ErbB2|ERBB2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PANDAR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Lymphoma, Large-Cell, Diffuse",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins p21(ras),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,protein kinase C zeta,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,parathyroid hormone-related protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CNS disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BRCA1 gene|BRCA1,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,"Antiretroviral Therapy, Highly Active",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cytotoxic T-Lymphocyte-Associated Protein 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vitamin D Deficiency,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,APP gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fatty-acid synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL4 gene|IL4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KLF8 gene|KLF8,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Membrane Proteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,KNG1 gene|KNG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proteome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,germacrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADAR1|ADAR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fibroblast Growth Factor Receptor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acute inflammation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Proteins,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,COX7A2L gene|COX7A2L,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chemokine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PORPHOBILINOGEN SYNTHASE|ALAD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Clinical Treatment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyaluronan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,DDX3X,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,[M]Skin appendage adenoma,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,mead acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metabolic syndrome,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Protein antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLC19A3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,May-Hegglin anomaly,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,ANXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIRN182 gene|MIR182,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sulfonylurea Compounds,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,bone morphogenetic protein 4,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,multicatalytic endopeptidase complex,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BMI1 gene|BMI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,beta catenin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,angiogenin|ANG,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,DOK7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NKX2-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antihypertensive Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epidermal Growth Factor Receptor|EGFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,apolipoprotein E-2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pyridoxine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GPR55,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Dyslipidemias,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,"Cystadenocarcinoma, Serous",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cathepsin L|CTSL,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Adenosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anthracyclines,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Inflammatory disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CCT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DEFA1|CBX5|DEFA1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MFAP5 gene|MFAP5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stopped work,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cyclin-dependent kinase 3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,preference,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Gene Expression,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,DMPK|IGHD1-7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NF-kappa B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TRIM28,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Consanguinous Mating,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Biotin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PAQR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PTF1A,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,temozolomide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease Progression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SUMO1P3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SMAD3 gene|SMAD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secretory Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cilium biogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Echinococcosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fatty Acid-Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immune defect,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC4A7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Benzene,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,5'-NUCLEOTIDASE|NT5E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumorigenesis,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,KISS1 gene|KISS1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Sleep Disorders,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,copper-binding protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ID2 gene|ID2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MIRN21 gene|MIR21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PRDX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,phospholipase C delta 1|DLK1|DLL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tamoxifen,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Interleukin-18,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ARHGEF5 gene|ARHGEF5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCAT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SENP2 gene|SENP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Acetate,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Fibroblast Growth Factor Receptor 1|FGFR1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TRPS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,nuclear receptor coactivator 1,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Thioctic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNA amplification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,inorganic phosphate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RBM38,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,F2-Isoprostanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,stromelysin 3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IkappaB Kinase beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,BCL2 gene|BCL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Pathogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MDM2 gene|MDM2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADAMTS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinogenesis,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,ETS1 gene|ETS1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cantaloupes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Need for isolation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Colorectal cancer metastatic,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Quinones,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Glucocorticoid Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,D4-GDI,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Benzodiazepine Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,E2F4 gene|E2F4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DMBT1 gene|DMBT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,retinoic acid receptor beta 2,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,alpha Catenin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Phosphoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclic AMP-Responsive DNA-Binding Protein|CAMP,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,BANCR,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,LINC00310,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gonadotropins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SIRT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,attenuation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Quercetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Smoking,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Rice,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PTGER1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Pancreatitis,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,PHGDH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,fulvestrant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin-Like Growth Factor Binding Protein 3|IGFBP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GAB2 gene|GAB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant Neoplasms,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,Lysine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Is informed,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NFKB1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tumor Promoters,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Signaling Molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fatty fish,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Combined Oral Contraceptives,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Serpins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA1 Protein|BRCA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hydroxyl Radical,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lindane,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Irritable Mood,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cytochrome P-450 CYP1A1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Gelatinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transcription Repressor/Corepressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Local excision,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Transcript,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TWSG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Endometriosis, site unspecified",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,G22P1 gene|XRCC6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Invasive Lesion,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,PTGIS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease Progression,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,nuclear receptor coactivator 1|SRC,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TBXAS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"TERT protein, human|TERT","Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,CBS gene|CBS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,childhood brain tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MNX1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MMP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EEF1A2 gene|EEF1A2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Light,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coconut milk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gonadal Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SKP2 gene|SKP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,bilateral breast cancer,Other,0.3988,0.0,Female Breast Cancer
AFFECTS,Epithelial hyperplasia,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,"RNA, Messenger",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Testosterone,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,FAU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GLO1 gene|GLO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GNRHR gene|GNRHR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"RNA, Messenger","Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,PPAR gamma|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,2-hydroxyestrone,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Non-Aspirin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"TACSTD2 protein, human|TACSTD2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TACSTD2 gene|TACSTD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bioluminescence,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CXCR3 gene|CXCR3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epstein-Barr Virus Infections,Malignant neoplasm of breast,Herpetic Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RUNX2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,MED28,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,Proteins,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,IL23R gene|IL23R,Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Proteins,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Family problems,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TOX3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,BRCA2 gene|BRCA2,Contralateral breast cancer,Genetic Factors,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,MIRN27A gene|MIR27A,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,C19orf12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AR gene|AR,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Sexual exposure,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,vitamin supplement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Physical therapy exercises,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prohibitin|PHB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DDX3X,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RHOC gene|RHOC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neprilysin|MME,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ionizing radiation,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Vaccination,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,WNT2 gene|WNT2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,daidzein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Agent,Breast cancer metastatic,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,XRCC3 gene|XRCC3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Sequence,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,VEGFA,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Inorganic arsenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prolactin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,drospirenone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SLC5A7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STK11 gene|STK11,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Norethindrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ADM gene|ADM,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Vascular Endothelial Growth Factor C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gonadal Steroid Hormones,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,chronic stressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Expressed Sequence Tags,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metformin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,FOS gene|FOS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MIRN370 gene|MIR370,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mRNA Expression,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ADAM12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Lamins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Homologous Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Insulin, Regular, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metric,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,ixabepilone,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,pertuzumab,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,BAG1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bulimia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tissue Model,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"2-methyl-5,6-cyclopentapyrimidine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Insulin-Like-Growth Factor I Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,crocetin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Study models,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DIO3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prevention,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,French fries,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclooxygenase 2 Inhibitors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Opioids,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,FOXP3,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"Receptors, Progesterone|PGR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Digoxin,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,AGAP2-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aspirin,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,CNTN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prolactin|PRL,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Androgens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epirubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IL1A gene|IL1A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,allograft inflammatory factor-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Transforming Growth Factor beta,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Tobacco smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,matriptase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of breast,Breast cancer recurrent,Other,0.3988,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Olive oil - dietary,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VDR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,apolipoprotein E-4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Anti-Inflammatory Agents, Non-Steroidal",Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,FOXQ1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,letrozole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antimony,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sirolimus (substance),Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cessation of life,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,proto-oncogene protein c-crk,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Antipsychotic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Telomerase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gelatinase B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sterically Stabilized Liposome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Materials,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TCF4 gene|TCF4|TCF7L2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Functional RNA,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,Insulin-Like Growth Factor I|IGF1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phosphatidylethanolamine Binding Protein|ZHX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PGLS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,2'-Deoxythymidine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunoliposome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Fibroblast Growth Factor 7,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,YARS gene|YARS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,inhibin B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Interleukin-4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEK2 gene|CHEK2,Female Breast Carcinoma,Genetic Factors,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,Cysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Harvest of stem cells,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,calcification,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Dioxins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TGM2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,methionine synthase reductase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinoma in Situ,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,GC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Positive Lymph Node,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,perchlorate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ASAP1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Calcium Channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sexual Dysfunction,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FTY 720,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIRN210 gene|MIR210,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,C1QBP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MCAM gene|MCAM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CCL2 gene|CCL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PITX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KISS1 gene|KISS1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Dissociation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mammography,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,"PTTG1 protein, human|PTTG1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CA-15-3 Antigen,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Protein Expression,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"PER2 protein, mammalian",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,bilateral breast cancer,Malignant neoplasm of breast,Other,0.0179,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor Status,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TP53 gene|TP53,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,MAPK12 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,membership,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,astaxanthine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,tomography,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,CD151,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HSPA5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Promoter (Genetics),Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,thrombocytosis,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,CHD8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single Nucleotide Polymorphism,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
CAUSES,Endometrial Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Aryl Hydrocarbon Receptor|AHR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,aldehyde dehydrogenases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Environmental Tobacco Smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AOX1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTGS2 gene|PTGS2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,hepcidin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PROTEIN KINASE|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RHBDD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Obesity,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,GABARAP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SEMA4C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Systemic Therapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AUGMENTS,E2F5 gene|E2F5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gynecological history NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
DISRUPTS,Fertility Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrinogen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TOP2A gene|TOP2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cataract,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Antithrombin III,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,METHOTREXATE TREATMENT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glutamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SP7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCND1 gene|CCND1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,disorder control,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Environmental Tobacco Smoke,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,citron rho-interacting kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MUTYH,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Opioids,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,IMPAD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTPRC gene|PTPRC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,desires,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,CXCL14 gene|CXCL14,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMEM68,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ovariectomy,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,Bone Morphogenetic Proteins,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ENPP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,syringin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KPNA2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Propofol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ELK3 gene|ELK3|KCNH8,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,"Metabolic Detoxication, Drug",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FRZB,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Therapeutic regimen,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PSMD3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CYP4Z1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FOXP3,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Infiltration,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Nuclear Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta-Chemokines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Redness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CYP4Z2P,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RANTES|CCL5,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,PDCD1 gene|PDCD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CST1|CLSTN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Azurin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Macrophage Chemotactic Factors,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Peptide YY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LINC00968,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Glucose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Intraductal Hyperplasia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Moderate Exercise,Breast cancer invasive NOS,Behavioral Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,"Carcinoma, Ductal, Breast",Other,0.3988,0.0029970029970029,Female Breast Cancer
AFFECTS,PIK3CA gene|PIK3CA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PHLDB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitronectin|VTN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LINC00707,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Glucocorticoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,C1orf106,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sedentary lifestyle,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,CUL2 gene|CUL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,heparanase|HPSE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PIK3CA protein, human|PIK3CA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,metabolomics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lymphocytic infiltration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Porifera,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carbon Dioxide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,survivin|BIRC5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phosphotransferases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ADCY4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SRC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CLDN1 gene|CLDN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SIDT1 gene|SIDT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Respiration,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Minerals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Translation, Genetic",Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Integrin alpha4beta1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,E-Cadherin,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Ablation,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,tacrolimus binding protein 4|FKBP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"FBXW7 protein, human|FBXW7",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,protein kinase C nu|DIO3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Toll-Like Receptor 5,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Genes, Regulator",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC01614,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RASAL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EIF4A1|EIF4A2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,SFN gene|SFN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,B lymphocyte-induced maturation protein 1|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunity,Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Desire for food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Short Sleeper Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,other medicated shampoos in ATC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Matrix Metalloproteinase 9,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,Minisatellite Repeats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC-ROR gene|LINC-ROR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,derivatives,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"RNA, Messenger",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Pharmaceutical Preparations,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,stevioside,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Breast Microcalcification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"CD69 protein, human|CD69",Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,hydroxybenzoic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Household composition,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ELAVL1 gene|ELAVL1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MicroRNA 335-5p,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Stat3 protein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Healthy Lifestyle,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,copper,Lobular carcinoma in situ of breast,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,"RNA, Long Untranslated",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,gamma-Tocopherol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"FRAP1 protein, human|MTOR",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TSIX gene|TSIX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,multiple pathologies,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Adiponectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,peer support,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCL18 gene|CCL18,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,rasagiline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"ITK protein, human|ITK",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DOK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RPS6KA6 gene|RPS6KA6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Growth Hormone Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,veliparib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,elements of cancer genetics risk assessment and counseling,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Clinical information:Finding:Point in time:^Patient:Narrative,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,artesunate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pads,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cannabinoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Checkpoint kinase 1,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,PLSCR1 gene|PLSCR1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,vinorelbine,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,CXXC5 gene|CXXC5,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,MYH10 gene|MYH10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Marital Status,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single Nucleotide Polymorphism,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,assessment.initial,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ethyl acetate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,N-acetyltransferase 1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,BRCA1 Gene Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PROM1,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Adjuvant Therapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Genes,Ductal Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,CLDN15,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,DNASE1L2 gene|DNASE1L2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Syndrome,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
AUGMENTS,diethylstilbestrol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,WDR41 gene|WDR41,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,NEUROD1 gene|NEUROD1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZNF326 gene|ZNF326,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Multiple malignancy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,C5 gene|C5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,water,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Fatty Acids, Essential",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,catechin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Energy Metabolism,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,methacrylamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GAS5 gene|GAS5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TGFB1 gene|TGFB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypersensitivity,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,NEDD9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SHC3 wt Allele|GDF1|RNH1|PPP1R13L|SHC3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,timosaponin AIII,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RCC2-AS1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SPX gene|SPX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNF5 gene|RNF5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MVP wt Allele|RPSA|LRP1|PTPRA|MVP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mastitis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Insulin Resistance,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,phosphorus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chronic inflammatory disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tumor Antigens,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Peptide Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Anticoagulants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Human cells,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Beta protein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,paclitaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AGTR1 gene|AGTR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Educational Status,malignant neoplasm of breast staging,Educational Factors,0.0,0.0,Female Breast Cancer
AFFECTS,LINC01705 gene|LINC01705,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATF3 gene|ATF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pseudouridine synthase 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CONOTRUNCAL ANOMALY FACE SYNDROME,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AXL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,parathyroid hormone,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,PTTG1 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PDCD4-AS1 gene|PDCD4-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,MIR30E gene|MIR30E,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"SLC6A2 protein, human|SLC6A2",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,cytokine,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,SETD5 gene|SETD5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CPEB1 gene|CPEB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIR497 gene|MIR497,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SYVN1 gene|SYVN1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Heating,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SOX4 gene|SOX4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP27A1 gene|CYP27A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SEMA7A gene|SEMA7A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hemeproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cellular signal transduction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FABP7 gene|FABP7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Advanced Breast Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,metformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZC3H13 gene|ZC3H13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ING4 gene|ING4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glucocorticoids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GAS6 gene|GAS6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NUDT3 gene|NUDT3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,hormone response element,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADIPOQ wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Risk Scores,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Neoadjuvant Chemotherapy,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Geographic pattern,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC00511 gene|LINC00511,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IQGAP1 gene|IQGAP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CARNS1 gene|CARNS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dihydroartemisinin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TWIST1 gene|TWIST1,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,IMPACT gene,malignant neoplasm of breast staging,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,HNF1A-AS1 gene|HNF1A-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,cyclic compound,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GFUS gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TP53,Hereditary Breast and Ovarian Cancer Syndrome,Other,0.0,0.0,Female Breast Cancer
AFFECTS,SEMA7A gene|SEMA7A,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,LINC00665 gene|LINC00665,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Biological Factors,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,LINC00665 gene|LINC00665,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lupus Coagulation Inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"GAS41 protein, human|YEATS4",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Bariatric Surgery,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,hippo signaling,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,valine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Social Risk Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Sodium metavanadate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Anthracyclines,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,Epigenome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,prenatal exposure,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Post-mastectomy radiotherapy,Locally advanced breast cancer,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,PCAT1 gene|PCAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCC9 gene|ABCC9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Piwi-Interacting RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prognosis bad,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Imaging Techniques,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Paste,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNHG6 gene|SNHG6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,POU4F1 gene|POU4F1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PPARGC1B protein, human|PPARGC1B",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,multiple pathologies,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Neurofibromatosis 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00511 gene|LINC00511,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Syndecan-4,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
CAUSES,MicroRNAs,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Vitiligo,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Matrix Metalloproteinase 9,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,R & C,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Negative,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MIR137 gene|MIR137,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,FZD2 gene|FZD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NME1 gene|NME1,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,triclosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MALAT1 gene|MALAT1,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,IMPACT gene,Recurrent Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Recurrent Breast Cancer
AFFECTS,lapatinib,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,DNAJA1 gene|DNAJA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,hyaluronic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Handling,"Breast Cancer, Familial",Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,pamidronate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LRRC3B gene|LRRC3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Non-Cancer Related Death,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSP90AA2P gene|HSP90AA2P,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,estrophilin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,STAT5A gene|STAT5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"IL5 protein, human|IL5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FOXP3 gene|FOXP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"WWTR1 protein, human|WWTR1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Very Important,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDKL3 gene|CDKL3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
COMPLICATES,FBXL16 gene|FBXL16,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fulvestrant,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,"CD69 protein, human|CD69",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,Primary MicroRNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDH4 gene|CDH4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SEPTIN9 gene|SEPT9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,cadmium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,everolimus,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,RUNX2 gene|RUNX2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Stat3 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Teratogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FBXL20,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZNF24 gene|ZNF24,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,6-Phosphofructokinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,DNA Modification Methylases|DNMT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,phytochlorin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNAI2 gene|SNAI2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CK-34 beta E12,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,H1-5 gene|HIST1H1B,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,STC1 gene|STC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinomatosis,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Interleukin-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRIM31 gene|TRIM31,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin-Dependent Kinase Inhibitor Proteins,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,DNA Modification Methylases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Integral Membrane Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,>65 years,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cholesterol,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Functional modification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,YAP1 gene|YAP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Monosaccharides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aurora Kinase A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antral Follicle Count,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,mifepristone,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Aquaporin 1|AQP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,removal technique,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,UNC 0638,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MCM4 gene|MCM4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EIF4EBP1 gene|EIF4EBP1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Stat3 protein,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,echinacoside,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Protein Phosphatase 2A,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,CDK1 gene|CDK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Growth Differentiation Factor 15,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Metabolite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CI 994,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aryl Hydrocarbon Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast Cancer Model,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,VEGFA gene|VEGFA,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Promoter Regions, Genetic",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,rasagiline,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit 1, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Early Diagnosis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,SP6 gene|SP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRIM32 gene|TRIM32,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,tissue markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ATP11B gene|ATP11B,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,ATG4A gene|ATG4A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"TFF3 protein, human|TFF3",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ATP2B1 gene|ATP2B1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MRPS30-DT gene|MRPS30-DT,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MIR342 gene|MIR342,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"BMI1 protein, human|BMI1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Antibodies, Anti-Idiotypic",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Hepatitis B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypoxia,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,STING1 gene,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,CLTC gene|CLTC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GAS5 gene|GAS5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WTAP gene|WTAP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PPP1R14C gene|PPP1R14C,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,liraglutide,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,DSTN gene|DSTN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,norethindrone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRIM28 gene|TRIM28,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PSAT1 gene|PSAT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,LINC00466 gene|LINC00466,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,NAA25 gene|NAA25,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oncogenes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CD29 Antigen|B3GNT2|B3GNTL1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,TLN1 gene|TLN1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Binding Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ergocalciferol,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,vexibinol,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,DANCR gene|DANCR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic Breast Density,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,WASF3 gene|WASF3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Diet, Healthy",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
COMPLICATES,Acne,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,"Peroxisome Proliferator-Activated Receptor Gamma, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATP6AP2 gene|ATP6AP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PINK1 gene|PINK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AKAP3 gene|AKAP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Diet, High-Fat",Triple Negative Breast Neoplasms,Behavioral Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SETDB1 gene|SETDB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KLF8 gene|KLF8,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,E2F1 gene|E2F1|UBE2L3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Late chronotype,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ginsenoside M1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,VARIANT OF UNKNOWN SIGNIFICANCE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NEK2 gene|NEK2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Interleukin-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Catabolism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,pimozide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Aurora Kinase A,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,andrographolide,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Apoptosis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MAFG-DT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXD3-AS1 gene|FOXD3-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protac,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ADGRF1 gene|ADGRF1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Liver Cirrhosis,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Breast present,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MND1 gene|MND1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,1 time,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,survivin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MAFG-DT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,calcium,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,CDK11A gene|CDK11A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,oleanolic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MBNL1-AS1 gene|MBNL1-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"SDC1 protein, human|SDC1",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,LINC02620 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Scorpion Venoms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Toxic Epidermal Necrolysis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primary Sj??gren's syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRIM4 gene|TRIM4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Oxysterols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MFNG gene|MFNG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Disease,Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Heat-Shock Proteins 70,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CBL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erbB-2 Receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Cytochrome P450,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenic Process,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,MAZ gene|MAZ,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FANCM gene|FANCM,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,BIRC5 gene|BIRC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,NR2E1 gene|NR2E1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,TNFRSF9 gene|TNFRSF9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,multiple pathologies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NAT10 gene|NAT10,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,caveolin 1,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,IGHE gene|IGHE,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hematoxylin,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
COMPLICATES,NUP210 gene|NUP210,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Elective Surgical Procedures,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,MIR409 gene|MIR409,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CENPK gene|CENPK,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Operation on breast,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,metformin,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,TRIO gene,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Positron Emission Tomography and Magnetic Resonance Imaging,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,JMJD6 gene|JMJD6,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,MCAM gene|MCAM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ROS1 wt Allele|ROS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,UBE2C gene|UBE2C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ROBO3 gene|ROBO3,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,carbidopa,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,"TRIM25 protein, human|TRIM25",estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,trastuzumab,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,"GTP-Binding Nuclear Protein Ran, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,stigmasterol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Small Molecule,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Polypeptides,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Coitus,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD274,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTPN7 gene|PTPN7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,COL11A1 gene|COL11A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZNF217,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,benzopyrene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ELAVL2 gene|ELAVL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endometriosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GNG5 gene|GNG5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Acclimatization,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Response Modifier Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,iron increased,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ICOS gene|ICOS,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Neonicotinoid insecticide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SYNJ2BP-COX16 gene|SYNJ2BP-COX16,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IL1RN gene|IL1RN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WFDC21P gene|WFDC21P,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,ST8SIA1,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Dietary Selenium,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,HER2-positive carcinoma of breast,Other,0.3988,0.0089910089910089,Female Breast Cancer
AUGMENTS,tamoxifen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TBATA gene|TBATA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WNT9B gene|WNT9B,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,olaparib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Benign Prostatic Hyperplasia,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SAV1 gene|SAV1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,pyridine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RNF126 gene|RNF126,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,FAC1 protein|PDC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,lapatinib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Hormones,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,DNA Binding Agent,Triple Negative Breast Neoplasms,Demographic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Neuregulins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PFKP gene|PFKP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ultrasound-Guided Core Biopsy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,ADCY5 gene|ADCY5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,progesterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRDM16 gene|PRDM16,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adult Liver Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IGF2BP2 gene|IGF2BP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Lignans,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cancer/Testis Antigen,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,ABCB1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,acrylamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adverse reaction to drug,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lymphatic Invasion,Invasive Ductal Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Uveitis,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,laser irradiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Amides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carbohydrates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endocrine Disruptors,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,"DNA, Catalytic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PHGDH gene|PHGDH,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High Level,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,Selective Estrogen Receptor Down Regulator,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adjuvant Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"PON2 protein, human|PON2",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,KLF9 gene|KLF9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"CD274 protein, human|CD274",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,pimagedine,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNF43 gene|RNF43,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,myosin VI,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,doxorubicin liposome,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,MIR31HG gene|MIR31HG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Proteome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Place of Birth,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CLDN4 gene|CLDN4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogen Receptor alpha,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Malignant neoplasm of endometrium,hereditary breast/ovarian cancer - BRCA1,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,CHMP4A gene|CHMP4A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PCAT19 gene|PCAT19,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of lung,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,vitamin E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Very low density lipoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"NEK9 protein, human|NEK9",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PZP gene|PZP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fixatives,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,ethanol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AEBP1 gene|AEBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,dose-response relationship,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ERBB2,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,GABRD gene|GABRD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR93 gene|MIR93|MIR9-3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,benzopyrene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antisense RNA,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,3 times,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RNA,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,Tn antigen,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,royal jelly,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,BARRIER,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Apoptosis Inhibiting Proteins,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Aurora Kinase A,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cell-Free DNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Structural modification,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,KRT1 gene|KRT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Poly(ADP-ribose) Polymerase Inhibitors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,personal health,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,metformin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SOAT1 gene|SOAT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,interferon type II|IFNG,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,bruceine D,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,bone morphogenesis,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,Proto-Oncogene Proteins p21(ras)|CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Feces,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cervical Cancer Screening,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Ultrasonography,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,SNHG11 gene|SNHG11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,sevoflurane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Postoperative chemotherapy,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Peptides,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Triple Negative Breast Neoplasms,Other,0.3988,0.0189810189810189,Female Breast Cancer
AFFECTS,calcium,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Dietary Zinc,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Platelets, CTCAE",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Analgesics, Opioid",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,hydrocortisone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"RNA, Circular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Osteopenia,Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
AFFECTS,cantharidin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CD24 gene|CD24,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,pregnane X receptor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MIR195 gene|MIR195,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,White meat intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"7,3'-dihydroxy-4'-methoxyisoflavone",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SPATA13 gene|SPATA13,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,"RNA, Untranslated",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,Carcinoembryonic Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RARB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNAJB4 gene|DNAJB4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"IL7 protein, human|IL7",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
CAUSES,fos-related antigen 1|FOS,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,USP10 gene|USP10,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Aurora Kinase A,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,risk factors,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Stat3 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,echinacoside,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Administration, Oral",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Matrix,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,CKS2 gene|CKS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CYP3A4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,abemaciclib,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cell markers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,beta-eudesmol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,TIPARP gene|TIPARP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CDC2 Protein Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,LILRB1 gene|LILRB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,antineoplaston A10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TENM1 gene|TENM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,vasomotor symptom,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lindane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of breast,Invasive carcinoma of breast,Other,0.3988,0.0089910089910089,Female Breast Cancer
AFFECTS,ULBP2 gene|ULBP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PDGFRB gene|PDGFRB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Suppressor Genes,estrogen receptor-negative breast cancer,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,doxorubicin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHRNA6 gene|CHRNA6,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LINC-ROR gene|LINC-ROR,Invasive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,GPNMB gene|GPNMB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Decreased Immunologic Activity [PE],Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,POU4F1 gene|POU4F1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,BCSC-1 Protein|VWA5A,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Intrapartum fetal hypoxia,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,FNDC5 gene|FNDC5,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,SNORA73B gene|SNORA73B,Early-Stage Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,"9,10-Dimethyl-1,2-benzanthracene",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,"PIK3CB protein, human|PIK3CB",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,metacresol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,paired basic amino acid cleaving enzyme,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Hypolipidemic Agents,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HDAC2 gene|HDAC2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Cancer Prevention,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,elongin B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"BSG protein, human|BSG",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,astaxanthin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"Receptor, PAR-1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,HINT1 gene|HINT1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,LILRB2 gene|LILRB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Comorbidity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"glutamate carboxypeptidase II, human|FOLH1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,pyruvate dehydrogenase kinase 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Low-Density Lipoproteins,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Fat-free mass,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PKN1 protein, human|PKN1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estrogen Receptors,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,cyclooxygenase 2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,"N-succinyl-1,2-dioleoylphosphatidylethanolamine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Binding Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,alpha-adrenergic receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oral form sodium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phentolamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TET1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,caffeic acid phenethyl ester,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Secondary malignant neoplasm of skin NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin-Dependent Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"MCL1 protein, human|MCL1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BUB1 gene|BUB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Protein Isoforms|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Pharmaceutical Preparations,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CCAAT-Enhancer-Binding Proteins|EBP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methylation,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,EB 1089,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,RAD51C gene|RAD51C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RARRES1|GPRC5A|MED15,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,heparanase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Quantitative Trait Loci,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,alkylglycerophosphoethanolamine phosphodiesterase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Biological Phenomena,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CDK7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibrosing adenosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FGF10 gene|FGF10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TACC2 gene|TACC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Anticoagulants,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,targeted prevention,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,pigment epithelium-derived factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MicroRNAs,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MIRN23A gene|MIR23A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vitamin D,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,NEDD9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vegetable Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,XBP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RBM5 gene|RBM5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,perfluorooctanoic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Genes,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Docosahexaenoic Acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RECK,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Agent,Familial cancer of breast,Demographic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,MIRN326 gene|MIR326,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,GRN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HOTAIR,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SP1 gene|SP1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Mucins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Chemotherapeutic agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phosphatidylethanolamine N-Methyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Carcinogens,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,Estrogen Receptor beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SP1 gene|SP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,discoidin domain receptor 2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Annexin A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Excision,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ABL2|RERE,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,SPAG5,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Benign ovarian cyst,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,hormonal changes,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AUGMENTS,PKM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Methylnitrosourea,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,THY1,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Weaning,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Adaptor Signaling Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PARP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HOXA9 gene|HOXA9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIRN195 gene|MIR195,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,XRCC5 gene|XRCC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PAWR gene|PAWR,Breast cancer recurrent,Genetic Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,N-Acetylneuraminic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,IGKV1-16|FAM49B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FOXA1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Metalloproteases,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Paclitaxel,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Radioisotopes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PITPNM3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,HIC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CpG Islands,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Organochlorine pesticide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MCM3AP|FIG4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TNFRSF12A,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CTSG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Sporadic Breast Carcinoma,Malignant neoplasm of breast,Other,0.0365,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MYC Family Genes|MYC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Kinesin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2 gene|ERBB2,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,"EZH2 protein, human|EZH2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phosphatidylinositols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IL33,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Developmental Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,OPRM1,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,K-ras Oncogene|KRAS,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transforming Growth Factors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Growth Factor Gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High energy food,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Medical follow-up,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ADGRF5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,sulfamate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Malondialdehyde,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"3,4-Methylenedioxyamphetamine",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant transformation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nucleic Acids,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,pioglitazone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interleukin-8,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,rosiglitazone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Telomerase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cocci,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,KRT5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CCL28,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,calusterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,"Leukemia, Myelocytic, Acute",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Soy Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Serine Proteinase Inhibitors,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,DELIVER,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,bone sialoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical findings,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,prohibitin|PHB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Maximal Voluntary Ventilation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NCOA2 gene|NCOA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hepatocyte Growth Factor,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Acylation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primary biliary cirrhosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ELP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DDT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Conception,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Lactalbumin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,paclitaxel liposome,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,CTU1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glucose Transporter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Drug resistance,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Thrombospondins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cesarean section (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,particle,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Thrombospondin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GSTO2 gene|GSTO2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Running,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Asthenia,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,midkine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Prolactinoma,bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Misonidazole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Abdominal obesity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Complement System Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,cholanthrene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adriamycin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Lymph Node Involvement,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogen Receptors|EREG|ESR1,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Caffeine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Carcinoma, Cribriform","Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,"3,4-Methylenedioxyamphetamine",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dietary Fats,Breast cancer metastatic,Behavioral Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Endocrine Surgical Procedures,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PROTEIN INTAKE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ras Oncogene,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
COMPLICATES,Malignant Neoplasms,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Cholestyramine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Diethylstilbestrol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Immunologic Deficiency Syndromes,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Estrogenic,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,radical mastectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Markers, DNA",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Serum,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Rheumatoid Arthritis,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,ptaquiloside,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,monoclonal antibody CC49,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fibroblast Growth Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AUGMENTS,Prolactin|PRL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cycasin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Bromocriptine,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,impaired glucose tolerance,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prolonged periods,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,leukemia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Transferase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Trimetrexate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Stabilization,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ras Oncogene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Paroxetine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bone Density,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PTPRF,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,N-Acetylneuraminic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Endopeptidases|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,SYK gene|SYK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,heparanase|HPSE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fenretinide,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,"Estrogens, Catechol",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metalloproteases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Proline,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Free Radicals,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Sedentary lifestyle,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Acetate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Vitamin E intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Physical activity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,parathyroid hormone-related protein|PTHLH,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,alpha-Linolenic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BCAS2 gene|BCAS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Nitrites,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ingestion,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Endopeptidases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,P-Glycoprotein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sarcoidosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,LGD 1069,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tetranucleotide Repeats,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Endometrial adenocarcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,chemokine receptor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"polio, NOS",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SMAD4 gene|SMAD4,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,ETS Variant Gene 6 Protein|ETV6,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,parathyroid hormone-related protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Leukemia P388,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Cardiovascular Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Peptides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Treatment/Psychosocial Effects,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Silicones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,chromosome 11q,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Chemotherapeutic agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Lymphocyte antigen CD82|CD82,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,6-nitrochrysene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,GSTP1 gene|GSTP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,17q23,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Tenascin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,PTEN gene|PTEN,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dissection,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,WWOX,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cytochrome P-450 CYP1A1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Agent,Carcinoma of Male Breast,Demographic Factors,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,beta-hexachlorocyclohexane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,inhibitors,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Growth Factor Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLC12A3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epidermal Growth Factor Receptor|EGF,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Adrenalectomy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Thyroidectomy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant Neoplasms,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,BCL2 gene|BCL2,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Polyamines,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Restriction fragment length polymorphism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Transforming Growth Factor alpha,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Fats, Unsaturated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prostaglandins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,WWOX gene|WWOX,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Therapeutic agent (substance),Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Selective Estrogen Receptor Modulators,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Premature Birth,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
CAUSES,"Cell Transformation, Neoplastic",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"PRSS8 protein, human|PRSS8",Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Axillary Lymph Node Dissection,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Radioisotopes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenic Switch,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,"Liver Failure, Acute",Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,Estradiol,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Gene Amplification,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Gene Mutation,Familial cancer of breast,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,CD55|TCN2,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AFFECTS,Pharmaceutical Adjuvants,Malignant neoplasm of breast,Immunological Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Durapatite,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cysteine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Protein Tyrosine Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Estrogens, Synthetic",Malignant neoplasm of breast,Hormonal Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Growth Factor Receptors,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,SELPLG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Gruyere cheese,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Study models,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,chemokine receptor D6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DPYS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HFE,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
DISRUPTS,"Linoleic Acids, Conjugated",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NUCLEAR MITOTIC APPARATUS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CLEC14A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thrombospondins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Angiotensinogen|AGT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Sermorelin|GH1|GGH,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Night shift worker,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ASAP1|MYCBPAP,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,NELFB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ITGB3BP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ubiquitin-protein ligase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,isopeptidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Specific antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Breast radiotherapies,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AUGMENTS,glutathione S-transferase pi,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"O-(glucuronic acid 2-sulfate)-(1--3)-O-(2,5)-andydrotalitol 6-sulfate",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tumor Suppressor Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADH1C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Adenomatous Polyposis Coli,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,methyl group,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,gamma-Tocopherol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Polymorphism, Genetic",Sporadic Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,CXCL12 gene|CXCL12,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Fibroblast Growth Factor Receptor 2|FGF7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STK6 gene|AURKA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Tocopherols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Regulatory Sequences, Nucleic Acid",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Environmental Estrogen,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,Genistein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Disease,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,exemestane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PREDICTED,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,RNF115,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Aromatic Amines,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,NOD2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hyperandrogenism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDK10 gene|CDK10,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Protein-tyrosine kinase inhibitor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Grapes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PDIA6,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Thalidomide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,multicatalytic endopeptidase complex,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Fatty-acid synthase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Benzene,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,andrographolide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atrophy of vagina,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,APC gene|APC,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,docetaxel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"FOLR1 protein, human|FOLR1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RIN1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FOXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HBP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HSD17B2 gene|HSD17B2|HSD17B7P2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Dietary Modification,Familial cancer of breast,Behavioral Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,Aborted pregnancy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Second Primary Cancers,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,5'-NUCLEOTIDASE|NT5E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glial Fibrillary Acidic Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Oncogene Proteins,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Interleukin-8|EREG|ESR1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SNAI1,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Tumor proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PPIA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CYP2C19 gene|CYP2C19,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S-Adenosylmethionine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alpha tocopheryl succinate,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,NCSTN gene|NCSTN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Stearates,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Aryl Hydrocarbon Receptor|AHR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,estrone sulfate,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,DEK gene|DEK,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dihydrofolate Reductase|DHFR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Acrylamide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Silicon,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
DISRUPTS,IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Xenograft procedure,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Long chain fatty acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERBB2 gene|ERBB2,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Prognostic Factor,bilateral breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,RAB27B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PARP1|COL11A2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,D4-GDI,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TIMM17A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Heat shock proteins,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,ADM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erbB-2 Receptor|ERBB2,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,docetaxel,Breast cancer stage II,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,BCAR1 gene|BCAR1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,exemestane,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,SOX4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TEK gene|TEK,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Alleles,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Sleep Deprivation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MST1R gene|MST1R,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ITGA5 gene|ITGA5,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Interstitial Collagenase,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,epithelial cell differentiation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Human Papilloma Virus Vaccine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Quinones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ERBB2|NEU1|NEURL1,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Garlic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,VCP gene|VCP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GLI1 gene|GLI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VEGFA,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Body mass index procedure,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,"PTH protein, human|PTH",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AVP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Genes,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,SPDYA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CD24,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,cytochrome P-450 CYP1B1|CYP1B1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ORALIT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lithium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,nuclear receptor coactivator 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,phenylalanylphenylalanine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Norepinephrine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Carcinoid Tumor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,High Density Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IL8 gene|CXCL8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogens,Breast Carcinoma,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,caveolin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CDKN1A|TCEAL1|NSG1|H3F3AP6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MAPK15,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Velcade,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNAJA3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GATA3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,collagenase 3,Breast cancer metastatic,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,HSPA1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"progesterone, micronized",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Carcinoma, Ductal, Breast",Malignant neoplasm of breast,Other,0.0396,0.3386613386613387,Female Breast Cancer
AUGMENTS,casein kinase II,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paget's Disease,Breast Carcinoma,Demographic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tristetraprolin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SUSD3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"[M]Adenocarcinoma, metastatic, NOS",Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,"CTTN protein, human|CTTN",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,iturin A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SNX9 gene|SNX9,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PSPHP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PML gene|PML,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Post-Transcriptional Regulation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Genistein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Naphthalene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Purines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,toll-like receptor 4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Interleukin 6 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Epstein-Barr virus DNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Growth stimulant,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLOPE,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CLOCK,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PTGER2|SPAG11B,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Vitamin D Deficiency,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,BRCA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MIRN10A gene|MIR10A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SULF2 gene|SULF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Metaplastic carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,CD4 gene|CD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AMOTL1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tubeimoside I,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,1/24,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RORA gene|RORA,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SH3PXD2A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LY6K,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"DICER1 protein, human|DICER1","Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,cofilin|CFL1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Little's Disease,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MLLT11,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,FOXP3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Uridine Diphosphate Sugars,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FBXO42,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CMTS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARGININOSUCCINATE LYASE|ASL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Functional RNA,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mitogen-Activated Protein Kinase 13|MAPK13,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Platinum,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,9-deoxy-delta-9-prostaglandin D2,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,EGFR gene|EGFR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"Ribosomal Protein S6 Kinases, 70-kDa",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Transcript,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,bone morphogenetic protein 6,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,SOD1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vitamin B1 Intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CDKN1C gene|CDKN1C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TP53 gene|TP53,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ESR2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RHOC gene|RHOC,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,costunolide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LATS2 gene|LATS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RELN gene|RELN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,anthracene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MEG3|FAM129B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,chemokine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF143,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibrosing adenosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EIF2S1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cytokine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Increased effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"PER2 protein, mammalian|PGR|PR@|PRH2|TMEM37|ERVK-7|ERVK-8|ERVK-10|ERVK-9|ERVK-21|ERVK-18|ERVK-25|ERVK-24|ERVK-19",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NF-Kappa B p65,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Hazards, Environmental",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,mitochondrial DNA replication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NF-AT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,peptide T amide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ERBB2,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"HDAC5 protein, human|HDAC5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,indoleamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FYN gene|FYN,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FOXO3A gene|FOXO3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,EHMT2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ethylene glycol,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Pasta intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Beads,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thioridazine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SCARA5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CDCA7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,DDAVP,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Pyruvate Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,hepatitis B virus X protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Prolactin,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,nicotinamide phosphoribosyltransferase|NAMPT,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Morphine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NOTCH1 gene,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Doxorubicin,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Estrogens,"Carcinoma, Ductal, Breast",Hormonal Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,LAPTM4B gene|LAPTM4B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Oncogene ErbB2|ERBB2|NEU1|NEURL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Activated-Leukocyte Cell Adhesion Molecule,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,B-pyridine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Alkanes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fusion Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Prior Therapy,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,SNHG14,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,parathyroid hormone-related protein|PTHLH,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Vitamin D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ACKR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,LACTB,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IkappaB Kinase beta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PAWR gene|PAWR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Granulocyte Colony-Stimulating Factor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,BCL6 gene|BCL6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Growth Factor,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Diet, Fat-Restricted",Breast cancer recurrent,Behavioral Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,ITGB3 gene|ITGB3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIRN423 gene|MIR423,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NNT-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KISS1R,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IL32,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ferrocene,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PPP2R2A,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,schizandrin B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CHI3L1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,osteoactivin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Phosphoric Monoester Hydrolases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,N-myristoyltransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caspase-3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Platelet Factor 4|PF4,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Chromosomal Rearrangement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Tomography, Emission-Computed",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,P3H1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lymphocyte product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DICER1 gene|DICER1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,IkappaB Kinase epsilon,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Peutz-Jeghers Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pancreatic carcinoma,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,SYK gene|SYK,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ZNF326,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZIC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Polymerase|ERVK-9|ERVK-19|ERVK-11,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HNRPM gene|HNRNPM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LBH589,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmaceutical Preparations,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,ADRA1D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Saethre-Chotzen Syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"UBD protein, human|UBD",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,8-hydroxy-2'-deoxyguanosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thromboplastin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,WWC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mammographic breast density,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,PGC,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ERR1 protein|ESRRA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Estradiol Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Oncogenes,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
COMPLICATES,Sterol Regulatory Element Binding Protein 2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cryptochrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,MMP2 gene|MMP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,alpha-Fetoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Fusion Protein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,BLM gene|BLM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DDR2 gene|DDR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SMYD3 gene|SMYD3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"HDAC5 protein, human|HDAC5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TAZ gene|TAZ,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,REPS2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ARHI gene|DIRAS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Somatostatin analog|SST,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CYP2B6 gene|CYP2B6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Atherosclerosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,versican|VCAN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Urokinase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,ARHI gene|DIRAS3,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,participation,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Tenascin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Organic solvent product,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fat tissue increased,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Androgen Receptor|AR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Tegafur,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Desipramine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Serpins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Angiogenesis Factor,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Size of lymph node,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADH1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Malignant neoplasm of prostate,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,"Transcription, Genetic",Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,decisiveness,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Vaccines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,caffeinated beverage,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,High Density Lipoproteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pharmacotherapy,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Monocyte Chemoattractant Protein-1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Gene Products, Protein",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RAC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Oncogene, RET|RET",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cultural differences,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Epiregulin|EREG,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Fertility,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Buformin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RGS17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,protein kinase D,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
DISRUPTS,Adrenergic beta-Antagonists,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"CHEK1 protein, human|CHEK1",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,RGS17,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Vitamin E,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytochrome P-450 CYP2D6,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
CAUSES,Invasive Carcinoma,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,Nucleolar Organizer Region,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Mayonnaise,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ING1|LTB|CENPK,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Hormone level abnormal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibromyalgia,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Signal Pathways,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Body mass index,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
AFFECTS,Increased Metabolic Rate,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,PROM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,monocyte activation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,retinoic acid receptor alpha,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Signaling Molecule,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,STARD3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estratest,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,ERBB2 gene|ERBB2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
CAUSES,Nucleosides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GLO1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Myristic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cell Cycle Checkpoint Genes,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Gonadotropin-Releasing Hormone Analog,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Doxorubicin,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,BMP4|BMP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NOS3 gene|NOS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Recreation,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Malignant neoplasm of thyroid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Primigravida,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Alcohol consumption,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,PPARGC1B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CD4 gene|CD4,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DDIT4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Axillary Lymph Node Involvement,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor beta|ESR2,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Leukocyte Elastase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,[D]Mammogram abnormal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NEUROD1|TUBB4B,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Hay fever,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Down-Regulation,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Recombinant Interferon-gamma|IFNG,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,URI1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LAPTM4B gene|LAPTM4B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ABCC5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,IL17F,Sporadic Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,POP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CSH1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,patient characteristics,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,Smoking Behavior,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PSMD10 protein, human|PSMD10",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CLDN1 gene|CLDN1,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
CAUSES,XRCC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrone,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,PRL gene|PRL,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sex Hormone-Binding Globulin,Breast cancer invasive NOS,Demographic Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,Liver and Intrahepatic Biliary Tract Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mangifera indica extract,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cytotoxic agent,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NAP1L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNAJC27,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of lymph node,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Endocrine therapy,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,TRANSCRIPTION FACTOR,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,RBL2 gene|RBL2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Folate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MASS LESION,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,"Anesthesia, Conduction",Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,TGFBR2 gene|TGFBR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Stathmin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sequela of disorder,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cigarette Smoking,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,astragaloside IV,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PRRX2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,crocin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ING5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Radiation therapy,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Annexin A2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Microcalcification,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Endocrine Gland Neoplasms,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TRANSCRIPTION FACTOR,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Proton therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,brucine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Oncogenic Viruses,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,histone deacetylase 3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Growth Factor Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Encounter due to Screening for malignant neoplasm of breast,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Infiltration,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,FTO,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SDC1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Metals, Heavy",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KLHL7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RETN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PIP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Glutamic Acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,stem cell therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibroblast Growth Factor 7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,genetic element,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"SBEM protein, human|MUCL1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WT1 gene|WT1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytochrome P-450 CYP2D6,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PTGS2 gene|PTGS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CHES1 gene|FOXN3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ACACA|BMS1,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,decorin|DCN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,inhibitors,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
DISRUPTS,Phospholipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Financial circumstances,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,beta catenin,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,2q33-q34,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PERP,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,XRCC5 gene|XRCC5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,NEK2,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Interleukin-10,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Osteonectin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Candidate Disease Gene|AR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Carcinoma in situ of breast,Other,0.3988,0.0019980019980019,Female Breast Cancer
PREDISPOSES,"Subarachnoid Hemorrhage, Aneurysmal",Noninfiltrating Intraductal Carcinoma,Demographic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Placental Hormones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,thiopurine,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,NFKBIA gene|NFKBIA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Body mass index,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Mutation,Inflammatory Breast Carcinoma,Genetic Factors,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Cholesterol Esters,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CYP17A1 gene|CYP17A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Boiled potato,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypothyroidism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TNFRSF1B gene|TNFRSF1B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CHEST SYMPTOM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ERBB2|NEU1|NEURL1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Morphogenesis,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,Ritonavir,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Estrogen-progestin preparation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Soluble ErbB-1|EGFR,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,RANTES,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Microsatellite Repeats,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,CCAAT-Enhancer-Binding Protein-delta,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Local Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Thymidylate Synthase,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CD68,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DES EXPOSURE,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF365 gene|ZNF365,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LHX1 gene|LHX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ERCC3 gene|ERCC3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,RNASE3L gene|DROSHA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SABER,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,BABAM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Estrogenic,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Xenobiotics,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ductal Carcinoma,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,oncoprotein p21|CDKN1A|SLC12A9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hematoxylin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Single Nucleotide Polymorphism,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Dietary Modification,Breast cancer recurrent,Behavioral Factors,0.0,0.0049950049950049,Recurrent Breast Cancer
AFFECTS,Mitogens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SCREEN TECHNIQUES,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,erbB-2 Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Adenomatous goiter,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PFKFB4,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Mutagens,Malignant neoplasm of breast,Demographic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,ETV4 gene|ETV4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ovulation Induction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SRC gene|SRC,Breast cancer invasive NOS,Genetic Factors,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Disintegrins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FCGR3A gene|FCGR3A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,S 1 (combination),Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,CONSTITUTIONAL ORIGIN,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HSPA5,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Abdominal circumference,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tibolone,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,LAMTOR3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DSCAM-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Bone Morphogenetic Proteins,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Epstein-Barr Virus Infections,Breast Carcinoma,Herpetic Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Cooking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lymphedema,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Diuretics,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,TRANCE protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Trihalomethanes,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
PREDISPOSES,Syndrome,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Angiogenesis Factor,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PMS2 gene|PMS2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,fatty acid amide hydrolase,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
PREDISPOSES,Histologic type,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Endocrine System Diseases,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,"Iron, Dietary",Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,JMJD6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cadaverine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,cytokine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,XRCC1 gene|XRCC1,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,FRA16D,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,S100A7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Thioglucosides,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary fat intake,Breast cancer invasive NOS,Behavioral Factors,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,PNU,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MED19,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CYTOR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Phytoestrogens,Breast Carcinoma,Hormonal Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,ID2 gene|ID2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Fruit,Breast cancer recurrent,Other,0.0,0.0049950049950049,Recurrent Breast Cancer
PREDISPOSES,UBE2N,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,GJB2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Chemotherapy, Adjuvant",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,LATS1 gene|LATS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MDM2 gene|MDM2,Breast cancer metastatic,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,ENPP2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KRT8,Breast cancer invasive NOS,Other,0.0,0.0099900099900099,Female Breast Cancer
AFFECTS,PTCSC3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ubiquitin-protein ligase,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
CAUSES,Arsenic,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AQP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,salinomycin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,HMGN2 Protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Proliferating Cell Nuclear Antigen,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mandibular right first molar abutment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Genome, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cathepsins B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,FAM84B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,AQP7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Ca(2+)-Transporting ATPase|CA2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,therapeutic use,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GJB2 gene|GJB2,"Carcinoma, Ductal, Breast",Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,verbenone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PTH-Parathyroid hormone level result,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Recurrent Carcinoma,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,moderate drinking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,RBM12B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CASC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EIF4EBP1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIRN106A gene|MIR106A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FUT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,1-Phosphatidylinositol 4-Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cullin 1,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Transferrin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PIEZO2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vinegar,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,v-myb Genes|MYB,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Interferon Type I,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,UCHL3,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Kinesin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,BCL11A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Circadian Rhythm Disorders,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Dipeptidyl-Peptidase IV|DPP4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,lysyllysine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDK6-associated protein p18,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ubiquitin-protein ligase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAM13A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC01133,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,APOBEC3B,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
DISRUPTS,honokiol,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,reverse transcription polymerase chain reaction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,H19 gene|H19|HILS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TSLP protein, human|TSLP",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secondary malignant neoplasm of spinal cord,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,bone sialoprotein,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Ephrin B Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Obesity,Contralateral breast cancer,Other,0.0,0.0019980019980019,Female Breast Cancer
PREDISPOSES,ATXN3,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,PCB 118,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CERS6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ingredient,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PIM1 gene|PIM1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cardamonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"Oligonucleotides, Antisense",Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,RAB1A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cyclin-Dependent Kinase Inhibitor 2A|CDK4,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Solvents,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DSCAM-AS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pancreatic carcinoma,Ductal Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
PREDISPOSES,centromere protein F,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,paracrine,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Adrenergic Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MIRN133B gene|MIR133B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCB 101,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Docosahexaenoate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Bleomycin|BLM,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MDM1,Familial cancer of breast,Other,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,WISP1 gene|WISP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Paracrine Communication,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Cisplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cathepsins|CTSS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LIMS1 gene|LIMS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SORBS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,erbB-2 Receptor|ECD,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SIX1 gene|SIX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hydrogel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SULF1 gene|SULF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Dopamine Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,p65|RELA|SYT1|GORASP1|WNK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MAGI2-AS3 gene|MAGI2-AS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cell-Free DNA,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Annexin A1|ANXA1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,beta-site APP cleaving enzyme 1,"Carcinoma, Ductal, Breast",Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,SOX5,Breast cancer metastatic,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,OGDHL,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Postmenopause,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,SP 1049C,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,systemic administration,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Chronic disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Parabens,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,talazoparib,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,insulin isophane,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,KDM6A gene|KDM6A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interferon Signaling Process,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fibroblast Growth Factor 2|FGF2,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,UGT1A4 gene|UGT1A4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Alcohol intake above recommended sensible limits,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ATOX1 gene|ATOX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"KISS1R protein, human|KISS1R",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Infertility risk,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,levothyroxine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DNA Repair Gene,Hereditary Breast and Ovarian Cancer Syndrome,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,DNA Modification Methylases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ceramide kinase,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,"Promoter Regions, Genetic",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GAS1 gene|GAS1,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Primary Neoplasm,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,cisplatin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,F2R gene|F2R,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,"Receptor, Notch4",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,LINC00668 gene|LINC00668,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,chitosan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,tumor protein D52|TPD52,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IGFBP7|SFPQ,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,SH2B3 gene|SH2B3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,Carcinogens,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,physiological aspects,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,prothrombin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,cisplatin,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,MRTFA gene|MKL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FDG-Positron Emission Tomography and Computed Tomography Scan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,lead,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SEPT7 gene|SEPT7,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,"E2F1 protein, human|E2F1|UBE2L3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Apolipoprotein E|APOE,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GATA3 gene|GATA3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,methylene chloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,AGO1 gene|AGO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,tryptophan,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antineoplastic Agents,Carcinoma breast stage IV,Demographic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,CSK gene|CSK,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
PREDISPOSES,"Receptors, Progesterone",Breast cancer stage III,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Microinvasive tumor,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,Estrogen Receptors,Breast cancer stage III,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,Estrogen Antagonists,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,OSW 1,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Saponin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ATF4 gene|ATF4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Genes, Essential",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Late Relapse,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,PBX1 gene|PBX1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,VLDLR gene|VLDLR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,WNT6 gene|WNT6,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,EXT1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SIRT3 gene|SIRT3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TGFB1 gene|TGFB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZBTB1 gene|ZBTB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Cyclin B1|CCNB1,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Growth pattern,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Biological Markers,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
DISRUPTS,ELK1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypoxia,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Ginkgo biloba extract,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,CXCR2 gene|CXCR2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fenamole,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Rocky,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,IQGAP1 gene|IQGAP1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,PSMG3-AS1 gene|PSMG3-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lactones,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sapphire,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Antioxidants,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,HER2/Neu Positive,HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,FBXW5 gene|FBXW5,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,MIR451A wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Protein Kinases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,EPDR1 gene|EPDR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,bis(4-hydroxyphenyl)sulfone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SPINT1-AS1 gene|SPINT1-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCR1 gene|CXCR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR26B gene|MIR26B,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,TUFT1 gene|TUFT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Alternative Splicing,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,S100P,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,glycogen synthase kinase 3 beta,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Ingredient,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ZG16B gene|ZG16B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,triptolide,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Photosensitizing Agents,Carcinoma breast stage IV,Demographic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,Isolate - microorganism,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Potassium Channel,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,KMT5A gene|KMT5A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG7 gene|SNHG7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,resistin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Treatment Status,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SETD2 gene|SETD2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"BMPR1B protein, human|BMPR1B",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PKM gene|PKM,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Lymphangiogenesis,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Nucleic Acid Probes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,shikonin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Suppressor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,berbamine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Germ-Line Mutation,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"Discoidin Domain-Containing Receptor 2, Human|DDR2",Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,MEDAG gene|MEDAG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cell Cycle Control,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MicroRNAs,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
DISRUPTS,Protein Quaking,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malaria,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,arginine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,STIP1 gene|STIP1|TFIP11|NECAB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of oropharynx,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,prolactin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Non-infiltrating lobular carcinoma,Recurrent Breast Carcinoma,Other,0.0,0.0009990009990009,Recurrent Breast Cancer
DISRUPTS,Stat3 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Collagen Type IV,Carcinoma breast stage IV,Demographic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,TPX2 gene|TPX2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,IFNGR1 gene|IFNGR1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,proline,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,VEGFA gene|VEGFA,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Echogenic,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,crocin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Open Reading Frames,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR374B gene|MIR374B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AQP3 gene|AQP3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Metric (substance),Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,FGD5-AS1 gene|FGD5-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SNHG15 gene|SNHG15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,methylate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ginsenoside Rh1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNA 19B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cryptotanshinone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,cyclin A2|CCNA2,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,alpha-hydroxyglutarate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ZNF213 gene|ZNF213,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SRSF1 gene|SRSF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,FAT3 gene|FAT3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Low expression,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MYC,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Tumor Burden,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
CAUSES,Transgenes,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
DISRUPTS,metformin,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,IL6ST gene|IL6ST,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cytokinesis,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,NME1 gene|NME1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Challenge:Type:Point in time:^Patient:Nominal,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,CUL4B,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,HOXB7 gene|HOXB7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"BAG Family Molecular Chaperone Regulator 3, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary carbohydrate intake,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mouse Model,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,cinnamic aldehyde,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,FBXO15 gene|FBXO15,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,RNA Polymerase I|ERVW-4,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,FGD5-AS1 gene|FGD5-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TRAPPC10 gene|TRAPPC10,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,CT83 gene|CT83,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Thyroid microsomal antibodies,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,cytokine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PSMC2 gene|PSMC2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Cell Adhesion Molecules,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,FTO gene|FTO,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,4-aminohippuric acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Increased risk,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PTPRT gene|PTPRT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Serine-tRNA Ligase|TRNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Coal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,PCYT1A wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BRD4 gene|BRD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PDCD11 gene|PDCD11,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Beta-glucuronidase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ruyiping,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Multiparity,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Glucocorticoids,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Genes,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,MIR31 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,AEBP2 gene|AEBP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Breast Density,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,erbB-2 Receptor|ERBB2,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AUGMENTS,GATA3 gene|GATA3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,HOXA1 gene|HOXA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Progranulins,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,DPP8 gene|DPP8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ACE2 gene|ACE2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PCNT gene|PCNT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TIMM17A gene|TIMM17A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCR5 gene|CXCR5,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,DPP7 gene|DPP7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Phytochemical,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR34A,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Neoadjuvant Therapy,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,PALB2 gene|PALB2,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Lymphocyte antigen CD82|CD82,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SMUG1 gene|SMUG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,GABPA|NFE2L2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SEMA4C gene|SEMA4C,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,SEPTIN9 gene|SEPT9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,UBQLN1 gene|UBQLN1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,cyclin-dependent kinase inhibitor 1B|IFI27|PSMD9|SSSCA1|DCTN6|TMED7,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,human papillomavirus,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,PITPNM1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ADAR gene|ADAR,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,RBMS3 gene|RBMS3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SOX10 gene|SOX10,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,Cell Growth,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,MAL2,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Ribosomal Proteins,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Interventional procedure,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,T-Cell Receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Immunohistochemistry,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
DISRUPTS,CDK1 gene|CDK1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Indicators,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,ketamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ADAMTS9-AS1 gene|ADAMTS9-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NAA50 gene|NAA50,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Analgesics, Opioid",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Inflammatory Bowel Diseases,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,FBXL16 gene|FBXL16,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Triglycerides,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,"N-methylsulfonyl-12,12-dibromododec-11-enamide",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PVT1 gene|PVT1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
PREDISPOSES,Dietary Polyphenol,Malignant neoplasm of breast,Behavioral Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,VIRMA gene|VIRMA,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Core needle biopsy,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,HOTAIR gene|HOTAIR,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,MicroRNAs,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,CSTB wt Allele|CST6,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Molecular Target,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Thioredoxin 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,LINC00174 gene|LINC00174,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Carcinoma breast stage IV,Other,0.3988,0.0,Female Breast Cancer
AFFECTS,quiescence,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,chromosome loss,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,BCLAF1 gene|BCLAF1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,decitabine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,NR2F1-AS1 gene|NR2F1-AS1,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,docetaxel,Triple-Negative Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
AFFECTS,GNG13 gene|GNG13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,False Positive,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
AFFECTS,IGLC2 gene|IGLC2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Neoplasm Metastasis,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,chemokine receptor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Food Consumption,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"herstatin protein, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IRAK3 gene|IRAK3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,SLC2A1 gene|SLC2A1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,cytidylyl-3'-5'-guanosine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MicroRNA 1246,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,curcumin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Orosomucoid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,WTAP gene|WTAP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Married (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"NOS1 protein, human|NOS1|NANOS1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Androgen Receptor,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,ESR1,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Premature Menopause,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CALCIUM/VITAMIN D,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
PREDISPOSES,CGAS gene|CGAS,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Postmenopausal status NOS,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"TNF protein, human|TNF",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Cellular Apoptosis Susceptibility Protein,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,carbohydrate analog,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,TRIM72 gene|TRIM72,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Fatty-acid synthase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Fatty pancreas,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MicroRNA 205-5p,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,cholesterol,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,MIR451A wt Allele,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,secretory protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Calcium Signaling,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,DUSP8 gene|DUSP8,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
COMPLICATES,Adrenal Gland Hyperfunction,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Sodium Butyrate,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ethanol,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Procedure findings:Finding:Point in time:^Patient:Narrative,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Body position,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,PSAT1 gene|PSAT1,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,CCNE1 gene|CCNE1,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AUGMENTS,dehydrodolichyl diphosphate synthase,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Oxysterols,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,sinomenine hydrochloride,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SIN3A gene|SIN3A,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Malignant neoplasm of breast,Basal-Like Breast Carcinoma,Other,0.3988,0.0039960039960039,Female Breast Cancer
PREDISPOSES,MicroRNAs,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,YTHDF3 gene|YTHDF3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,"RNA, Long Untranslated",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,>40 years,Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,PNO1 gene|PNO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,GSDME gene|GSDME,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,TRANSCRIPTION FACTOR,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,FERMT1 gene|FERMT1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Cell Cycle Checkpoints,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,G-Protein-Coupled Receptors,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MIR449A gene|MIR449A,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Hypersensitivity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Warburg Effect,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,CDK18 gene|CDK18,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Revival,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genes,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,ILF3 gene|ILF3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ROS1 gene|ROS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,fluid flow,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CCNA2 gene|CCNA2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NSRP1 gene|NSRP1,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,SOX13 gene|SOX13,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Segmental Mastectomy,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,Methylnitrosourea,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,MAFG-DT gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,LINC00665 gene|LINC00665,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Long Intergenic Non-Protein Coding RNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,JAG1 gene|JAG1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PIEZO1 gene|PIEZO1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,CHAC1 gene|CHAC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Retinoblastoma Protein|RB1,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Discoidin Domain Receptor 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,inecalcitol,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SDC1 gene|SDC1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,specific immunity,Triple Negative Breast Neoplasms,Immunological Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,H19 gene|H19|HILS1,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,CDH2 gene|CDH2,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,Diagnosis,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
CAUSES,Molecular Target,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Candidate Disease Gene,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,"Membrane Potential, Mitochondrial",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,asparagine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SERPINB2 gene|SERPINB2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Leisure physical activity,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,DST gene|DST,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ISYNA1 gene|ISYNA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"TLR2 protein, human|TLR2",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,TFE3 gene|TFE3,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,"FRAP1 protein, human|MTOR",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Vitamin D Analog,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,ST8SIA6-AS1 gene|ST8SIA6-AS1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Primary Sj??gren's syndrome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,margetuximab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"ERCC5 protein, human|ERCC5",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PROM1,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,gamma-Glutamylcyclotransferase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SLC16A3 gene|SLC16A3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ELOVL5 gene|ELOVL5,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Transforming Growth Factor beta Receptors,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Adipokines,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,PTPN18 gene|PTPN18,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,ezogabine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SPI1 gene|SPI1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,SARS1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,VDR,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,tumor growth,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"Radiosurgery, Stereotactic",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SEMA3B-AS1 gene|SEMA3B-AS1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Antibody-Drug Conjugates,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Phytochemicals,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Trichorhinophalangeal dysplasia type I,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Chemoimmunotherapy,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,hla gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,testosterone,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Tandem Repeat Sequences,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SAA1 gene|SAA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Wild Type,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Offered,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PRSS22 gene|PRSS22,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,glutamic acid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Pesticides,Malignant neoplasm of female breast,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,copper,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Thyroid dysfunction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"PTK2 protein, human|PTK2",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,navitoclax,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Heterogeneous-Nuclear Ribonucleoprotein U,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MIR217 gene|MIR217,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,dihydrotanshinone I,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,TP53 gene|TP53,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
AFFECTS,inhibitors,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,pertuzumab,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Circulating MicroRNA,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Emotional hypersensitivity,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AUGMENTS,USP46 gene|USP46,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,BCAR4 gene|BCAR4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Genetic Carriers,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,chromium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,TMEM9 gene|TMEM9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,USP10 gene|USP10,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,Neoplastic Cell Transformation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Hormone Receptor Positive,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,Positive Regulation of Apoptosis,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,IFNK gene|IFNK,Basal-Like Breast Carcinoma,Genetic Factors,0.0,0.0039960039960039,Female Breast Cancer
AFFECTS,sulfoenolpyruvate,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Surviving free of recurrence of neoplastic disease,contralateral breast cancer,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,IGSF9 gene|IGSF9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Liver carcinoma,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,icariin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,TP53 gene|TP53,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Pyruvate Kinase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dietary Intake,estrogen receptor-positive breast cancer,Behavioral Factors,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Performance,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,omega-3 fatty acids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Pyrimidine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Soluble Interleukin-6 Receptor Subunit Alpha, Human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CMTM7 gene|CMTM7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Genes, Duplicate",Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Sphingolipids,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,NAD+ kinase,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,GDF2 gene|GDF2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ENPP1 gene|ENPP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,ANXA1 gene|ANXA1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Fibronectins,Inflammatory Breast Carcinoma,Other,0.0,0.0009990009990009,Female Breast Cancer
CAUSES,fructose,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,GLIS3 gene|GLIS3,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,ABCG1 gene|ABCG1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Mucin-1 Antigen,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"estrogen receptor alpha, human",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,DACH1 gene|DACH1,Carcinoma of Male Breast,Genetic Factors,0.0,0.0049950049950049,Male Breast Cancer
PREDISPOSES,Skin tanning,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,"DKK3 protein, human|DKK3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DPT gene|DPT,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,MYC,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Experimental Result,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Diagnostic assessment,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Puberty,estrogen receptor-positive breast cancer,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Oral health,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CLDN6 gene|CLDN6,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,TNF receptor-associated factor 6|TRAF6,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"RNA, Circular",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,NORAD gene|NORAD,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,AKR1A1 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,CXCL8,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ethanol,Female Breast Carcinoma,Other,0.0,0.0049950049950049,Female Breast Cancer
AUGMENTS,LONG INTERGENIC NONCODING RNA PINKY|PNKY,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Acetyl-CoA Carboxylase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Secretome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,histone deacetylase 2,Invasive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
PREDISPOSES,Cancer Vaccines,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"interleukin-1, beta|IL1A|IL1B",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MIR223 gene|MIR223,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,abemaciclib,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AFFECTS,SPARCL1 gene|SPARCL1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SFRP2 gene|SFRP2,Noninfiltrating Intraductal Carcinoma,Genetic Factors,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,"YAP1 protein, human|YAP1",Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AUGMENTS,MAP kinase kinase kinase 7,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,"SFRP1 protein, human|SFRP1",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AFFECTS,Treatment Protocols,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Immunologic Factors,Secondary malignant neoplasm of breast,Immunological Factors,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,cathepsin Z,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Basis,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
AFFECTS,TPBG gene|TPBG,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Estrogen Receptor Status - Clinical Trial Eligibility Criteria,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Pathologic Processes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DSCR9 gene|DSCR9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,"DDIT3 protein, human|DDIT3",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,nerve growth factor,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Ultrasonography,malignant neoplasm of breast staging,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,Nicotinamide N-Methyltransferase,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
AUGMENTS,Biological Response Modifiers,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,garcinone E,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,GW 4869,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,imipramine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,ARHGAP25 gene|ARHGAP25,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Abnormal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,NLRP12 gene|NLRP12,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,FBXW2 gene|FBXW2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"RTN4 protein, human|RTN4",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,interleukin-8,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
CAUSES,TAF8 wt Allele,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,PEDS1 gene,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,IL19 gene|IL19,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Lactates,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,DNAJB6 gene|DNAJB6,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,UBE3B gene|UBE3B,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,ZNF703 gene|ZNF703,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Extraction,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,metformin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,Performance,Papillary carcinoma of the breast,Other,0.0,0.0,Female Breast Cancer
AFFECTS,Terpenes,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,OTUB1 gene|OTUB1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,MAF1 gene|MAF1,HER2-positive carcinoma of breast,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
AFFECTS,magnoflorine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Squalene monooxygenase,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"plY protein, Streptococcus pneumoniae",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Malignant neoplasm of thyroid,estrogen receptor-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,KLF5 gene|KLF5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,directive therapy,Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,interleukin-10,HER2-negative breast cancer,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,iridium,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Fresh fruit,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Does ask questions,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,zinc pyrithione,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,Transgenes,Secondary malignant neoplasm of breast,Genetic Factors,0.0,0.0029970029970029,Female Breast Cancer
DISRUPTS,SFRP2 gene|SFRP2,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,SOCS3 gene|SOCS3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Post-mastectomy radiotherapy,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Focal Adhesion Kinase 1,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,KDM2A gene|KDM2A,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,oxaliplatin,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,SIAE gene|SIAE,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,secreted frizzled related protein 1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,LINC02086 gene|LINC02086,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SERPINA5 gene|SERPINA5,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Dried fruit intake,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Aptamer,Breast Carcinoma,Other,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,GRAMD1B gene|GRAMD1B,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,DACH1 gene|DACH1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"PIK3CB protein, human|PIK3CB",Carcinoma breast stage IV,Other,0.0,0.0,Female Breast Cancer
PREDISPOSES,GBP1 gene|GBP1,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,MBD4 gene|MBD4,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Vitamin supplementation,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,gene therapy,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,MUTYH Gene Mutation,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Tobacco,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Detected (finding),Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Carcinogens,Basal-Like Breast Carcinoma,Other,0.0,0.0039960039960039,Female Breast Cancer
CAUSES,Malignant neoplasm of thyroid,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,CHD4 gene|CHD4,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,SLC7A11 gene|SLC7A11,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Liposomes,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"CREB3L4 protein, human|CREB3L4",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
DISRUPTS,beta catenin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,tomography,Early-Stage Breast Carcinoma,Other,0.0,0.0,Female Breast Cancer
DISRUPTS,NOTCH3 gene,Carcinoma breast stage IV,Genetic Factors,0.0,0.0,Female Breast Cancer
CAUSES,ROS1 wt Allele|ROS1,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,EPYC gene|EPYC,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,Neoadjuvant Systemic Therapy,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Nuclear magnetic resonance normal,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,EIF4E gene|EIF4E,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,Stat3 protein,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,"DICER1 protein, human|DICER1",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,reserpine,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,MGP gene|MGP,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Cytokeratin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
PREDISPOSES,VAMP7 gene|VAMP7,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,"Discharge, body substance",Noninfiltrating Intraductal Carcinoma,Other,0.0,0.0109890109890109,Female Breast Cancer
AUGMENTS,QSOX2 gene|QSOX2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
AUGMENTS,NUP155 gene|NUP155,Breast Carcinoma,Genetic Factors,0.0,0.0279720279720279,Female Breast Cancer
AFFECTS,scopolamine,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,ZNF410 gene|ZNF410,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,"Culture Media, Conditioned",Malignant neoplasm of breast,Ethical and Cultural Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,CD8A wt Allele|CD8A,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Luteinizing Hormone-releasing Hormone Agonist,Carcinoma of Male Breast,Other,0.0,0.0049950049950049,Male Breast Cancer
AFFECTS,Saturated fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Histone Deacetylase|HDAC9,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Sugars,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Scutellaria barbata extract,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,Erianin,Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,"CDK12 protein, human|CDK12",HER2-positive carcinoma of breast,Other,0.0,0.0089910089910089,Female Breast Cancer
AUGMENTS,MIR190B gene|MIR190B,estrogen receptor-positive breast cancer,Genetic Factors,0.0,0.0089910089910089,Female Breast Cancer
DISRUPTS,Friend Leukemia Integration 1 Transcription Factor,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SCARNA4 gene|SCARNA4,Early-Stage Breast Carcinoma,Genetic Factors,0.0,0.0,Female Breast Cancer
AUGMENTS,"RAI3 protein, human|GPRC5A",Triple Negative Breast Neoplasms,Other,0.0,0.0189810189810189,Female Breast Cancer
AFFECTS,"PLK1 protein, human|PLK1",Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,Total body fat,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,JMJD1C gene|JMJD1C,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
PREDISPOSES,PPP1R21 gene|PPP1R21,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,BICD1 gene|BICD1,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
CAUSES,Secretome,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AUGMENTS,SLC16A3 gene|SLC16A3,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Hypertensive disease,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
DISRUPTS,Triterpenes,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,ANXA9 gene|ANXA9,Malignant neoplasm of breast,Genetic Factors,0.0,0.3386613386613387,Female Breast Cancer
CAUSES,Mammary Neoplasms,Secondary malignant neoplasm of breast,Other,0.0,0.0029970029970029,Female Breast Cancer
PREDISPOSES,Histopathology finding,Malignant neoplasm of breast,Other,0.0,0.3386613386613387,Female Breast Cancer
AFFECTS,Gene Mutation,"Breast Cancer, Familial",Genetic Factors,0.0,0.0,Female Breast Cancer
PREDISPOSES,EMP2 gene|EMP2,Triple Negative Breast Neoplasms,Genetic Factors,0.0,0.0189810189810189,Female Breast Cancer
